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CHAPTER 1   
 
1 Introduction 
Parkinson’s disease (Pd) is an age-related neurodegenerative disorder. 
Pharmacotherapy is the first line symptomatic treatment of this neurological disease 
[1]. Currently Levodopa is still considered the drug of first choice, but its suspected 
neurotoxicity and the induction of movement disability after chronic use demand for 
alternative therapies.  
An attractive alternative is the use of (semi-)synthetic dopamine agonists. It has been 
suggested that continuous dopamine receptor stimulation is the best symptomatic 
treatment of Parkinson’s disease [2-4]. Therefore the administration of dopamine 
agonists in a continuous, well-controlled manner by transdermal iontophoresis is an 
attractive therapeutic strategy in the symptomatic treatment of Parkinson’s disease. 
In addition, by modulation of the current density and the donor concentration of the 
drug it will be possible to adjust the rate of administration to the requirements of the 
individual patient.  
This thesis describes the investigation and optimization of the transdermal 
iontophoretic delivery of novel dopaminergic (pro)drugs for the symptomatic 
treatment of Parkinson’s disease. In this chapter, firstly the current strategy for the 
treatment of Pd is discussed. Secondly the role of transdermal iontophoretic delivery 
of dopamine agonists in the symptomatic treatment of Pd is addressed. Thirdly, the 
use of compartmental modeling in drug development for transdermal iontophoresis is 
reviewed. 
2 Current strategies for the treatment of Parkinson’s disease 
2.1 The condition 
Parkinson’s disease, first described in 1817 as ‘shaking palsy’ by James Parkinson, is 
an age-related neurodegenerative movement disorder with a prevalence in Europe of 
1.28-1.50 % in the age group above 60 [6]. This number will increase in the coming 
decades, since the life expectancy is augmenting and the ‘grey’ population is 
expanding. Pd has a world-wide distribution and has no gender preference [4]. The 
mean age of onset of Pd is about 60 years, but in case of young-onset Pd and 
juvenile-onset Pd, symptoms already may occur at the age of 21 to 40 years, and 
occasionally even earlier [2].   
The clinical character of Pd is described by four cardinal features: resting tremor, 
rigidity, bradykinesia or slowness of movement, and gait disturbance with postural 
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instability. In addition Pd, mainly considered as a movement disorder, is often 
accompanied by nonmotor features including autonomic dysfunction, sleep 
disturbances, depression, addiction, dementia, speech problems, dysphagia, 
micrographia and hyposmia…[1, 3].  
The causes of Pd are still not fully understood, but several studies on inherited 
parkinsonisms and studies with transgenic Pd-like animal models suggest that the 
aetiology of this disease lies within the complex interaction between multiple cellular 
factors, including genetic influences on cellular mechanism, together with exposure 
to environmental toxins and the unique vulnerability of the dopamine neurons in the 
substantia nigra [7]. The understanding of the involvement of genetic factors in the 
aetiology of Pd has been strengthened by the discovery of 13 genetic loci and 9 
pathogenic genes. Their involvement in Parkinson’s disease, however, is not 
completely clear [8-10]. Moreover it is currently believed that only 5% of all cases of 
Parkinson’s disease have a genetic cause [1, 9]. Several environmental factors, 
especially long-term exposure to pesticides have been reported as risk factors for Pd.  
Furthermore an excess of vitamine E and viral and bacteriological infection have 
been associated with Pd, however proving evidence is still lacking [1]. Intriguingly 
smoking and intake of caffeine are believed to reduce the prevalence of the disease 
[11]. 
For many years it is known that the basal ganglia are involved in controlling and 
regulating voluntary movement. The basal ganglia, a group of subcortical nuclei, 
consist of the striatum (caudate and putamen), globus pallidus (interna and externa), 
substantia nigra (pars compacta and recticularis) and the subthalamic nucleus. 
Pathways from these nuclei form loops between the motor cortex and the motor 
thalamus. The first neurological hallmark of Pd is a degeneration of nigrostriatal 
dopaminergic neurons in the substantia nigra pars compacta (SNc) [12]. Therefore in 
patients with Pd the balance of the excitatory and inhibitory loops, which is 
modulated by the dopaminergic pathway from the substantia nigra, will be disturbed 
and will result via a pathway of overexcitation and excessive inhibition of the 
different basal nuclei in a reduced activity towards the motor cortex (Figure 1). As a 
consequence the conscious control of the skeletal muscles, controlled by the long 
axons of the neurons of the motor cortex, which project to the spinal cord, is 
disturbed. The second neurological feature of Pd is the presence of Lewy bodies, 
predominantly present in the brainstem. The exact role of these proteinaceous 
intracellular inclusions is currently under debate. It is unclear if Lewy bodies are a 
result of the disease or are involved in the cause of the pathology. It has been 
suggested that Lewy bodies are a results of a failed attempt to protect the damaged 
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neurons against certain toxins [13]. Furthermore excessive quantities of toxic α-
synuclein inside Lewy bodies may disturb the normal cell physiology, resulting in 
cell death [3, 14-15]. Contrastingly Lewy bodies may act as simple biomarker for 
neuronal cell loss, not actively involved in the pathophosiology of Pd. Lewy bodies 
are also found in patients with other neurodegenerative disorders, including 
Figure 1: Diagram of the key neuronal pathways potentially involved in Parkinson’s 
disease. Furthermore the changes in activity (increased activity: thick line; decreased 
activity: intermittent line) are indicated as a result of the reduction of the dopaminergic 
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Alzheimer disease, progressive supranuclear palsy (PSP), multiple system atrophy 
(MSA) and dementia with Lewy Bodies (DLB).  
The diagnosis of Pd is performed clinically and based on careful history taking and 
physical examination. Currently there are neither laboratory tests nor imaging 
techniques that can confirm with 100% certainty the diagnosis. The ultimate 
diagnosis can only be performed post mortem [16]. It can be very difficult to 
distinguish idiopathic Parkinson’s disease from other certain neurological disorders, 
making the diagnosis of Pd very challenging. It has been estimated that around 10% 
of the patients are misdiagnosed [1, 17-18].  Especially in the early stages a lot of 
overlap can be observed between the features of Pd and other forms of parkinsonism. 
Since the proper diagnosis is essential for the prognosis and therapeutic treatment, 
the identification of a possible secondary cause of parkinsonian symptoms is 
essential.  In practice 3 secondary causes of parkinsonian symptoms are considered 
for differentiation from Pd: essential tremor, drug induced parkinsonism and 
Parkinson’s plus syndromes.  
2.2 Current treatment of Parkinson’s disease 
The therapeutic strategy of Parkinson’s disease is to minimize the effect of depletion 
of dopamine in the striatum. The two general approaches used in the clinic today for 
the symptomatic treatment of Pd are surgery and pharmacotherapy.  
2.2.1 Surgical therapy  
Because of the limitations of levodopa, improvements in stereotactic operative 
techniques, the use of microelectrode recording to more accurately define the target 
site, improved imaging and insights into the anatomical and physiological 
organization of the basal ganglia, surgery in the treatment of Pd has gained more 
interest in the last few years [4, 19]. Overactivity in the subthalamic nucleus, the 
globus pallidus and the thalamus results in inappropriate activity from the thalamus 
to the motor cortex and consequently development of the symptoms of Pd [1]. Two 
surgical approaches are currently applied to inactivate the particular region in the 
basal ganglia. Firstly ablation, a structural lesion in the brain, can provide some anti-
dyskinetic benefits. Because of the irreversibility and the side effects (e.g. 
hemorrhage, damage to neighboring structures), associated with these techniques, 
physicians now prefer the second surgical approach, i.e. high-frequency deep brain 
stimulation (DBS). With this technique an electrode is implanted into the brain 
target. It is associated with marked benefits in reducing drug-induced motor 
fluctuations and dyskinesias. Furthermore a minimal morbidity is observed in 
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Parkinson patients that undergo this surgical procedure [20]. The use of DBS in 
patients with depression, dementia or other mental health problems is however not 
recommended. These therapies are only designed to compensate for damaged 
neuronal circuits and therefore used in advanced Pd [21]. 
The most recent evolution in surgery is the possible neuroprotective effect of cell 
based therapies and gene therapies. Cell based therapies aim to stimulate the 
production of intrinsic dopamine by transplanting dopamine-producing cells. Firstly, 
although the implantation of embryonic dopaminergic neurons has been proven to be 
successful in animal studies, up to now no double-blind trial has proven the benefit 
of cell based therapies over placebo [22-24]. Secondly though the use of stem cells 
may look promising, the research is still in an initial stage since stem cell 
transplantation in animal models did not show beneficial effects compared to fetal 
nigral transplantation [25-26]. Gene delivery, using viral vectors to introduce the 
desired protein DNA in the target region, is also actively being investigated as 
possible treatment for Pd [27]. In analogy to cell based therapies, no placebo 
controlled double-blind clinical trial, considered as the gold standard for evaluating a 
new therapy, can clearly confirm the safety and efficacy of gene therapy for the 
treatment of Pd [23, 28-29]. 
2.2.2 Pharmacological approach 
As discussed above, surgery still compels certain risks and mostly is used only in the 
treatment of advanced Pd. This makes pharmacotherapy the first line treatment of 
Parkinson’s disease. As no curative therapy has yet been discovered, the 
pharmacotherapeutic strategy is the symptomatic treatment of the disease. Usually 
pharmacotherapy is initiated with levodopa (combined with benserazide or 
cardidopa) as such or in combination with dopamine agonists. Although levodopa is 
most effective and still considered as the gold standard, it remains associated with 
serious motor complications after long term use [30-31]. This emphasizes the need 
for alternative therapies to treat the symptoms of Pd, certainly in the early stage of 
the disease. Up to date the most attractive alternative class of drugs are the dopamine 
agonists, which activate directly the dopamine receptor. Dopamine agonists can be 
divided into ergot derivatives (bromocriptine, pergolide, lisuride, cabergoline) and 
non-ergot derivatives (apomorphine, ropinirole, pramipexol, rotigotine) based on 
their molecular structure. Dopamine agonists have shown their efficacy as 
monotherapy and as adjunctive therapy for patients using levodopa. Several trials 
have shown that dopamine agonists can reduce the ’off’ time and reduce or delay the 
use of levodopa [1]. In early stages of Pd, another class of drugs, monoamine oxidase 
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type (MAO-B) inhibitors, that stimulate the dopamine receptor indirectly by 
inhibiting the breakdown of dopamine, is also used. MAO-B inhibitors, such as 
selegiline, rasagaline and safinamide, can provide modest anti-parkinsonian effects 
and delay the use of levodopa [32-33]. Moreover this class of drugs gained more 
interest because of their possible, however not clinically proven, neuroprotection 
[34-36]. Less frequently used as monotherapy are catechol-O-methyltransferase 
(COMT) inhibitors, such as tolcapone and entecapone with the same working 
principle as MAO-B inhibitors. Finally because of their lack of efficacy and serious 
side effects, anticholinergics and amantadine are sparingly prescribed for Pd [1]. As 
Pd progresses, the need for therapy tailoring increases and becomes more 
challenging. Besides an increase in the severity of the symptoms, the management of 
the long term motor complications, caused by levodopa will play a central role in 
pharmacotherapy. For patients in an advanced state of Parkinson’s disease a 
combination therapy of levodopa with dopamine agonists, MAO-B inhibitors or 
COMT inhibitors is used. Since levodopa and dopamine agonists are still the first 
choice in the treatment of early and advanced Pd, these compounds will be discussed 
in more detail in the next paragraphs. 
2.3 Limitations of current pharmacotherapy 
Since its introduction in the early 60’s levodopa, a precursor for dopamine, remains 
the `gold standard` for the treatment of Pd [37]. To prevent side effects (such as 
nausea and vomiting), because of the peripheral metabolism of levodopa, levodopa is 
administered in combination with a peripheral decarboxylase inhibitor such as 
carbidopa or benserazide [38]. As mentioned earlier, levodopa is excellent in 
minimizing the symptoms of Pd and improves the activities of daily living, 
independence, employability and survival of the patient. However the use of 
levodopa has been put in question, because of its possible neurotoxicity and the 
induction of movement disorders after chronic long term use. Firstly in vitro toxicity 
studies showed that levodopa is able to degenerate cultured dopaminergic neurons, 
but in humans or animals no clear proof is given so far that levodopa is toxic [23, 39-
40]. In some reports neuroprotection has even been suggested [40]. Secondly and 
more importantly it is generally believed that chronic treatment with L-dopa can 
cause dyskinesias and motor fluctuations, including a wearing off and on-off 
phenomenon in the later stages of the disease.  50-80 % of Pd patients, who have 
received this drug for 5 to 10 years, experience these complications following long 
term use [30-31]. A recent study Early vs Later Levodopa Therapy in Pd 
(ELLDOPA) showed that indeed higher doses result in greater clinical benefits, but 
pose a greater risk for developing motor complications [1, 23, 41]. These L-DOPA 
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associated complications are a source of severe disability for patients with Pd. 
Management of these motor complications is very difficult and requires 
individualized therapy [42]. Current strategy to manage these symptoms can be a 
combination of low and multiple doses of L-DOPA with or without a combination 
with dopamine agonists (DA) [42] or functional surgery [43]. Although dopamine 
agonist (e.g. bromocriptine, pergolide, cabergoline, pramipexole, ropinorole, 
rotigotine) may be less effective, these drugs are still less associated with motor 
complications after long term use when used as the initial treatment in early Pd [44-
45]. This reduction in motor complication is associated with their increased half-lives 
and L-DOPA sparing effect. 
2.4 Continuous dopaminergic stimulation 
Under normal physiological conditions nigral neurons fire continuously, providing a 
constant level of dopamine in the striatum, resulting in a constant stimulation of the 
dopaminergic neurons [46-47]. In addition a re-uptake mechanism into pre-synaptic 
terminals functions as a buffer to external stimuli and ensures a constant extracellular 
dopamine concentration [46-47]. In Pd, there is a loss of nigral neurons and their 
striatal terminals that normally store and regulate the release of dopamine. As the 
disease progresses, the buffer capacity reduces and pulsatile stimulation of the 
dopamine receptors increases [47]. In addition to the pulsatile stimulation, the 
exposure to fluctuating levels of dopaminergic agents, is also believed to be 
responsible for the development of motor fluctuations[47-49]. This emphasizes the 
need for dopaminergic treatments that provide non-pulsatile stimulation and thus 
mimics the normal physiological state more closely. This therapeutic strategy is 
believed not only to reduce the dyskinesia and motor response disturbances, but also 
can provide a beneficial effect for other symptoms, like nocturnal disturbances [47]. 
2.5 Strategies for continuous dopaminergic stimulation  
A continuous stimulation of dopamine receptors can be achieved by prolonging the 
activity of levodopa by modifying the release or the delivery of this short-acting 
dopaminergic agent. For this purpose oral sustained release formulations of levodopa 
Madopar HBS® and Sinemet CR®, were developed. These long-acting controlled 
release formulations showed improvement in activities of daily living of the patient, 
however not in controlling motor fluctuations [47, 50-51]. In addition the intake of 
small doses of a liquid formulation of levodopa/carbidopa improved the ’on’-time 
without worsening the dyskinesia, but did not affect the pulsatile levodopa plasma 
concentration or the motor response fluctuations [52]. In contrast clinical trials 
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showed an improvement in motor dysfunction after chronic IV infusion of levodopa 
[53]. A more recent small open-label clinical trial, in which continuous intravenous 
levodopa [54] was compared to oral administration, also shows a reduced risk of 
motor complications in the infusion group [55]. Besides IV infusion, duodenal 
infusion via a portable pump of low doses of levodopa ameliorates plasma 
fluctuations and dyskinesia with a satisfactory therapeutic window in advanced Pd 
patients [51, 56]. 
Dopamine agonists in general have significant longer half-lives compared to 
levodopa [57]. Several studies in patients have discovered that DA are less likely to 
induce motor fluctuations after chronic treatment. In addition some studies have 
suggested a neuroprotective effect of DA [50, 58-59]. Therefore this class of drugs 
has gained more popularity over the recent years as alternative to or in combination 
with levodopa. In accordance to the levodopa treatment, the current strategy is to 
achieve continuous stimulation of the dopamine receptors to reduce development of 
motor fluctuations. This led to the development of long-acting therapeutic 
formulations of DA. For instance the slow-release formulation of a dopamine 
agonist, bromocriptine, showed promising efficacy but has not been widely used in 
Parkinson’s disease [51]. Furthermore ropinirole, formulated as extended release 
tablets, requires only one dose intake per day. The incidence of motor complications 
is reduced, while the adverse effects are comparable to other dopamine agonists [50, 
60]. Although promising results were obtained with oral modified release 
formulations, other delivery routes were explored to achieve continuous drug 
delivery. Various routes of administration of apomorphine, a potent short acting 
dopamine agonist, have been investigated, but currently only subcutaneous infusion 
is used in clinical practice [61]. Apomorphine is useful in the treatment of acute and 
long term treatment of ’off’-periods and reduces the levodopa intake [50, 61]. 
Similar results were obtained with subcutaneous infusion of lisuride, an ergot 
dopamine agonist [62]. Skin nodules, however, were present in most patients after 
long term use, making this administration route for R-apomorhine and lisuride less 
attractive [63].  
In summary there is a need for new delivery strategies for the symptomatic treatment 
of Pd that fulfill following requirements. Firstly, the drug delivery is continuous, 
resulting in continuous stimulation of the dopamine receptor. Secondly, the 
administration is non-invasive, reducing costs and inconvenience for the patient. 
Thirdly, the dose is easily adjustable to the demand of the therapy. Rapid dose 
changes are often required, certainly when initiating therapy. Fourthly, ideally the 
delivery device also includes a feedback system. During delivery, such a device also 
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monitors a relevant end-point/biomarker, which via a feedback system controls the 
drug delivery. As discussed earlier with oral delivery it is difficult to achieve a 
continuous administration. Moreover the aforementioned non-oral strategies to 
achieve a continuous delivery are invasive, cumbersome and inconvenient for the 
patient. This emphasizes the need for alternative non-invasive delivery methods that 
ideally can fulfill all the requirements stated in the previous paragraph. 
3 Transdermal drug delivery of dopamine agonists 
Transdermal iontophoretic delivery is an attractive alternative delivery technique to 
provide continuous delivery. Therefore transdermal iontophoretic delivery of 
dopamine agonist can be an interesting therapeutic strategy for the symptomatic 
treatment of Parkinson’s disease. 
3.1 Skin structure and skin barrier function  
Transdermal delivery is the administration of the drug via the skin into the systemic 
circulation. Compared to oral and parental delivery, transdermal delivery has certain 
distinct advantages: 1) it offers the possibility for non-invasive delivery 2) it 
circumvents the first pass metabolism 3) this administration route can be beneficial 
for drugs that are sensitive to gastrointestinal degradation 4) transdermal delivery can 
be useful for therapeutics that are poorly absorbed via the GI tract, due to their 
physicochemical properties or due to disease progression 5) it can provide a 
sustained delivery during a longer period of time, increasing the applicability of the 
technique 6) it can deliver drugs with a zero order mass input, reducing plasma 
fluctuations. 
However the barrier function of the skin challenges the design of transdermal 
therapeutic systems and limits the number of potential drug candidates for this 
administration route. The skin is the largest organ of the human body, comprises 
about 10% of the body mass and has a surface area of around 1.5 to 2.0 m2 [64]. A 
typical square centimeter comprises 10 hair follicles, 12 nerves, 15 sebaceous glands, 
100 sweat glands, 3 blood vessels with 92 cm total length, 360 cm of nerves and 
3x106 cells [65]. Two distinctive tissue layers can be found in human skin. The most 
upper layer is the stratified, avascular, cellular epidermis with the stratum basale, 
stratum spinosum, stratum granulosum, stratum lucidum and stratum corneum from 
the inner to the outermost layer. The epidermis is supported by a much thicker layer, 
the dermis. This layer consists of a matrix of connective tissue which is embedded in 
an amorphous substance of mucopolysaccharide. Blood vessels, nerves and 
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Figure 2: Graphical representation of the suggested transport pathways during transdermal 
transport: across the intact stratum cornuem via the intercellular route (a) or via the 
transcellular route (b) and the appendageal route via the hair follicles (c1) or sweat pores 
(c2). (This figure was adapted from ref. [5]) 
 
 
lymphatic vessels cross this matrix and skin appendages (sweat glands and 
pilosebaceous units) penetrate it. The lower side of the dermis is connected with the 
subcutaneous fat. Human skin displays two main types. The first type, hairy skin, 
encloses follicles and sebaceous glands, however no encapsulated sense organs. The 
second type, glabrous skin of the palms and the soles, consists mainly of thick 
epidermis with a compact and thick stratum corneum [65]. The stratum corneum, the 
outermost layer of the skin, is very lipophilic and forms the main barrier, protecting 
the body from water loss and penetration of exogenous agents. The stratum corneum 
or horny layer consists of corneocytes embedded in a highly organized lipid matrix 
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in a brick and mortar like structure [66]. Both the corneocytes and the lipid matrix 
are important for the transport of drugs across the stratum corneum [67].  
3.2 Passive diffusion 
3.2.1 Basic concepts 
Different transport routes have been proposed for passive penetration of molecules 
through the stratum corneum, a thin (10-20 µm), relative impermeable layer, which 
provides the rate limiting step for percutaneous penetration. Several macroroutes for 
penetration from the surface of the human skin into the subepidermal tissue are 
displayed in Figure 2 [5, 65, 68]: 1) via the sweat ducts 2) through the hair follicles 
with their associated sebaceous glands or 3) across the continuous stratum corneum 
between these appendages. It is generally believed that transport of most small 
lipophilic molecules occurs mostly via the latter pathway. This pathway can be 
subdivided into the transcellular route, though the corneocytes and lipid lamellae, 
and the intercellular pathway, solely through the lipid regions [65, 67]. For larger 
hydrophilic molecules and ions the appendegeal route may play also a significant 
role [68]. 
3.2.2 Dopamine agonists 
Due to the difficult permeability properties of the skin, the choice of potential 
candidates of dopamine agonists for passive transdermal delivery is limited. In order 
to penetrate the skin, the permeant should be potent, since the relative bioavailability 
is low and should have specific physicochemical properties: moderate hydrophilicity 
and low molecular weight (<500 Mw). Despite these restrictions several molecules 
have been investigated for the symptomatic treatment of Parkinson’s disease with 
transdermal passive delivery. All the DA of which the feasibility of (passive and/or 
iontophoretic) transdermal delivery has been investigated together with the structure 
of levodopa are depicted in Figure 3. 
In the 1980’s naxagolide was identified as a very potent dopamine agonist and a 
potential candidate for transdermal delivery due to its moderate lipophilic nature. 
Despite the very promising results that were obtained in vitro and later in vivo in 
primates and humans [69-70], the further development was discontinued because of 
the lack of efficacy as monotherapy and concerns about the toxicity [71]. These 
results encouraged further investigations with other potential candidates. 
A number of gel formulations for bromocriptine, an ergot derived dopamine agonist, 
were developed and transdermal delivery was compared with oral delivery in rabbits. 
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It was observed that a gel, formulated with chitosan showed similar plasma 
concentration profile as with a commercially available tablet [72]. An enhancement 
in transdermal transport in vitro of pergolide, another ergot derived dopamine 
agonist, was obtained using elastic vesicles, but further investigation in vivo is 
necessary [73]. Transdermal delivery of a third ergot derivative dopamine agonist, 
lisuride showed promising efficacy as add-on therapy for Pd. Axxonis Pharma, a 
pharmaceutical company in Germany, recently submitted a European marketing 
authorization application for the transdermal patch and subcutaneous infusion of 
lisuride [50, 74]. The non-ergot derivatives, such as piribedil, apomorphine and 
rotigotine do not cause serious fibrotic reactions, associated with the use of the older 
ergot-derived compounds, described above. For this reason the non-ergot derivatives 
are the preferred dopamine agonists to commence therapy, especially in younger 
patients [1]. A randomized double blind clinical study, including 72 patients with Pd, 
failed however to show clinical efficacy of transdermal delivery of piribedil, 
explained by low plasma concentrations [75]. However one year later a study was 
published on transdermal peribidil that demonstrated, a long-lasting effect (reversal 
of motor deficits) in MPTP-treated common marmosets [76]. 
Apomorphine is regarded as a potent dopamine agonist, since its introduction for the 
treatment for Pd in 1951. Different administration routes have been explored for this 
D1/D2 dopamine agonist, including transdermal delivery [1]. The transdermal 
delivery of apomorphine, formulated as a hydroxyl-propyl-methyl-cellulose gel and 
formulated in microemulsions was investigated in rabbits and mice, respectively. 
Both studies reported sufficient bioavailability and suggested potential use in humans 
[77-78]. One of the two microemulsions, used for the in vivo study in mice, was 
applied transdermally in 21 patients with Pd. The transdermal delivery of this micro-
emulsion, containing apomorphine, provided a sustained release of apomorphine, 
resulting in stable therapeutic plasma levels and reduction of off periods [79]. 
However the clinical efficacy and tolerability has not been investigated in a placebo 
controlled double blind study. 
Another potent dopamine agonist rotigotine, the (-)-enantiomer of the aminotetralin 
derivative, 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin, is the first 
transdermal delivery system (Neupro®) approved by the regulatory authorities for the 
symptomatic treatment of all stages of Pd in Europe and  of early-stage Pd in USA 
[80]. Due to drug stability (crystallization inside the patch), compromising the 
bioavailability, the EMEA limited the supply of rotigotine and the FDA asked 
professionals and patients for a recall of Neupro® [80]. After adjustments concerning 
storage conditions, Neupro® is since June 2009 available in Europe for symptomatic  
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Figure 3: The chemical structures and Mw of levodopa and ergot and non-ergot dopamine 
agonists, that were investigated for administration with passive and/or iontophoretic 
transdermal delivery for the symptomatic treatment of Pd. 
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treatment of Pd. In the USA up to the present time Neupro® is not yet available on 
the market. In addition to approval for the symptomatic treatment of Pd, Neupro® has 
been approved for the treatment of moderate to severe restless leg syndrome in adult 
patients [81]. Patches releasing 1, 2, 4, 6, 8 mg of rotigotine during 24 h are available 
[82]. In 63 patients with early Pd after repeated daily administration of 8 mg/24h 
stable steady-state plasma concentrations were observed [83] and animal studies 
demonstrated that continuous plasma concentrations translate into continuous 
dopamine stimulation [47, 84]. Three large-scale placebo-controlled phase III trials 
investigated the efficacy of transdermal delivery of rotigotine as mono-therapy for 
early stage Pd. All three trials showed an improvement in UPDRS (unified 
Parkinson’s disease rating scale)-ADL (activities daily living)-Motor subscores in 
baseline vs placebo [80, 85-87]. In addition the first phase III clinical trial reported 
that response reached a plateau when delivering between 6 and 8 mg/24h. This was 
the base to set the maximum approved dose as monotherapy in the USA and Europe 
to 6 and 8 mg rotigotine per 24h, respectively [80]. Furthermore a subgroup analysis 
in the second trial showed that the efficacy is independent of gender, age, disease 
severity and disease duration [80]. Finally the third trial, which compared 
transdermal rotigotine vs ropinirole over a 37-week period, reported that ropinirole 
resulted in a better symptomatic effect than rotigotine, which could be explained by 
possible under-dosing of the patients receiving rotigotine, compared to ropinirole 
[87]. Two large phase III trials (PREFER and CLEOPATRA PD-study) investigated 
the efficacy of transdermal rotigotine as adjunct therapy to L-dopa in advanced Pd 
[80, 88-89]. The phase III trials showed a significant improvement in the UPDRS-
Motor score and one phase III trial did not show any reduction in the required L-
dopa dose. However both phase III trials showed a significant reduction in daily off 
time and an increase in on time without dyskinesia after waking for rotigotine vs 
placebo [88-89].  Thus as monotherapy for early stage Pd and as adjunct therapy for 
advanced stage Pd, transdermal rotigotine has been proven to be efficacious and 
useful. In addition, continuous dopamine stimulation has been suggested to 
contribute to the prevention of motor complications later in the disease course. 
Moreover dopamine agonists have been less associated with motor complication than 
levodopa, emphasizing the potential of transdermal rotigotine to play an important 
role in the symptomatic treatment of Pd. 
Although the passive delivery of dopamine agonist has great potential, investigations 
to improve the transdermal delivery are required to increase the delivery rate and to 
expand the number of potential candidates for continuous delivery via the skin. The 
first major approach to overcome the skin barrier and to improve transdermal 
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delivery is the use of chemical enhancers, such as azones, glycols, terpenes etc. They 
facilitate stratum corneum transport by interaction with the lipids in the skin and/or 
increase partitioning [90]. A second approach is the use of particulate systems (e.g. 
nano-particles, vesicles, liposomes). These systems can increase the skin transport by 
improving drug solubilization in the formulation, drug partitioning into the skin and 
skin permeability [91]. The use of chemical enhancers and particulate systems can 
cause skin irritation and therefore limit the number and concentration (in 
formulation) of enhancers used [90]. Finally a third approach for permeation increase 
is the use of physical enhancement methods, such as sonophoresis (ultrasound), 
electroporation, microneedles thermal ablation, microdermabrasion and 
iontophoresis [91]. Whereas ultrasound, microneedles and thermal ablation show 
potential for delivery of macromolecules, such as vaccines and therapeutic proteins 
[91], iontophoresis is promising method for the delivery of small and moderate 
hydrophilic molecules, such as dopamine agonists.  
3.3 Iontophoresis   
3.3.1 Basic concepts  
Transdermal iontophoresis is one of the promising alternative techniques for non-
invasive continuous delivery of dopamine agonists. By applying a small electrical 
current (≤ 500 µA.cm-2) across the skin it is possible to enhance the transdermal 
delivery of small ionized therapeutic agents as illustrated in Figure 4. Besides a 
continuous administration and increased bioavailability, a particular advantage of 
iontophoresis is the possibility to adjust the delivery rate to the demand of the 
therapy. Especially in symptomatic treatment of Pd this can be very important, since 
individual titration is often required when administering dopaminergic agents. Three 
transport mechanisms are involved in transdermal iontophoretic delivery: 1) passive 
diffusion, resulting from a concentration gradient between the patch and the systemic 
circulation 2) the electromigration which is the result from the current flow from the 
anode (+ electrode) to the cathode (- electrode) across the skin and 3) electroosmosis, 
which can be attributed to the current induced solvent flow across the skin in the 
counter direction of the skin charge [92]. For small charged molecules the 
contribution of the passive flow is often negligible, making electromigration and 
electroosmosis the principle transport mechanisms with a dominating transport due 
to electromigration. With increasing molecular size, however, the contribution of the 
electroosmosis increases and may be really important for large peptides and proteins 
[92].  
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In addition for uncharged molecules electroosmosis is considered to be the only 
transporting mechanism involved in transdermal iontophoresis. Therefore marker 
molecules, such as mannitol and acetaminophen, are used to quantify the 
electroosmotic contribution during iontophoretic transport of various molecules. In 
the last few years acetaminophen has gained more interest over 14C-mannitol, 
because of its practical advantages [93-97]. 
Current application across the skin will drive the molecules through the pathway of 
least electrical resistance. In case of iontophoresis of the three suggested penetration 
routes (transcellular, intercellular and transappendageal), transport is reported to 
occur primarily via the intercellular and transappendageal route (Figure 2). The 
major contribution is via the appendages in the skin, including hair follicles and 
sweat glands [98]. In addition ions can also migrate via the damaged structures in the 
skin [90]. These penetration pathways can exist in parallel [65], as was suggested for 
the percutaneous penetration of methothrexate [99]. The relative contribution of the 
different pathways is presumably dependent on the physicochemical properties of the 
permeant. For instance Jadoul et al. showed that fentanyl, a relatively lipophilic 
molecule, was distributed across the whole human stratum corneum (HSC), while the 
more hydrophilic thyrotropin releasing hormone was mainly localized in the pores 
after iontophoresis [100]. Confocal laser scanning microscopy studies with calcein, a 














Figure 4: Iontophoresis set-up in vivo with the transport of positively charged ions across 
the skin during current application 
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charged hydrophilic dye and nile red, a neutral lipophilic dye, confirmed that the 
more lipophilic compound is transported via the lipid-filled intercellular regions of 
the stratum corneum, while iontophoresis enhanced the transcutaneous transport of 
calcein mainly in the follicular structures [101]. 
Up to today 2 iontophoretic delivery systems made it to the market. In 2007 EMEA 
approved IONSYS®, manufactured by ALZA corporation, a credit card system 
delivering fentanyl.HCl for analgesia [102]. However because of safety issues 
Janssen-Cilag withdrew IONSYS® voluntary from the market and as a consequence 
the EMEA suspended its registration [103]. Currently the only commercialized 
iontophoresis system on the market is Lidosite® from Vyteris, delivering the 
anesthetic lidocaine.HCl. Lidosite® can be applied for local analgesia prior to blood 
sampling, venipunctures or small dermatological procedures [104]. 
Instead of delivery of molecules, it is also possible with iontophoresis to extract 
molecules from the skin. Therefore so-called ‘reverse iontophoresis’ has been 
explored in the last two decades to monitor subdermal levels of several molecules 
like lithium [105], phenytoin [106], valproate [107], lactate [108], urea [109], amino 
acids [110] and glucose [111]. The GlucoWatch® Biographer (Johnson & Johnson, 
New Brunswick, NJ) was approved in 2002 by the FDA to monitor the glycaemia for 
up to 12h [111]. These results show the potential of reverse iontophoresis to monitor 
different molecules subdermally. By monitoring a relevant biomarker it may even be 
possible to design a feedback system that can control the delivery of the therapeutic 
drug. 
3.3.2 Dopamine agonists  
Transdermal iontophoresis of various non-ergot dopamine agonists have been 
studied in vitro and in vivo for symptomatic treatment of Pd. Several studies on the 
transdermal iontophoretic delivery of R-apomorphine have been reported. After 
promising results in vitro across human skin [112], in small scale clinical studies 
apomorphine was applied using transdermal iontophoresis in patients with Pd. After 
application of 2 different current densities (250 and 375 µA.cm-²) for 1 hour, in all 
patients measurable plasma concentrations were observed. However these plasma 
levels were subtherapeutic in all patients, except one [113]. Li et al. showed an 
improvement of the transdermal iontophoretic delivery of this dopamine agonist after 
non-occlusive pretreatment of the skin with a surfactant formulations [114]. A 2-fold 
and 1.4 fold increase in flux was observed in studies across HSC and dermatomed 
human skin (DHS), respectively [115]. These findings led to further exploration of 
the feasibility of the transdermal iontophoretic delivery of apomorphine in a clinical 
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study including 16 patients. 2 groups of patients were compared receiving R-
apomorphine using transdermal iontophoresis (250 µA.cm-², 3 hours) with or without 
pretreatment of with the surfactant formulation, respectively. With a similar 
enhancement ratio (1.3 times) as was observed for transport across DHS, the 
surfactant pretreatment increased the iontophoretic delivery. In this study 62.5% and 
37.5% respectively, of the surfactant pretreated and control group, reported clinical 
improvement [116]. 
The feasibility of transdermal iontophoretic administration of ropinirole was 
explored, because of its suitable fysicochemical properties (Mw: 260.4 g.mol-1; pKa: 
9.68 and 12.43; logP=3.32) [117]. Studies, investigating in vitro transport across full 
piglet skin in the absence of competing co-ions, showed that the flux of ropinirole 
was independent of the donor concentration, however linearly dependent of the 
current density [118]. In a follow-up study with hairless rats, similar plasma profiles 
were observed, despite the 10-fold difference in donor concentration. The absence of 
competing co-ions results in a constant flux, independent of the donor concentration 
and dependent on the mobility of the drug, the skin diffusivity and the counterion in 
the skin (mainly Cl-). The authors concluded that, based on the in vitro flux and in 
vivo plasma concentrations, therapeutic levels of ropinirole in humans can be 
achieved with transdermal iontophoresis, providing an alternative administration 
route for the drug, as a tablet available [117]. 
Finally several studies were conducted to investigate the iontophoretic delivery of 2 
dopamine agonist of the 2-aminotetralin group. Most dopamine agonists of this 
group are shown to be very potent [119-125]. In addition the low molecular weight, 
the chargeability of the nitrogengroup and the moderate lipophilicity, make several 
members of the 2-aminotetralingroup interesting candidates for transdermal 
iontophoresis. Therefore Nugroho et al. studied the transdermal iontophoretic 
delivery of rotigotine.HCl (Mw: 351.9 g.mol-1; pKa (nitrogen): 7.9; logP: 4.03) and 
of 5-OH-DPAT.HBr (Mw: 328.3 g.mol-1; pKa (nitrogen): 8.12; logP: 2.19) [126-
127]. In vitro transdermal iontophoresis studies of the potent dopamine receptor 
agonist rotigotine, currently on the market as passive delivery system (cf. supra), 
were performed. Increasing the pH of the donor phase increases the flux, doubling 
the NaCl concentration reduces the flux and lowering the pH of the acceptor phase 
does not affect the flux. Furthermore electroosmosis contributed only 2% to the total 
flux [128]. In a follow up assay it was shown that in the concentration range tested, 
the flux was linearly dependent on the donor concentration and the current density. 
Replacing HSC by DHS reduced, while higher temperatures increased it [126]. 
Although the maximum flux of 80 nmol.cm-2.h-1 is considered to be sufficient for 
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therapeutic levels, the limited solubility of this compound prevented the researchers 
to further increase the iontophoretic delivery. 
The second 2-aminotetralin investigated was 5-hydroxy-2-(N,N,-di-n-
propylamino)tetralin (5-OH-DPAT). This dopamine agonist has similar structure and 
potency as rotigotine [127]. The absence of the thienylgroup in the side chain of 5-
OH-DPAT makes this compound less lipophilic, which could lead to increased 
solubility and a faster transdermal transport because of less retardation in the 
lipophilic environment of the skin. In vitro studies showed a higher flux for 5-OH-
DPAT, compared to rotigotine. The flux was linearly dependent on the concentration 
in the given concentration range (0-7 mM) and on the current density. Increasing the 
salt concentration from 0.07 M to 0.14 M dramatically decreased the flux with 
almost 10 fold. In analogy to rotigotine, transport across DHS was less compared to 
transport across HSC [127]. Although the in vitro transport of this potent dopamine 
agonist has not yet been fully characterized, these results showed an improved 
transport compared to rotigotine. Therefore the authors continued with 5-OH-DPAT 
to explore the potential of transdermal iontophoresis in a series of in vivo studies. 
The pharmacodynamic effect of 5-OH-DPAT was investigated in an anaesthetized 
rat model with the dopamine level as pharmacodynamic end-point, measured by 
online microdialysis. Administration of 5-OH-DPAT with transdermal iontophoresis 
during 3 hours using a current density of 250 µA.cm-² resulted in a strong and long 
lasting effect, which was suggested to persist for 24 hours post-iontophoresis [129]. 
The pharmacokinetic and pharmacodynamic data were analyzed using 
compartmental modeling. A more detailed discussion of this approach is provided in 
the next section.   
In conclusion transdermal iontophoresis has great potential as novel delivery strategy 
for symptomatic treatment of Pd. Firstly, the results presented in this section show 
that this non-invasive delivery technique can provide continuous delivery that can be 
controlled mainly by donor concentration and current density. This makes 
iontophoresis a flexible delivery technique, enabling rapid titration of drug delivery. 
Secondly, several dopamine agonists are successfully administered with transdermal 
iontophoresis in vitro, in animals and even in patients. Thirdly, monitoring 
biomarkers with reverse iontophoresis opens the door to design a feedback system to 
control drug delivery. Despite these promising results there is still a need for 
improvement in delivery efficiency. In addition a better understanding of the 
different transport mechanisms involved in iontophoretic delivery will also 
contribute to improve drug delivery. This demands for further optimization of the 
iontophoretic delivery of previously investigated DA and for further exploration of 
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novel potent dopaminergic drugs with the desired physicochemical properties for 
transdermal iontophoresis.  
4 Modeling transdermal iontophoretic delivery in vitro and in vivo 
Describing the profile of a drug in different parts of the body (e.g. plasma, urine, 
brain, skin,…) during and after administration with various delivery techniques has 
been a challenge in drug development for many years. The complexity of the skin as 
biological membrane makes mathematical modeling of transdermal (iontophoretic) 
delivery difficult. Most of the models found in literature focus on the transport 
mechanisms during transport of the molecules [93, 130-141]. In some of these 
reports a correlation was suggested between the physicochemical properties (pKa, 
electrophoretic mobility, lipophilicity, Mw,…) of the solutes and the corresponding 
transport efficiency [93, 130, 132, 134-135, 139-141]. One of the limitations of these 
physicochemical property-transport relationships is that they are based on a single 
parameter to describe the transdermal iontophoretic transport. With this approach the 
information on the shape of the iontophoretic flux curve is neglected, which makes 
extrapolation from in vitro experiments towards the in vivo situation more difficult. 
However, very little research has been performed on development of models 
describing the whole transport profile during iontophoresis in vitro and in vivo. Most 
of the models used to describe the plasma concentration following transdermal 
iontophoresis were based on a zero order mass input from the donor solution into the 
systemic circulation in analogy to intravenous infusion [142-144].  However this 
assumes that immediate steady state conditions would apply after turning on the 
current. But the development of a steady state takes time, because of the barrier 
function of this biological membrane. This is clearly demonstrated by the profiles 
that have been published [112-113, 116, 129, 145-148].  
To account for the change of input rate during iontophoresis before reaching steady 
state more complex kinetic models have been developed by Nugroho et al. [147-
148]. In these models the rate of mass transfer (I0) from the patch into the skin during 
iontophoresis is assumed to be constant due to the iontophoretic driving force. 
Furthermore it is believed that the release from the skin into the acceptor solution (in 
vitro) and in the systemic circulation (in vivo) is according to a first order process 
with a release constant KR. This approach was successfully applied to describe the 
iontophoretic transport in vitro [147] and in vivo [148] during and also after current 
application. The proposed in vivo pharmacokinetic (PK) models were combined with 
a pharmacological model (indirect response type I) to analyze the pharmacokinetics 
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and pharmacodynamics (PD) of 5-OH-DPAT following transdermal iontophoresis. 
Besides adequately describing the plasma concentration and the pharmacodynamic 
effect in rats, it was shown that based on results from in vitro transport studies across 
rat stratum corneum and dermatomed rat skin it was possible to predict the plasma 
profile as well as the dopaminergic effect [129].  
These results illustrate several strong benefits of compartmental modeling. Firstly an 
integrated approach makes it possible to combine data from several experiments, 
facilitating analysis of different experiments. Secondly compartmental modeling can 
be helpful in understanding the different mechanisms involved in iontophoretic 
transport. In addition the establishment of a PK-PD relationship gives more insight in 
the causal path from blood to the pharmacodynamic effect. Thirdly a robust in vitro-
in vivo correlation can be very useful for screening newly developed compounds and 
can be a powerful tool to design new assays at various stages of drug development. 
To improve screening a next step would be the identification of the relationships 
between the molecular and physicochemical properties and the different transport 
parameters, which can offer a base for selecting potential candidates.  
In conclusion the compartmental modeling approach can reduce, refine, and maybe 
even replace in vivo studies, which are often very costly and time consuming 
certainly at later stages of drug development.  
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1 Objective of the thesis 
In the previous chapter the transdermal iontophoretic delivery of several dopamine 
agonists was reviewed. Despite the promising results further optimization of the 
transdermal iontophoretic delivery of dopamine agonists is required. The general 
objective of the presented research is the optimization of the transdermal 
iontophoretic delivery of dopamine agonists and its prodrugs for the symptomatic 
treatment of Parkinson’s disease (Pd). To achieve this goal, the following specific 
items are considered: 
1. Optimizing the transdermal iontophoretic delivery in vitro of a series of potent 
dopamine agonists, including rotigotine, 5-OH-DPAT and other potent 
structural analogs. In addition the mechanisms driving the iontophoretic 
transport are addressed. 
2. Synthesis of novel dopaminergic prodrugs of 5-OH-DPAT with an extra 
chargeable group for transdermal iontophoretic delivery. Subsequently the 
chemical and enzymatic stability are examined. This part of the investigations 
was performed by Jeroen De Graan and will result in a dissertation at the 
Rijks Universiteit Groningen, Groningen, The Netherlands 
3. In vitro iontophoresis of selected prodrugs of 5-OH-DPAT to investigate the 
feasibility for transdermal iontophoretic delivery  
4. Pharmacokinetic-pharmacodynamic (PK-PD) studies in an animal model with 
the most promising candidates with a special focus on controlling the plasma 
concentration and the pharmacodynamic effect with transdermal iontophoresis 
5. Evaluation and optimization of the kinetic models, developed by Nugroho et 
al. for the characterization of transdermal iontophoretic transport in vitro and 














2 Outline of the thesis 
Part I-Optimizing the in vitro transdermal iontophoretic delivery of 
dopaminergic drugs  
Although the potential of transdermal iontophoretic delivery of 5-OH-DPAT has 
already been demonstrated [3-4], a comprehensive characterization of iontophoresis 
of this potent dopamine agonist is necessary. Specifically, understanding of the 
mechanisms during iontophoresis driving 5-OH-DPAT across the skin barrier is 
essential to further improve the delivery in vivo in patients. In CHAPTER 3 the 
optimization of the iontophoretic delivery of 5-OH-DPAT is approached from a 
mechanistic perspective. The influence of the following parameters is investigated: 
drug donor concentration, electro-osmotic contribution, influence of co-ions, current 
density and composition of the acceptor phase. In addition the feasibility of 
acetaminophen as a marker for the electro-osmotic flux is examined.  
Rotigotine, another more lipophilic dopamine agonist from the 2-aminotetraline 
group (like 5-OH-DPAT), showed promising results when administered with 
transdermal iontophoresis [5-6]. However in these studies the solubility of the 
compound was the limiting factor for further increasing its delivery. Besides 
changing the donor formulation, the solubility and consequently the iontophoretic 
delivery can be improved by changing the salt form of the compound. In CHAPTER 
4 the influence of different salt forms of rotigotine (H3PO4 vs HCl) on the solubility 
and on the passive and iontophoretic transport efficiency is investigated. In addition 
the in vitro transport parameters are analyzed using compartmental modeling. The 
estimated parameters are combined with pharmacokinetic parameters from literature 
to evaluate the iontophoretic delivery in vivo in a series of simulations.  
Next to 5-OH-DPAT and rotigotine, also other members of the 2-aminotetralins are 
very potent at the D1- and/or D2-receptor in the striatum and are potential candidates 
for transdermal iontophoresis. In CHAPTER 5 the transdermal iontophoretic 
delivery of a series of novel dopamine agonists across human stratum corneum 
(HSC) and dermatomed human skin (DHS) is investigated. The molecules from the 
2-aminotetraline group were selected based on their potency and molecular structure: 
5-OH-MPAT, 5-OH-EPAT, 5,6-di-OH-MPAT and 5,6-di-OH-DPAT. In addition a 
potent chromanamine (8-OH-DPAC), which is structurally closely related to the 
above mentioned group, is added to the investigations. In these investigations the 
applicability of the kinetic models for the characterization of transdermal 
iontophoresis, developed by Nugroho et al., are also evaluated. The small structural 




changes between the compounds tested allowed us to investigate the influence of the 
molecular structure and physicochemical properties on the iontophoretic delivery.  
Part II-In vivo assessment of controlling the iontophoretic delivery 
of (S)-5-OH-DPAT  
In CHAPTER 6 the pharmacokinetics (PK) and pharmacodynamics (PD) following 
transdermal iontophoretic delivery of the active enantiomer of 5-OH-DPAT, (S)-5-
OH-DPAT is investigated in male Wistar rats. The first aim of this study is to 
examine the relationship between the current density, the in vivo iontophoretic 
transport and the (S)-5-OH-DPAT plasma profile. To conduct transdermal 
iontophoresis studies, it is necessary to anesthetize the animals. Therefore the second 
aim of the present study is to examine the effect of the anesthetic mixture, together 
with the effect of transdermal iontophoresis, and blood sampling on the striatal 
dopamine release. This is important since the striatal dopamine release is the 
pharmacodynamic end-point chosen to monitor the pharmacological response 
following transdermal iontophoresis. The third aim is to address the PK-PD 
relationship following transdermal iontophoresis of (S)-5-OH-DPAT under non-
saturated conditions. This implies the establishment of a controlled and reversible 
effect. The effect is monitored in the striatum with on-line microdialysis, while 
simultaneously blood samples are taken. In this chapter extensive analysis is 
performed with non-linear mixed effects modeling, using an integrated 
compartmental PK-PD model. 
Part III-Transdermal iontophoretic delivery of ester prodrugs of      
5-OH-DPAT: from synthesis to in vivo studies 
In CHAPTER 7 the transdermal delivery of 4 new ester prodrugs of 5-OH-DPAT is 
studied: glycine-, proline, valine- and β-alanine-5-OH-DPAT. Since ester prodrugs 
are susceptible to hydrolysis, stability assays are performed to select the optimal 
candidate(s) for further investigations. Furthermore the solubility of the prodrugs is 
investigated and compared to the parent drug 5-OH-DPAT. In a series of transport 
studies the iontophoretic delivery across HSC and DHS is examined. The main focus 
of the in vitro transport studies is to identify a prodrug that is efficiently transported 
with iontophoresis and which is hydrolyzed during transport through the skin. These 
results lead to the selection of the optimal prodrug for follow-up studies in vivo.  
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The pharmacokinetics and pharmacodynamic effect of the prodrug of (S)-5-OH-
DPAT are examined in the newly developed animal model, described in CHAPTER 
6. The resulting PK-PD parameters of the prodrug, obtained with compartmental 
modeling, are discussed and compared to the parameters of the parent drug (S)-5-
OH-DPAT. 
In CHAPTER 8 a summary of all the results of the presented research is provided. 
Furthermore these results are discussed and put in perspective to the general 
applicability of transdermal iontophoresis of dopamine agonist for the treatment of 
Parkinson’s disease. Finally future perspectives of transdermal iontophoresis of 
dopamine agonists are addressed from a mechanistic, mathematical and clinical point 
of view. 
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CHAPTER 3  
Abstract 
A characterization and optimization of the in vitro transdermal iontophoretic 
transport of 5-hydroxy-2-(N,N,-di-n-propylamino)tetralin (5-OH-DPAT) is 
presented. The utility of acetaminophen as a marker of electroosmotic flow was 
studied as well. The following parameters of iontophoretic transport of 5-OH-DPAT 
were examined: drug donor concentration, electroosmotic contribution, influence of 
co-ions, current density and composition of the acceptor phase. The steady-state flux 
(Fluxss) of acetaminophen was linearly correlated with the donor concentration and 
co-iontophoresis of acetaminophen did not influence the iontophoretic flux of 5-OH-
DPAT, indicating that acetaminophen is an excellent marker of electroosmotic flow. 
Lowering the Na+ concentration from 78 mM to 10 mM in the donor phase, resulted 
in a 2.5 fold enhancement of the Fluxss. The Fluxss showed a non-linear relation with 
the drug donor concentration and an excellent linear correlation with the current 
density. Reducing the pH of the acceptor phase from 7.4 to 6.2 resulted in a dramatic 
decrease of the Fluxss of 5-OH-DPAT, explained by a reduced electroosmotic flow 
and an increased counter-ion flow. Optimization of the conditions resulted in a 
maximum Fluxss of 5-OH-DPAT of 1.0 µmol.cm-2.h-1 demonstrating the potential of 
the iontophoretic delivery of this dopamine agonist for the symptomatic treatment of 
Parkinson’s disease. 
Key words:  Controlled release; Skin; Transdermal drug delivery; Iontophoresis; 
Percutaneous;  Electroosmosis; Acceptor phase; Dopamine agonist; Parkinson’s 
disease 
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1 Introduction  
Parkinson’s disease is an age-related progressive neurological disorder with a 
prevalence of 1-2 % in people over the age of 50. Pharmacotherapy is the first line 
symptomatic treatment of this disease [1]. Currently orally administered levodopa is 
still considered the golden standard, but its possible neurotoxicity and the induction 
of movement disorders after chronic use demands for the development of alternative 
therapies [2].  One of the most important alternatives is the use of dopamine agonists, 
such as apomorphine, carbergoline, ropinirole and rotigotine which directly activate 
the postsynaptic dopamine receptor [3]. However when these dopamine agonists are 
administered orally, often fluctuations in plasma concentrations occur resulting in 
pulsatile dopaminergic stimulation. Therefore, the continuous dopamine stimulation 
may be the optimal symptomatic treatment of Parkinson’s disease, reducing off 
periods and dyskenisias [2, 4].  
Transdermal iontophoresis is one of the promising techniques for non-invasive 
continuous delivery of dopamine agonists. By applying an electric current across the 
skin it is possible to enhance the transdermal delivery of small charged molecules. In 
addition by modulation of the current and donor concentration it will be possible to 
adjust the rate of administration to the requirements of the individual patient, which 
will be an important advantage. In the last ten years several dopamine agonists have 
been studied for their ability to be administered by iontophoresis [5-10]. The potent 
dopamine agonist 5-hydroxy-2-(N,N,-di-n-propylamino)tetralin (5-OH-DPAT) [11-
12], has already been proven to be suitable for iontophoretic delivery in vitro as well 
as in vivo [5, 13]. However characterization of the transport mechanisms driving the 
iontophoretic delivery in vitro is crucial to understand and optimize the iontophoretic 
delivery in vivo to patients.  
Transdermal migration of chemicals during iontophoresis is influenced by several 
factors such as pH, the presence of ions having the same charge (co-ions) and ions 
having the opposite charge [14]. This implies that the iontophoretic transport of 
chemicals is influenced by the composition of the donor phase as well as the acceptor 
phase. In contrast to the donor phase, the effect of the composition in the acceptor 
phase has not been widely studied [14-16].  
The aim of the present study was to fully characterize the transdermal iontophoretic 
transport of the dopamine agonist 5-OH-DPAT across the skin. Especially the 
electroosmotic contribution, the influence of ion composition in the donor and 
acceptor phase on the iontophoretic delivery of 5-OH-DPAT were studied.  
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Several marker molecules, like 14C-mannitol and acetaminophen, are available to 
estimate the electroosmotic contribution during iontophoretic transport [17-21]. In 
the last few years acetaminophen has gained more interest over 14C-mannitol, 
because of its practical advantages. Although acetaminophen has been widely used 
as a marker for electroosmosis, until now its transport has not been fully 
characterized. Therefore in the current study acetaminophen as a marker molecule 
for electroosmosis is evaluated as well. 
2 Materials and methods  
2.1 Materials 
5-OH-DPAT (HBr salt, purity>98%) was synthesized at the Department of 
Medicinal Chemistry of the University of Groningen, Groningen, the Netherlands. 
Silver, silver chloride (purity>99.99%), Trypsin (Type III from bovine pancreas) and 
trypsin inhibitor (Type II-S from soybean) were obtained from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Acetaminophen was purchased from Brocacef BV 
(Maarssen, the Netherlands) and D(-)Mannitol was obtained from BDH Laboratory 
supplies (Poole, UK). Bacteriological agar was purchased from Life Technologies 
(Paisley, Scotland).  Spectra/Por® RC dialysis membrane disks (cut off value of 
6000-8000 Da) were purchased from Spectrum laboratories, Inc (Rancho 
Dominquez, Ca, USA). Tetrahydrofuran (THF, stabilized, purity>99.8%) was 
obtained from Biosolve (Valkenswaard, the Netherlands). Triethylamine (TEA, 
purity>99%) was obtained from Acros Organics (Geel, Belgium). All other 
chemicals and solvents were of analytical grade. All solutions were prepared in 
Millipore water with a restitivity of more than 18 MΩ.cm. 
2.2 Preparation of Human Stratum Corneum (HSC) 
The preparation of human stratum corneum was performed according to the method 
described previously [13]. Briefly, within 24h after surgical removal of the human 
skin residual subcutaneous fat was removed. Dermatomed human skin (DHS) was 
obtained by dermatoming the skin to a thickness of about 300 µm. In order to obtain 
HSC, DHS was incubated with the dermal side on Whatman paper soaked in a 
solution of 0.1% trypsin in 150 mM phosphate buffered saline (PBS) pH 7.4 (NaCl: 
8 g.L-1 , Na2HPO4: 2.86 g.L-1 , KH2PO4: 0.2 g.L-1 , KCl: 0.19 g.L-1) overnight at 4 
°C and subsequently for 1h at 37 °C after which HSC was peeled off from the 
underlying viable epidermis and dermis. HSC was subsequently washed in a 0.1% 
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trypsin inhibitor solution in Millipore water and several times in water and stored in 
a desiccator in a N2 environment.  
2.3 Preparation of salt bridge 
The use of salt bridges enables to reduce the amount of competing cations in the 
donor phase, while the salt bridge still contains enough Cl--ions, added as NaCl, to 
feed the anodal electrochemistry. An agar suspension was prepared as follows: 100 
mL of PBS pH 7.4 was heated in an Erlenmeyer flask to boiling. Then 3.0 g agar was 
added, stirring was commenced and the solution was continuously heated until a 
uniform suspension was formed. The mixture was transferred to a silicon tube of 
appropriate length (total volume 1.0 mL). The tube was then left at room temperature 
until the mixture had gelled. Thereafter the anode was placed carefully in the salt 
bridge. 
2.4 Solubility of 5-OH-DPAT 
The solubility was determined according to the method described previously [6]. 
Briefly, 5-OH-DPAT was solubilized in 5 mM citrate buffer pH 5.0 and 6.0, 
containing 68 mM NaCl. After adjusting the pH of the solution with 0.05 M NaOH 
or HCl, each solution was shaken for 48h at 700 rpm (IKA-VIBRAX-VXR, 
Omnilabo International BV, Breda, The Netherlands) at room temperature. All 
saturated solutions were centrifuged at 3600 rpm (AllegraTM 6R centrifuge, Beckman 
Coulter, Fullerton, CA, USA) for 30 minutes. Each supernatant was then filtered by 
using a 0.2 µm porous membrane (PTFE Acrodisc®, Pall, East Hills, NY, USA), 
after which the concentration was determined by HPLC. 
2.5 In vitro transport studies 
A 9-channel computer controlled power supply was used to provide a constant direct 
current (Electronics Department, Gorlaeus Laboratories, Leiden University, The 
Netherlands) during iontophoresis. The system was equipped with differential input 
channels per current source enabling on-line measurement of the electric resistance 
across HSC in each diffusion cell. Ag/AgCl was used as driver electrode pair. All 
transport studies were carried out, using a three chamber continuous flow through 
cell as described elsewhere [13]. In all experiments HSC of at least 2 different 
donors was used. The donor formulation was buffered with 5 mM citric acid and D-
mannitol was added to the donor phase to obtain iso-osmolar conditions. Unless 
stated otherwise the cathodal chamber was filled with PBS pH 7.4 and the acceptor 
chamber was continuously perfused with PBS pH 7.4 at a flow rate of ± 6.5 ml.min-1. 
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During the experiment the temperature of the acceptor phase was maintained at 32 
°C, the skin temperature in vivo. Unless stated otherwise, the following protocol was 
used for in vitro iontophoretic transport studies: 6h passive diffusion, followed by 9h 
of iontophoresis at a current density of 500 µA.cm-² and finishing with 5h passive 
diffusion. During the experiment the anodal and cathodal chamber were continuously 
stirred at 365 rpm. Samples were collected every hour with an automatic fraction 
collector (ISCO Retriever IV, Beun De Ronde BV, Abcoude, The Netherlands). The 
specific conditions for each individual series of experiments are described below. 
2.5.1 Acetaminophen as marker molecule for the electroosmotic flow 
To determine whether there is a linear correlation between the donor concentration 
acetaminophen and its iontophoretic transport, studies were performed with 3 
different donor concentrations acetaminophen (7.5 mM, 15 mM and 30 mM) in a 
citric buffer pH 5.0, containing 68 mM NaCl.  
The influence of co-iontophoresis of acetaminophen on the 5-OH-DPAT flux was 
also investigated. The donor formulation was at pH 5.0 in the presence of 68 mM 
NaCl and 3.9 mM 5-OH-DPAT. The iontophoretic transport of 5-OH-DPAT in 
presence (15 mM) and absence of acetaminophen was measured. 
2.5.2 Electromigrative and Electroosmotic contribution to the transport of 5-OH-
DPAT 
The concentration of 5-OH-DPAT in the donor concentration was 1.5 or 3.9 mM. 
Acetaminophen (15 mM) was added to the donor solution as a marker molecule for 
the electroosmosis. The donor solution was buffered with citric buffer at a pH of 
either 5.0 or 6.0. All experiments were performed in the presence of 68 mM NaCl in 
the donor solution. 
2.5.3 Influence of competing ions in the donor phase 
The influence of competing co-ions in the donor phase was investigated, using 
different concentrations of 5-OH-DPAT varying from 0.15 to 35.1 mM. The 
concentration of NaCl in the donor phase was either 0 or 68 mM. In the absence of 
NaCl the only source of Na+ was Na3citrate.2H2O, used to buffer the solution and the 
amount of Na+ was calculated at 10 mM. Therefore the total Na+-concentration was 
either 10 mM or 78 mM. In the case of 10 mM Na+ the Ag-electrode (anode) was 
placed in a salt bridge. The donor solution was buffered at pH 6.0.  
 
46 
                                         Transdermal iontophoretic delivery of 5-OH-DPAT in vitro 
2.5.4 Influence of the pH of the acceptor phase  
The iontophoretic delivery of 5-OH-DPAT was investigated using PBS with a 
different pH as acceptor phase. The acceptor solution was either PBS pH 7.4 or PBS 
pH 6.2. (8 g.L-1 NaCl, 0.19 g.L-1 KCl, 0.43 g.L-1 Na2HPO4.2H2O, 0.97 g.L-1 
KH2PO4), both at iso-osmolar conditions. The concentration of 5-OH-DPAT was 1.5, 
3.9 or 7.0 mM. All experiments were conducted in the presence of 68 mM NaCl in 
the donor solution, buffered at pH 5.0. 
The electroosmotic or water flow across HSC was investigated using PBS as 
acceptor phase. The pH of the acceptor solution was either 7.4 or 6.2. The 
concentration of acetaminophen, used as a marker molecule for the electroosmotic 
flow, was 15 mM. The donor solution was buffered at pH 6.0 using 5 mM citrate 
buffer. All experiments were conducted in the presence of 68 mM NaCl in the donor 
phase. 
The ion transport across HSC was investigated using PBS with different pH as 
acceptor phase. The pH of the acceptor solution was either 7.4 or 6.2. The pH of the 
donor solution was 6.0. A current of 500 µA.cm-² was applied during 19h. This 
experiment was performed in the absence of NaCl and the Ag-electrode (anode) was 
placed in a salt bridge. At regular time intervals (0, 2, 4, 6 and 19h) an aliquot of 100 
µL of the donor solution was sampled to measure the osmolarity with an osmometer 
(Micro-osmometer type 13, Roebling, Berlin, Germany).  
2.5.5 Influence of current density 
The iontophoretic transport of 5-OH-DPAT (3.9 mM), buffered at pH 6.0, across 
HSC was investigated at different current densities. The protocol used for these 
experiments is: 2h passive diffusion + 6h 125 µA.cm-² + 6h 250 µA.cm-² + 4h 500 
µA.cm-² + 6h passive diffusion. The Na+-concentration in the donor phase was 10 
mM and the Ag-electrode (anode) was placed in a salt bridge. 
2.6 Analytical methods 
Prior to and at the end of a transport study pH and osmolarity of donor and acceptor 
compartment were measured. All samples of the iontophoretic transport studies were 
analyzed by RP-HPLC using a Superspher® 60 RP-select B, 75 mm-4 mm column 
(Merck KGaA, Darmstadt, Germany). 5-OH-DPAT was detected using a scanning 
fluorescence detector (Waters™ 474, Millipore, Milford, MA, USA) at excitation 
and emission wavelengths of 275 and 302 nm. Acetaminophen was detected using a 
UV detector (Dual λ Absorbance Detector 2487, Waters, Milford, USA) at a 
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wavelength of 254 nm. Filtered and degassed mobile phase contained 100 mM 
acetate buffer (pH 3.6)/THF (95/5 v/v) with the addition of 30 mM TEA to prevent 
peak tailing. The injection volume was 50 µL and the flow rate was set to 1.5 
mL.min-1. Calibration curves showed a linear response when using concentrations of 
compounds between 0.1 and 40 µg.mL-1 (R2>0.9999). The limit of detection (LOD) 
and limit of quantification (LOQ) were experimentally determined for all compounds 
of interest: 5-OH-DPAT has a LOD and LOQ of 3.5 and 5.8 ng.mL-1 respectively. 
Acetaminophen has a LOD and LOQ of 5.8 and 9.6 ng.mL-1, respectively. 
2.7 Determination of electromigrative and electroosmotic contribution  
The total iontophoretic flux consists of the passive flux (Jpass), the electroosmotic flux 
(JEO) and the electromigrative flux (JEM). The passive flux is calculated during 6h 
prior to the iontophoretic phase. The electroosmotic flow is calculated as described 
below. The electromigrative flux is calculated by subtracting the passive and 
electroosmotic flux from the total flux. 
The water flow during iontophoresis can be derived from the flux of the neutral 





Vw =               (1) 
where Vw is the water flow, Jace is the steady state flux (Fluxss) and Cace the donor 
concentration of acetaminophen. When plotting the Jace as function of the donor 
concentration of acetaminophen Cace, the water flow can be calculated from the slope 
of the regression line. The electroosmotic flow of 5-OH-DPAT (JEO) is proportional 
to the volume flow (Vw) and the molar concentration of the solute, 5-OH-DPAT (C5-
OH-DPAT) [22] and can be calculated as follows: 
DPATOHwEO CVJ −−×= 5             (2) 
2.8 Data analysis 
The cumulative flux of 5-OH-DPAT and acetaminophen during iontophoretic 
transport was plotted as a function of time. The Fluxss was estimated from the linear 
part of the slope of this plot according to the permeation lag-time method [13]. All 
data are presented as mean ± standard deviations (SD). When the effect of two 
factors was investigated simultaneously two-way ANOVA was used for statistical 
analysis. When a statistical analysis was performed for only 2 groups, a Students t-
test was used. For all statistical analysis a significance level of p<0.05 was used.  
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3 Results 
3.1 Acetaminophen as marker molecule for the electroosmotic flow 
First the proportionality of the flux with the donor concentration was investigated, 
As depicted in Figure 1A a variation in donor concentration of acetaminophen of 7.5, 
15.0 and 30.0 mM resulted in steady state fluxes (Fluxss) of 30.6 ± 7.3, 48.6 ± 7.8 
and 103.5 ± 26.5 nmol.cm-2.h-1, respectively. The acetaminophen concentration and 
Fluxss are linearly related. The linear regression line was forced through zero 
(R2=0.995). According to Equation 1 the slope of the regression line represents the 
water flow during iontophoretic transport and is estimated at 3.39 ± 0.17 ml.cm-2.h-1. 
Furthermore as depicted in Figure 1B a change from pH 5.0 to 6.0 in the donor phase 
results in a significant increase in acetaminophen flux from 50.0 ± 11.0 nmol.cm-2.h-1 
to 68.0 ± 5.9 nmol.cm-2.h-1 (t-test; p<0.05). Secondly the influence of co-
iontophoresis of acetaminophen on the Fluxss of 5-OH-DPAT is presented in Table 1. 
The steady state flux of 5-OH-DPAT (3.9 mM), buffered at pH 5.0, remained 





















































Figure 1 A: The linear correlation between the steady state flux (Fluxss) vs the donor 
concentration during iontophoresis (500 µA.cm-2) of acetaminophen at donor pH 5.0. Data 
are presented as mean ± SD (n=5-7). The acceptor phase consisted of PBS pH 7.4.  
B: bar plot of the Fluxss of acetaminophen (15 mM) at donor pH 5.0 (white bar) and pH 6 
(black bar). Data are presented as mean + SD (n≥4). A current density of 500 µA.cm-2 was 
applied and PBS pH 7.4 was used as acceptor phase. A significant difference is observed
between the Fluxss at pH 5.0 and 6.0 (t-test; p<0.05). 
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unaffected when acetaminophen (15mM) was added to the donor phase (t-test; 
p>0.05). Moreover the iontophoretic flux profile of 5-OH-DPAT remained also 
unchanged (data not shown).   
3.2 Solubility of 5-OH-DPAT 
The solubility of 5-OH-DPAT was determined in a citric buffer (5 mM), containing 
68 mM NaCl at pH 5.0 and 6.0. The maximum solubility decreases with increasing 
pH from 56.7 ± 1.4 mM at pH 5.0 to 47.4 ± 1.4 mM at pH 6.0.  
3.3 Iontophoretic delivery of 5-OH-DPAT 
3.3.1 Electromigrative and electroosmotic contribution  
The passive flux appeared to be negligible, contributing only a maximum of 0.02% 
to the total flux. The results of the determination of the electromigrative and 
electroosmotic contribution are provided in Table 1. The electroosmosis flux has a 
minor but significant contribution to the 5-OH-DPAT iontophoretic flux. No 
 
 
Table 1: The steady state flux of 5-OH-DPAT after iontophoresis (500 µA.cm-2) by the 
difference in pH, acetaminophen concentration and Na+ concentration.  The acceptor phase 
consisted of PBS pH 7.4. Results are presented as mean ± SD (n≥3). 
    
Donor phase  Results





























         
      
3.9 0 78 5  188.9 ± 25.5 n.a. n.a. n.a. 
3.9 15 78 5  210.4 ± 13.0 13.7 ± 3.4 6.5 ± 1.7 196.7 ± 13.4
3.9 15 78 6  214.3 ± 6.0 14.5 ± 1.0 6.8 ± 0.5 199.8 ± 6.0 
3.9 15 10 6  482.0 ± 36.8 14.7 ± 4.4 3.0 ± 0.9 467.3 ± 37.0
         
n.a.: not applicable 
Ace: acetaminophen 
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significant change in the contribution of JEO and JEM to the total flux of 5-OH-DPAT 
is observed when changing the pH of the donor solution from pH 5.0 to 6.0 (p>0.05).  
 Also depicted in Table 1, at a donor concentration of 3.9 mM 5-OH-DPAT a pH 
change from 5.0 to 6.0 does not significantly change the 5-OH-DPAT Fluxss 
(p>0.05). When focusing on the influence of 5-OH-DPAT on the acetaminophen 
flux, 3.9 mM 5-OH-DPAT buffered at either pH 5.0 or 6.0 does not change the 
acetaminophen flux demonstrating that 5-OH-DPAT does not change the negative 
charge of the HSC and thus does not change the permselectivity of the HSC (data not 
shown). 
3.3.2 Influence of competing ions in the donor phase on the iontophoretic flux of 5-
OH-DPAT  
The effect of NaCl in the donor compartment was studied. The total concentration of 
Na+ in the donor phase was either 10 mM (absence of NaCl) or 78 mM (addition of 
68 mM NaCl). The transport studies were conducted with 5 different donor 
concentrations of 5-OH-DPAT varying between 0.15 and 35.1 mM 5-OH-DPAT. 
Figure 2A shows the flux profile of 5-OH-DPAT (1.5 mM) when 10 mM or 78 mM 




























































Figure 2 A: Iontophoretic flux (500 µA.cm-2) vs time profile of 5-OH-DPAT solution (1.5 
mM) buffered at pH 6.0 in the presence of 10 mM (open square) and 78 mM Na+ (closed 
triangle). PBS pH 7.4 was used as acceptor phase. Data are presented as mean ± SD (n=3). 
B: The non-linear correlation of the Fluxss vs the donor concentration in the presence of 10 
mM (open square) and 78 mM Na+ (closed triangle) in the donor phase, buffered at pH 6.0. 
A current density of 500 µA.cm-2 was applied and PBS pH 7.4 was used as acceptor phase.
Data are presented as mean ± SD (n=3-6). 
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Na+ was present in the donor phase. Reduction of the amount Na+ in the donor phase 
augments the flux of 5-OH-DPAT dramatically. These results show a clear steady 
state flux when 78 mM Na+ is present in the donor phase. However when the amount 
Na+ present in the donor phase is 10 mM the flux is reduced gradually during the 
iontophoretic period. 
As shown in Figure 2B non-linear regression analysis showed a hyperbolic 
correlation between the Fluxss vs donor concentration when the Na+ content in the 
donor phase was 10 mM (R²=0.997) and 78 mM (R²=0.994). In the presence of NaCl 
the Fluxss of 5-OH-DPAT gradually increased from 9.4 ± 0.3 (0.15 mM 5-OH-
DPAT) to 775.0 ± 28.4 nmol.cm-2.h-1 (31.4 mM 5-OH-DPAT). In the absence of 
NaCl there was an increase in Fluxss of 5-OH-DPAT from 25.7 ± 2.8 (0.15 mM 5-
OH-DPAT) to 1081.9 ± 377.8 nmol.cm-2.h-1 (35.1 mM 5-OH-DPAT). Comparing the 
5-OH-DPAT Fluxss at equal donor concentrations, an enhancement factor varying 
between 2.5 and 3.0 is observed when the amount of competing co-ions in the donor 
phase was reduced. As presented in Table 1 the addition of 68 mM NaCl to the donor 
solution has no influence on the absolute value of the electroosmotic flux of 3.9 mM 
5-OH-DPAT in a donor solution, buffered at pH 6.0 (p>0.05).  
 
Table 2: Comparison of the steady state flux of 5-OH-DPAT when using PBS pH 7.4 or 
PBS pH 6.2 as acceptor phase at different donor concentrations. The donor phase consisted 
of 5-OH-DPAT buffered at pH 5.0, containing 78 mM Na+ and a current density of 500 
µA.cm-2 was applied. Results are presented as mean ± SD (n=4-9). 
  








1.5 69.8 ± 7.2 68.2 ± 8.2 
3.9 211.9 ± 11.1a 137.7 ± 8.6a
7.0 358.9 ± 28.5b 208.9 ± 10.2b
a,b: t-test: p<0.05 
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Figure 3: The acetaminophen flux vs time profiles, during iontophoresis using PBS pH 7.4 
(closed triangle) and PBS pH 6.2 (open square) as acceptor phase. A buffered donor 
solution (pH 6.0) containing 15 mM acetaminophen was used, applying a current density of 
500 µA.cm-². Data are presented as mean ± SD (n=3-4). 
 
3.3.3 Influence of the pH of the acceptor phase on the 5-OH DPAT iontophoretic 
flux 
All 5-OH-DPAT steady state fluxes (Fluxss) during iontophoresis with different 
acceptor phase are summarized in Table 2. At a concentration of 1.5 mM 5-OH-
DPAT no difference in steady state flux was observed (p>0.05), however at 
increased 5-OH-DPAT concentrations of 3.9 mM and 7.0 mM an acceptor phase at 
pH 6.2 resulted in a dramatically lower steady state flux (p<0.001) compared to the 
5-OH-DPAT iontophoretic Fluxss using an acceptor phase at pH 7.4.  
As the pH value of the acceptor phase had a strong affect on the 5-OH-DPAT 
iontophoretic flux, several studies were performed to unravel the underlying 
mechanism. A reduction in the pH in the acceptor phase may reduce the charge 
density of the HSC and therefore reduce its permselectivity. The permselectivity with 
an acceptor phase of either pH 7.4 or pH 6.2 was studied by iontophoretic transport 
of acetaminophen. A reduction in pH of the acceptor phase from pH 7.4 to pH 6.2 
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Figure 4: Bar plot of the osmolarity of the donor phase at different time points when using 
PBS pH 6.2 (white bar) or PBS pH 7.4 (black bar) as acceptor phase. The donor solution, 
buffered at pH 6, contained 10 mM Na+, a salt bridge was used and a current density of 500 
µA.cm-2 was applied. Data are presented as mean ± SD (n=4-5).  
 
resulted in a decrease in the Fluxss of acetaminophen from 86.4 ± 5.5 nmol.cm-2.h-1 to 
51.2 ± 16.1 nmol.cm-2.h-1 (p<0.05) (Figure 3), demonstrating that the permselectivity 
of the stratum corneum is indeed reduced at the acceptor phase of 6.2. The flux 
pattern remained unaffected. 
A change in the permselective properties may influence the flux of ions during 
iontophoresis across the stratum corneum from donor to acceptor phase and from 
acceptor to donor phase and therefore affect the osmolarity in the donor phase when 
changing the pH in the acceptor phase from 7.4 to 6.2. The osmolarity of the donor 
phase was measured using the same iontophoretic conditions as in the studies 
described in the previous section. The osmolarity expressed as % osmolarity of the 
original donor solution, at different time points during current application, is 
depicted in Figure 4. Simultaneous linear regression of osmolarity vs time shows a 
good correlation for both conditions (R2=0.8642 for pH 7.4 and R²=0.9835 for pH 
6.2) and shows a significant difference between the slopes of both regression lines (t-
test; p<0.05). Decreasing the pH of the acceptor phase from 7.4 to 6.2 causes a 
higher increase in osmolarity in the donor phase. 
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Figure 5: Iontophoretic flux vs time profile of 5-OH-DPAT, using a salt bridge. The 
following protocol was used: 2h passive+ 6h 125 µA.cm-² + 6h 250 µA.cm-² + 4h 500 
µA.cm-² + 6h passive. The anodal compartment consisted of 3.9 mM 5-OH-DPAT in citric 
buffer at pH 6, containing 10 mM Na+ and the acceptor compartment consisted of PBS pH 
7.4. Data are presented as mean  ± SD (n=6). 
 
3.3.4 Effect of current density on iontophoretic transport of 5-OH-DPAT 
The relationship between the Fluxss and the current density was studied when 3.9 
mM 5-OH-DPAT and 10 mM Na+ were present in the donor compartment (pH=6.0). 
During iontophoretic transport studies the current density was increased using 6h 
time intervals from 125 µA.cm-² to 250 µA.cm-² and finally to a current density of 
500 µA.cm-². As shown in Figure 5, in which the flux vs time profile is plotted, an 
increase in the current density every 6h resulted in a significant increase in flux, 
which reaches steady state within the 6h of iontophoresis. A current density of 125, 
250 and 500 µA.cm-2 resulted in a Fluxss of 116.9 ± 20.9 nmol.cm-2.h-1, 239.2 ± 25.2 
nmol.cm-2.h-1 and 432.3 ± 42.2 nmol.cm-2.h-1, respectively. Linear regression 
analysis of the steady state flux vs the current density, showed an excellent linear 
correlation (R2 = 0.996).  
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4 Discussion 
The principal transport mechanisms during iontophoresis of small charged medium 
hydrophilic compounds, like 5-OH-DPAT, are electroosmosis and electromigration. 
To calculate the relative contribution of electroosmosis, neutral hydrophilic marker 
molecules are used. The first aim of this study is to evaluate acetaminophen as 
marker molecule for the electroosmotic flow. The second aim is to investigate the 
transport mechanisms of iontophoretic delivery of 5-OH-DPAT and to optimize the 
iontophoretic delivery of this potent dopamine agonist. 
4.1 Acetaminophen as marker molecule for electroosmosis 
The hydrophilic neutral permeant, acetaminophen, is a generally accepted marker for 
quantification of the electroosmotic contribution to the iontophoretic delivery of 
different compounds [17-18, 23-25]. When a marker molecule is used to quantify the 
electroosmotic flow 3 assumptions are made: (i) the compound of interest and the 
marker molecule are transported by the convective flow in the same manner, (ii) the 
flux of the marker molecule is proportional to its concentration in the donor 
compartment and (iii) the marker molecule does not influence the flux of the drug of 
interest [20, 24]. If the molecular weight of the compound of interest is in the same 
range as the marker molecule (< 2x Mw of acetaminophen), it is reasonable to 
assume that both molecules are transported similarly by the current induced solvent 
flow.   
First with respect to the proportionality of the steady state flux of acetaminophen to 
the donor concentration our data show that the Fluxss of acetaminophen is linearly 
proportional to its donor concentration (R2=0.995). According to Equation 1, these 
results show that the water flow, Vw, quantified by the Fluxss of acetaminophen 
divided by the donor concentration, remains constant in the selected concentration 
range.  
Secondly with respect to the effect of acetaminophen on the 5-OH-DPAT 
iontophoretic transport, acetaminophen did not affect the iontophoretic 5-OH-DPAT 
transport. Our results show that acetaminophen is an excellent  marker molecule to  
determine the electroosmotic flow contribution to the iontophoretic transport of 5 
OH-DPAT. 
4.2 Electromigrative and electroosmotic contribution  
In subsequent studies acetaminophen was used as a marker molecule to determine 
the contribution of the osmotic flow to the total iontophoretic 5-OH-DPAT transport. 
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At a pH of 6.0 the relative contributions of the JEO and JEM were estimated between 
6.5-13.5% and between 86.5-93.2%, respectively. Reducing the pH of the donor 
phase from 6.0 to 5.0 gave a slight but not statistically significant decrease in the 
electroosmotic transport of 5-OH-DPAT. Furthermore, 5-OH-DPAT did not inhibit 
the electroosmotic flow across the skin during iontophoresis. Even when a salt bridge 
is used and a high amount of 5-OH-DPAT is transported across the skin, no change 
in electroosmotic flux was observed, which can be explained by the relative high 
hydrophilicity of 5-OH-DPAT [6, 26-27].  
4.3 Effect of competing ions in the donor phase 
Addition of NaCl to the donor solution is required for feeding the electrochemical 
reaction. However, Na+ competes with 5-OH-DPAT as a carrier of charge transfer 
for iontophoretic transport through the skin. The steady-state flux of 5-OH-DPAT 
reduced dramatically when the NaCl concentration was doubled from 70 to 140 mM 
[13]. The reduction of Na+ level in the donor phase from 78 mM to 10 mM resulted 
in a 2.5 to 3 fold increase in 5-OH-DPAT Fluxss. This increase in transport can be 
attributed to an increase in the electromigration, since the electroosmosis was 
unaffected by the amount of Na+ present in the donor solution.  
The steady state flux of 5-OH-DPAT reaches a plateau towards the maximum 
solubility of 5-OH-DPAT in the donor phase (Figure 2B). When using low 
concentrations 5-OH-DPAT a dependency of the transport number on the donor 
concentration can still be observed. The plateau towards the maximum Fluxss, 
depending on the physicochemical properties of 5-OH-DPAT is reached at lower 
donor concentrations when competition of co-ions was reduced [28]. Thereby 
focusing on the flux pattern during iontophoresis, as shown in Figure 2A, a 
concentration of 1.5 mM 5-OH-DPAT shows a steady state flux when 78 mM Na+ is 
present in the donor phase. However when Na+ concentration is reduced to 10 mM, 
the steady state 5-OH-DPAT flux is reduced gradually during the 6h iontophoresis 
period, which can be explained by a depletion of 5-OH-DPAT in the donor phase 
due to the high 5-OH-DPAT transport after the iontophoretic phase: almost 40.2 % 
has been transported through HSC.   
The good correlation between the Fluxss and the current density (Figure 5) and 
between the Fluxss and donor concentration in presence and absence of NaCl in the 
donor phase are very important for the therapeutic treatment of Parkinson’s disease. 
By modulation of these two parameters it will be possible to titrate the administered 
dose of this dopamine agonist, adjusted to the demand of the patient and to account 
for the inter- and intra-individual variability.  
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In the assumption that the same flux can be achieved in vivo and in vitro, it is 
possible to deliver approximately 1.00 µmol.cm-².h-1. Previous studies showed that 5-
OH-DPAT is more potent compared to rotigotine [12, 29]. Therefore it is reasonable 
to assume that the required dose of 5-OH-DPAT equal or lower than that of 
Rotigotine.  The rotigotine patch Neupro® (UCB, Schwarz Pharma, Monheim, 
Germany) delivers 8 mg rotigotine in 24h, which corresponds with approximately 25 
µmol rotigotine base (Mw=315.45 g/mol) [7, 30-31]. This means that for 5-OH-
DPAT (35 mM in the patch) in the presence of 68 mM NaCl and applying a current 
density of 500 μA.cm-2 a patch size of approximately 2.0 cm² (anode and cathode 
patch) would be sufficient to provide the required amount of 5-OH-DPAT in 
combination with iontophoresis. When the patch size is increased, the donor 
concentration and the current density can be reduced. In addition, the use of a salt 
bridge results in even higher fluxes and therefore it will be possible to administer the 
same dose with a reduced amount of 5-OH-DPAT or a reduced current density. 
4.4 Influence of the composition of the acceptor compartment  
Conducting iontophoresis experiments with a different acceptor phase can provide 
more detailed insight in the transport mechanism during iontophoresis, important for 
selecting those conditions that result in the most efficient iontophoretic drug 
transport. Therefore a series of transport studies were conducted to compare the 
iontophoretic delivery of 5-OH-DPAT with a pH of 6.2 or 7.4 in the acceptor phase. 
In the present study the acceptor phase pH was varied in order to provide more 
insight in the mechanisms involved in the transport of 5-OH-DPAT. Our studies 
show that at a pH of 7.4 in the acceptor phase, 5-OH-DPAT is transported more 
efficiently than at a pH of 6.2. Similar results were found by Lai et al., who observed 
that a decrease in acceptor pH from 7.4 to 4.5 resulted in a decrease in the 
iontophoretic transport of a series of local anaesthetics [32]. Whether this is due to an 
increase in the negative charge density in the stratum corneum and a subsequent 
reduction in Cl-- transport, can be studied by measuring the acetaminophen transport 
and osmolarity in the donor compartment. As demonstrated in Figure 3, the pH of the 
acceptor phase influences the permselective properties of the stratum corneum, as the 
flux of acetaminophen, when using an acceptor pH of 6.2 is significantly lower 
compared to an acceptor pH of 7.4. Whether this also increases the ion transport 
from acceptor to donor compartment is indirectly monitored by measuring the 
osmolarity in the donor compartment (Figure 4). During the iontophoretic period a 
higher increase in osmolarity is observed with the acceptor phase at pH 6.2 compared 
to that at pH 7.4, most probably due to a higher ion transport (Cl--ion) from acceptor 
to donor compartment. This results in an increased competition for charge transfer 
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and thus in a reduction in 5-OH-DPAT transport at pH of 6.2 compared to the 
transport at pH of 7.4 in the acceptor phase. As clearly shown the transport of 5-OH-
DPAT is strongly affected by the composition of the acceptor phase, which is in 
agreement with the high sensitivity of 5-OH-DPAT iontophoretic transport for 
competitive ions such as Na+ in the donor phase. 
In conclusion, the research described in this paper demonstrates the high transport 
efficiency of 5-OH-DPAT and elucidates different mechanisms involved in its 
iontophoretic transport. Optimization of the composition of the donor phase resulted 
in high fluxes, making the drug an excellent candidate for treatment of Parkinson’s 
disease using transdermal iontophoresis. Acetaminophen, identified as a good marker 
molecule for the quantification of the electroosmotic flux can be used in future 
transport studies to characterize the iontophoretic delivery of other molecules. 
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Abstract 
The transdermal delivery of a new salt form of the dopamine agonist rotigotine, 
rotigotine.H3PO4 is presented and compared with rotigotine.HCl. A comparison was 
made on the level of solubility, passive and iontophoretic delivery. Different aspects 
of the delivery were investigated: delivery efficiency, maximum flux, donor pH, 
electroosmotic contribution and transport number. Changing the salt form from 
rotigotine.HCl to rotigotine.H3PO4 increases significantly the solubility and rules out 
the influence of NaCl on the solubility by the absence of the common ion effect. At 
low donor concentration no difference in transdermal delivery was observed between 
the salt forms. Due to an increase in the maximum solubility of rotigotine.H3PO4, a 
170% increase in maximum flux, compared to rotigotine.HCl, was achieved. A 
balance between solubility and delivery efficiency can be obtained by choosing the 
correct donor pH between 5 and 6. A slight increase in electroosmotic contribution 
and transport number was observed. Using the parameters, determined by modeling 
the in vitro transport, in vivo simulations revealed that with iontophoresis therapeutic 
levels can be achieved with a rapid onset time and be maintained in a controlled 
manner by adjusting the current density. 
 
Keywords: solubility, transdermal, iontophoresis, rotigotine, salt form, modeling 
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1 Introduction  
Transdermal drug delivery is an attractive alternative for oral drug delivery and 
hypodermic injections. Different delivery methods have been investigated over the 
years to increase the drug delivery through the skin. One of the possibilities is 
iontophoresis. By applying a small current across the skin it is possible to enhance 
the transdermal delivery of small charged ionic molecules. One of the interesting 
properties of this technique is the possibility to modulate the transport rate into and 
through the skin. This is an important advantage for drugs with a narrow therapeutic 
window, such as dopamine agonists.  Rotigotine is a dopamine agonist used for the 
symptomatic treatment of Parkinson’s disease. Studies, investigating the transdermal 
iontophoretic delivery of rotigotine.HCl revealed that by applying an electrical 
current across the skin higher steady state fluxes can be achieved with a shorter lag 
time compared to passive delivery. However in these studies the maximum solubility 
of rotigotine.HCl in the donor phase appeared to be the limiting factor for its 
iontophoretic transport through the skin [1-3]. Increasing the solubility of rotigotine 
can be achieved by changing the donor solution, e.g. by adding surfactants or co-
solvents or changing the source of Cl--ions. Another possibility to improve the 
solubility is altering the salt form of the drug of interest. In transdermal iontophoretic 
delivery the chloride anion is often added to the donor phase at the anodal side to 
feed the electrochemical reaction. To increase the solubility of rotigotine, another 
counterion may be chosen to destabilize the crystal structure and therefore to  
increase the solubility of rotigotine in the buffer solution. In the current study, H3PO4 
was chosen as an alternative salt form for rotigotine. H3PO4 accounts for 2% of the 
FDA approved NCE’s in the period from 1995 to 2006, is biocompatible, has a low 
molecular weight and circumvents the common ion effect in the donor phase, making 
it a very interesting candidate as salt form for iontophoresis [4]. Moreover in 
literature very few reports, investigating different salt forms for transdermal delivery 
were described. Fang et al. studied the passive and iontophoretic delivery of three 
different salts of the anion diclofenac, showing that the counter ion can affect the 
transdermal delivery [5-6]. 
In the current study the solubility and transdermal delivery of rotigotine.H3PO4 were 
evaluated in comparison to rotigotine.HCl to illustrate the influence of the choice of 
a salt form on the passive and iontophoretic transport through the skin. In addition 
the in vitro transport of rotigotine.H3PO4 was analyzed with compartmental modeling 
and the parameters were used to evaluate the iontophoretic delivery in vivo in a series 
of simulations.  
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2 Materials and methods 
2.1 Materials 
Rotigotine.H3PO4 and rotigotine.HCl were kindly supplied by UCB Schwarz 
Biosciences GmbH (Monheim, Germany). Silver, silver chloride (purity>99.99%), 
Trypsin (Type III from bovine pancreas), trypsin inhibitor (Type II-S from soybean) 
and methanesulfonic acid were obtained from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). Acetaminophen was purchased from Brocacef (Maarsen, The 
Netherlands) and D-Mannitol was obtained from Scharlau Chemie S.A. (Barcelona, 
Spain). Spectra/Por® RC dialysis membrane sheets (cut off value of 6000-8000 Da) 
were purchased from Spectrum laboratories, Inc (Rancho Dominquez, Ca, USA). 
Acetonitrile was purchased from Biosolve (Valkenswaard, the Netherlands). All 
other chemicals and solvents were of analytical grade. All solutions were prepared in 
Millipore water with a resistance of more than 18 MΩ.cm.  
2.2 Solubility of rotigotine.H3PO4 
In order to compare the maximum solubility of rotigotine.H3PO4 with rotigotine.HCl, 
the solubility studies of rotigotine.H3PO4 were carried out as described by Nugroho 
et al. [3], who determined the solubility of rotigotine.HCl. Briefly, rotigotine.H3PO4 
was solubilized in 10 mM citric buffer at pH 4.0, 5.0 and 6.0 with and without the 
presence of NaCl. Subsequent adjustment of pH in each test tube was performed by 
alternatingly adding small quantities of 1M NaOH under continuous shaking and 
subsequent pH measurements, until the pH of each solution had stabilized at the 
original buffer value. Each solution was shaken for an additional 48h, after which 
each solution was centrifuged and filtered. The concentration in each solution was 
determined by HPLC.   
2.3 Capillary electrophoresis 
The electrophoretic mobility of rotigotine.HCl and rotigotine.H3PO4 was investigated 
with capillary electrophoresis (CE). These experiments were performed according to 
a method, described elsewhere [7]. Briefly, the electrophoretic mobility of the 
samples (0.5 mM) was determined in triplicate using a phosphate buffer pH 7.4 
(Na2HPO4: 5.82 g.l-1; NaH2PO4: 5.1 g.l-1) as electrolyte solution (mobile phase). 
2.4 Preparation of human stratum corneum 
The preparation of human stratum corneum (HSC) was performed according to the 
method described previously [8]. Briefly, within 24h after surgical removal of the 
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human skin residual subcutaneous fat was removed. Dermatomed human skin (DHS) 
was obtained by dermatoming the skin to a thickness of about 300 µm. In order to 
obtain HSC, DHS was incubated with the dermal side on Whatman paper soaked in a 
solution of 0.1% trypsin in 150 mM phosphate buffered saline (PBS) pH 7.4 (NaCl: 
8 g.L-1, Na2HPO4: 2.86 g.L-1, KH2PO4: 0.2 g.L-1, KCl: 0.19 g.L-1) overnight at 4 °C 
and subsequently for 1h at 37 °C after which HSC was peeled off from the 
underlying viable epidermis and dermis. HSC was subsequently washed in a 0.1% 
trypsin inhibitor solution in Millipore water and several times in water and stored in 
a desiccator in a N2 environment.  
2.5 in vitro transport studies 
A 9-channel computer controlled power supply was used to provide a constant direct 
current (Electronics Department, Gorlaeus Laboratories, Leiden University, The 
Netherlands) during iontophoresis. The system was equipped with differential input 
channels per current source enabling on-line measurement of the electric resistance 
across HSC in each diffusion cell. Ag/AgCl was used as driver electrode pair. All 
transport experiments were carried out, using a three chamber continuous flow 
through cell as described elsewhere [8]. The donor formulation, buffered with a 10 
mM citric buffer, was applied at the anodal side. The cathodal chamber was filled 
with PBS pH 7.4. The acceptor phase, maintained at 32°C, was continuously 
perfused with PBS pH 6.2 (NaCl: 8 g.L-1, KCl: 0.19 g.L-1, Na2HPO4.2H2O: 0.43 g.L-
1, KH2PO4: 0.97 g.L-1) at a flow rate of 7.0 ml.h-1. Unless described elsewhere, the 
following protocol for the iontophoresis experiments was used: 6h of passive 
diffusion, followed by 9h of iontophoresis with a current density of 500 µA.cm-² and 
5h of passive diffusion. Samples were collected every hour with an automatic 
fraction collector (ISCO Retriever IV, Beun De Ronde BV, Abcoude, The 
Netherlands). The specific conditions of the individual transport studies are 
described below.  
2.5.1 Flux of rotigotine.H3PO4 vs rotigotine.HCl 
The donor concentration of rotigotine.H3PO4 and rotigotine.HCl was kept constant 
(3.7 mM). The donor phase was buffered at pH 5.0 and contained 68 mM NaCl.  
2.5.2 Fluxss vs donor concentration rotigotine.H3PO4 and influence of pH 
In these transport studies 4 different concentrations rotigotine.H3PO4 (4.4 mM, 9.5 
mM, 22.2 mM and 47.5 mM), buffered at pH 5.0, were used. Thereby the transport 
of rotigotine.H3PO4 (4.4 and 13.0 mM), buffered at pH 6.0 was investigated as well. 
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All transport experiments were performed in the presence of 68 mM NaCl in the 
donor phase.   
2.5.3 Electroosmotic flow 
The donor concentration of rotigotine.H3PO4 was 3.9 mM and 11.6 mM. 
Acetaminophen (15 mM) was added to the donor phase as a marker for the 
electroosmotic flow. The donor phase was buffered at pH 5.0 and contained 68 mM 
NaCl.  
2.5.4 Current density flux-relationship 
The relationship between the current density was studied with a rotigotine.H3PO4 
concentration of 31.3 mM, buffered with a citric buffer at pH 5.5, containing 68 mM 
NaCl. The following protocol was used: 6h passive+ 6h 166 µA.cm-²+ 6h 333 
µA.cm-² + 6h 500 µA.cm-² + 6h passive.  
2.6 Analytical method 
Prior to and at the end of a transport study the pH of donor and acceptor 
compartment was measured. All samples of the iontophoretic transport studies were 
analyzed by RP-HPLC using a Superspher® 60 RP-select B, 75 mm-4 mm column 
(Merck KGaA, Darmstadt, Germany). Rotigotine was detected using a scanning 
fluorescence detector (Waters™ 474, Millipore, Milford, MA, USA) at excitation 
and emission wavelengths of 276 and 302 nm. Acetaminophen was detected using a 
UV detector (Dual λ Absorbance Detector 2487, Waters, Milford, USA) at a 
wavelength of 254 nm. Filtered and degassed mobile phase contained 60% H2O 
(v/v), 40% ACN (v/v) and 0.05% methanesulfonic acid (v/v). The injection volume 
was 50 µL and the flow rate was set to 1.0 mL.min-1.  
The concentration of rotigotine was quantified according to 3 standards with a 
concentration of 0.005, 2 and 5 µg.mL-1. The intra-assay variation of the retention 
time and of the area was less then 2.0%. For acetaminophen, calibration curves 
showed a linear response when using concentrations of compounds between 0.1 and 
40 µg.mL-1 (R2>0.9999). The limit of detection (LOD) and limit of quantification 
(LOQ) of acetaminophen were experimentally determined at 5.8 and 9.6 ng.mL-1 
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2.7 Determination of the passive, electroosmotic and electromigrative flux 
The total iontophoretic flux consists of the passive flux (Jpass), the electroosmotic 
flux (JEO) and the electromigrative flux (JEM). The passive flux is calculated during 
6h prior to the iontophoretic phase. The neutral permeant acetaminophen was added 
to the donor solution as a marker molecule for quantification of the electroosmotic 
flow during iontophoretic transport. The electromigrative flux is calculated by 
subtracting the passive and electroosmotic flux from the total flux. 
2.8 Data analysis 
To calculate the steady state flux during passive and iontophoretic transport, the 
cumulative flux of the transport was plotted as a function of time. The steady state 
flux was estimated from the linear part of the slope of this plot according to the 
permeation lag-time method [8]. All data are presented as mean ± standard deviation 
(SD). When a statistical analysis was performed comparing only 2 groups, a 
Student’s t-test was used. When 3 or more groups were compared, a 1-way ANOVA 
statistical analysis was executed. If the overall p-value was less than 0.05, a 
bonferonni post-test was applied to compare different groups. For all statistical 
analysis a significance level of p<0.05 was used.  
2.9 in vitro modeling and in vivo simulation 
Next to the permeation lag-time method the data of the in vitro transport of 
rotigotine.H3PO4 at the selected condition (donor pH 5.0, donor conc 47 mM) was 
analyzed using non-linear mixed effects modeling with the compartmental models 
described elsewhere [9]. Briefly, in these models the starting point was a zero order 
mass transport from the donor solution into the skin during and after iontophoresis. 
The equations, to describe in vitro iontophoretic transport during current application: 
( ) )1()( .0 LR ttKe
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Where J(t) is the flux at time t and S is the diffusion area, KR is a first order skin 
release rate constant, I0 the zero-order iontophoretic mass transfer from the donor 
compartment into the skin compartment during current application, tL is the kinetic 
lag time parameter, introduced to address the time required for drug molecules to 
enter the skin compartment, T is time of current application and PPI is the zero order 
drug input due to the passive driving force in the post iontophoretic period. Fitting 
the data was performed using the subroutines ADVANCE6 TRANS1 TOL=5 from 
PREDPP in NONMEM (NONMEM version VI). Interindividual variability was 
modeled using an exponential error model and the residual error was characterized 
by an exponential and additive error model. The estimates of the population 
parameters were performed using a conventional first order method. The model was 
evaluated graphically by plotting the population predicted vs the observed flux and 
the individual predicted vs the observed flux. Finally, from the final parameter 
estimates a number of 100 samples were simulated. Post processing of NONMEM 
simulations creating plots of visual predictive check (VPC) was done using xpose 4, 
implemented in the software R (R version 2.7.0, R-foundation) [10]. 
The pharmacokinetic model used to simulate the iontophoretic delivery of rotigotine 
was based on a model, described elsewhere [9]. Assuming a 1-compartment model, 
different protocols were investigated for simulating the pharmacokinetic profile of 
iontophoretic delivery of rotigotine.H3PO4 during 24h using a patch size of 10 cm2:  
Protocol 1: 24h 350 μA.cm-2 
Protocol 2:  5h 350 μA.cm-2 + 19 h 150 μA.cm-2 
At time=24h the patch was removed. In this case the simulations were performed 
with the $SIMULATION function provided in NONMEM. A population of 5 
subjects was simulated and the simulated population prediction was displayed 
graphically.  
3 Results 
3.1 Solubility and electrophoretic mobility of rotigotine.H3PO4 
The results of the solubility assay of rotigotine.H3PO4 are presented in Table 1. At 
the selected pH values the addition of NaCl did not affect significantly the solubility 
of rotigotine.H3PO4 (2-way ANOVA; p>0.05). This is in contrast with the results 
obtained with rotigotine.HCl by Nugroho et al. [3]. For rotigotine.HCl the solubility  
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Table 1: The solubility of Rotigotine.H3PO4 and Rotigotine.HCl in different medium at 
pH 4.0, 5.0 and 6.0 in the presence and absence of 68 mM NaCl (n=2-3). 
 Rotigotine.H3PO4 Rotigotine.HCl* 
    
No NaCl 68 mM NaCl  No NaCl 68 mM NaCl  
mM mM mM mM 
pH 
(mean) (mean) (mean ± SD) (mean ± SD) 
          
4.00 83.48a 80.08c 24.39 ± 4.66 a,b 6.75 ± 0.31 b,c 
5.00 41.89a 42.95c 22.45 ± 0.63 a,b 6.35 ± 0.34 b,c 
6.00 15.67 14.44d 15.87 ± 1.25  b 6.52 ± 0.17 b,d 
*values obtained from literature: [3] 
a-c: p<0.001; d: p<0.01 
reduced tremendously after adding 68 mM NaCl. Furthermore decreasing the pH of 
the donor phase from 6.0 to 5.0 and again to pH 4.0 resulted in a significant increase 
in the solubility of rotigotine.H3PO4 (2-way ANOVA; p<0.05). The electrophoretic 
mobility of rotigotine.H3PO4 (1.53 ± 0.02 x10-4 cm2.s-1.V-1) showed no significant 
difference with the electrophoretic mobility of rotigotine.HCl (1.49 ± 0.04 x10-4 
cm2.s-1.V-1) (t-test; p=0.134). 
3.2 Passive diffusion of rotigotine.H3PO4  
A series of iontophoretic transport studies under various conditions were performed. 
During 6h prior to iontophoresis no current was applied and passive transport 
reached steady state conditions within this period. From the slope of the linear part of 
the cumulative flux vs time profile the passive steady state flux (Fluxpss) was 
calculated. Firstly, rotigotine.H3PO4 and rotigotine.HCl both at a concentration of 3.7 
mM, buffered at pH 5.0, showed no significant difference in Fluxpss (t-test; p>0.05) 
(Table 2). Secondly, the results of transport studies of rotigotine.H3PO4 at various 
donor concentrations, comparing a donor pH of 5.0 and 6.0 are depicted in Figure 1. 
A non-linear hyperbolic fit showed a correlation between the Fluxpss and the donor 
concentration at pH 5.0 (R2=0.889). Increasing the pH of the donor phase from 5.0 to 
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Table 2: Comparison of the steady state passive flux (Fluxpss) and the steady state 
iontophoretic flux (Fluxss) of Rotigotine.H3PO4 with Rotigotine.HCl at pH 5.0 in the 
presence of 68 mM NaCl. Results are presented as mean ± SD (n=3-4). 
 Fluxpss Fluxss 
    
 mM nmol.cm-2.h-1 nmol.cm-2.h-1 
 (mean ± SD) (mean ± SD)  
    
3.77 1.7 ± 0.8 69.4 ± 6.4 Rotigotine.HCl 
3.74 1.6 ± 0.4 73.8 ± 12.6 Rotigotine.H3PO4 
6.0 increased the passive flux of rotigotine.H3PO4 quite drastically: Close to 
saturation of rotogotine.H3PO4 in the donor phase the maximum flux that could be 
achieved was 10.8 ± 1.9 nmol.cm-2.h-1 at pH 5 and 24.9 ± 2.5 nmol.cm-2.h-1 at pH 
6.0. 
3.3 Iontophoresis of rotigotine.H3PO4 
A series of iontophoretic transport studies was conducted to investigate the 
iontophoretic transport of rotigotine.H3PO4 specially focusing on: (i) comparison 
with the iontophoretic flux of rotigotine.HCl, (ii) the relationship between the flux 
and donor concentration, (iii) the influence of the pH, (iv) the contribution of the 
electroosmotic flow and (v) the determination of the transport number. 
3.3.1 Flux of rotigotine.H3PO4 vs rotigotine.HCl  
During the transport studies after 6h of passive diffusion a current density was 
applied of 500 µA.cm-2 during 9h. The steady state flux (Fluxss) of rotigotine.H3PO4 
during iontophoresis showed no significant difference to the Fluxss of rotigotine.HCl 
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Figure 1: The Flux(p)ss of rotigotine.H3PO4 during the passive phase (square) (no current) 
and the iontophoretic phase (triangle) (current density=500 µA.cm-2) at various donor 
concentrations at donor pH 5.0 (closed) and pH 6.0 (open). The correlation of the Flux(p)ss 
vs donor concentration was determined at pH 5.0. The line of correlation of passive 
Fluxpss vs donor concentration is full and the line of correlation of the iontophoretic Fluxss 
vs donor concentration is intermittent. Data are presented as mean ± SD (n=3) 
 
3.3.2 Fluxss as function of donor concentration rotigotine.H3PO4 and influence of 
pH in donor formulation 
As shown in Figure 2, current application resulted in an immediate increase in the 
flux of rotigotine.H3PO4, which reached steady state within 4h. The results of a series 
of iontophoretic transport studies of rotigotine.H3PO4 at pH 5.0 and pH 6.0 are 
depicted in Figure 1. A non-linear relationship could be described between the Fluxss 
and the donor concentration at pH 5.0 (R2=0.825). Thereby the Fluxss at equal 
rotigotine.H3PO4 concentration increased with increasing pH of the donor solution. 
However, close to saturation in the donor phase, the Fluxss at pH 5.0 (135.8 ± 12.5 
nmol.cm-2.h-1) was not significantly different from the Flux at pH 6.0 (127.3 ± 4.0 
nmol.cm-2.h-1) (t-test; p>0.05).  
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Figure 2: The iontophoretic flux vs time profile of rotigotine.H3PO4 dissolved in citric 
buffer pH 5 at 2 different concentrations, 9.5 mM (open square) and 22.0 mM (closed 
triangle). Data are presented as mean ± SD (n=3) 
3.3.3 Electroosmotic contribution 
To quantify the electroosmotic contribution acetaminophen was co-transported with 
rotigotine. The electroosmotic flux was investigated at two different concentrations 
rotigotine.H3PO4 (3.9 and 11.6 mM) at pH 5.0 in the donor phase. The relative 
contributions of Jpass, JEO and JEM are depicted in Figure 3. With increasing donor 
concentrations the relative contribution of the passive flux significantly increased 
from 13.1 ± 0.1% for 3.9 mM to 17.6 ± 0.1% for 11.6 mM (t-test; p<0.05). An 
increase in rotigotine.H3PO4 concentration from 3.9 mM to 11.6 mM resulted in a 
significant decrease in the relative contribution of the electroosmotic flow from 5.1 ± 
0.1 % to 2.8 ± 0.3 % (t-test; p<0.05). Electromigration was the main driving force 
and accounted for 81.8 ± 0.03 and 79.5 ± 0.1 % of the total flux of 3.9 mM and 11.6 
mM rotigotine.H3PO4, respectively.  
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Figure 3: The relative contribution of the passive (grey), electroosmotic (black) and 
electromigrative (white) flux to the total (100%) flux of rotigotine.H3PO4 at 2 different 
concentrations (3.9 and 11.6 mM). The donor phase was buffered at pH 5 and the applied 
current density was 500 µA.cm-2. Data are presented as mean ± SD (n=3) 
 
3.3.4 Determination of transport number 
With increasing pH from 5.0 to 6.0 a decrease in solubility, but an increase in 
delivery efficiency was observed. At pH 5.5 a balance is expected between 
maximum solubility and delivery efficiency. At this selected pH under near to 
saturated conditions the transport number was determined. Therefore in a single 
experiment the relationship between the Fluxss and the current density was studied 
with a donor phase containing 31.3 mM rotigotine.H3PO4, which was 90% of the 
maximum solubility of rotigotine.H3PO4.  
An increase in the current density resulted in a significant increase in flux, which 
reached steady state within 6h of current application. A current density of 0 µA.cm-² 
(passive phase), 166 µA.cm-², 333 µA.cm-² and 500 µA.cm-² resulted in a Fluxss of 
24.4 ± 1.9 nmol.cm-2.h-1, 65.8 ± 9.3 nmol.cm-2.h-1, 109.7 ± 15.7 nmol.cm-2.h-1 and 
154.5 ± 27.0 nmol.cm-2.h-1, respectively.  An excellent linear correlation could be 
observed between the Fluxss and the current density (R²=0.999). The transport 
number was calculated from the slope of the correlation at 0.7%. 
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Table 3: Best fit-results of the estimated parameters, steady state flux (Fluxss) release 
constant (KR), the lag time (tL) and the passive flux post iontophoresis (pass) and 
comparison to the value obtained with the permeation lag time method. The data are 
presented as mean and standard error of the mean (SEM). Furthermore values of the 
elimination constant (ke), clearance (Cl) and apparent volume of distribution, considering 
the bioavailability (Vd/F) of rotigotine as found in literature, are depicted. 
  Model prediction 




 Unit Best fit 
value 
SEM Best fit 
value 
SEM  
Fluxss nmol.cm-².h-1 135 3.56 135.8 4.18  
KR h-1 1.08 0.04 n.d. n.d.  
tL h-1 negligible n.d. n.d.  
pass h 0.4 n.d. n.d.  12.3 
h-1   0.125 ke 
L.h-1   450 Cl 
L   3600 Vd/F 
*values obtained from ref. [11-17] 
n.d. not determined 
 
  
3.4 Modeling in vitro iontophoretic transport of rotigotine.H3PO4 
The in vitro iontophoretic transport across HSC was analyzed using compartment 
modeling. The kinetic model to describe the flux was based on zero-order mass 
transport from donor to skin and a first order release from skin to acceptor. The best-
fit results and the standard error of the mean (SEM) of Fluxss, the first order release 
constant (KR), the lag time (tL) and the passive flux post iontophoresis (pass) can be 
found in Table 3. No significant difference could be observed between the best fit of 
Fluxss, estimated by the compartmental model and by the permeation lag-time 
method (t-test; p>0.05). The quality of fitting and model parameter estimation was 
evaluated graphically. The diagnostic plots of the model can be found in Figure 4. 
The population predicted (PRED) vs the observed flux (Figure 4A) and the  
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Figure 4: Diagnostic plots of the compartemental modeling of the in vitro iontophoretic 
transport of rotigotine (47 mM), buffered at pH 5. A: plot of the population predicted flux 
(PRED) vs the observed flux. B: plot of the individual predicted flux (IPRED) vs the 
observed flux. C:Visual predictive check of the in vitro model: raw data superimposed on 
median, 2.5th and 97.5th percentiles of data simulated from model. Median (full line); 2.5th 
and 97.5th percentile (dashed line; raw data (open circle) 
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individual predicted (IPRED) vs the observed flux (Figure 4B) show that the model 
can describe adequately the in vitro iontophoretic transport. Moreover the visual 
predictive check, displayed in Figure 4C demonstrates that the observed data are well 
distributed in the 95% confidence interval of the simulated data. This suggests that 




In a previous study one of the major limitations in the iontophoretic transport of 
rotigotine.HCl was its low solubility. The maximum solubility of rotigotine.HCl was 
only 7.1 ± 0.4 mM at pH 5.0. In that study the iontophoretic transport at varying 
rotigotine.HCl concentrations between 1.4 and 3.9 mM showed a linear relationship 
between the Fluxss and the donor concentration [2]. This demonstrated that the 
maximum iontophoretic flux of rotigotine was not yet achieved, but the low 
solubility of rotigotine.HCl was the limiting factor for further increasing the 
iontophoretic flux. Higher donor concentrations could be achieved by replacing HCl 
by another salt [20-21]. As shown in Table 1, in the presence of 68 mM NaCl, the 
solubility of rotigotine increased substantially when HCl was replaced by H3PO4. 
Compared to rotigotine.HCl the solubility of rotigotine.H3PO4 is 2, 6, 10 fold higher 
at pH 6.0, 5.0 and 4.0, respectively. Furthermore in contrast to the solubility of the 
HCl-salt the presence of NaCl did not affect the solubility of rotigotine.H3PO4. This 
can be explained by an absence of the common ion effect. The next step was to 
investigate the transdermal delivery of rotigotine as H3PO4 salt. 
4.2 in vitro transdermal delivery  
The transdermal passive delivery of rotigotine.H3PO4 (3.77 mM) was investigated in 
comparison with rotigotine.HCl at the same donor concentration (3.74 mM). At pH 
5.0 no difference in passive delivery could be observed. The solubility of 
rotigotine.HCl at pH 5.0 was lower compared to the solubility of rotigotine.H3PO4. 
The higher thermodynamic activity of rotigotine.HCl under these conditions was 
expected to result in a higher passive flux for rotigotine.HCl [22]. It seems that 
replacement of HCl by H3PO4 in the rotigotine salt not only increases the solubility 
of rotigotine, but also increases the efficiency in passive transport of rotigotine 
across HSC. In analogy to the passive flux, no difference in total iontophoretic flux 
could be observed between rotigotine.H3PO4 (3.77 mM) and rotigotine.HCl (3.74 
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mM). This observation is strengthened by the observed equal electrophoretic 
mobility of both salt forms, determined with capillary electrophoresis. This indicates 
that under these conditions an equal part of the current is carried by rotigotine, 
regardless it salt form, resulting in the same total iontophoretic flux. 
The use of rotigotine.H3PO4 compared to that of rotigotine.HCl has two major 
advantages. (i) Increasing the donor pH from 5.0 to 6.0 significantly increases the 
passive flux of rotigotine.H3PO4. The maximum solubility of rotigotine.H3PO4 at pH 
6.0 is much lower than at pH 5.0. Consecutively the thermodynamic activity at equal 
concentration of this compound is higher at pH 6.0, which results in an increased 
passive diffusion [23]. Due to this increase in passive flux, an increase in total flux 
during the iontophoresis period was also observed with increasing pH. In contrast, 
the total iontophoretic flux of rotigotine.HCl did not change when the pH was 
increased from 5.0 to 6.0 [3]. (ii) The second advantage is the increase in maximum 
solubility of rotigotine.H3PO4 compared to that of rotigotine.HCl. Due to a higher 
maximum solubility of the phosphate salt, higher donor concentrations of rotigotine 
can be obtained. Iontophoretic delivery of higher donor concentrations results in an 
increase in the maximum iontophoretic transport. At pH 5.0 the maximum 
iontophoretic flux of rotigotine.HCl was 80.2 ± 14.4 nmol.cm-2.h-1, while with 
rotigotine.H3PO4 a maximum flux of 135.8 ± 12.5 nmol.cm-2.h-1 was achieved [2]. 
This means that the maximum flux can be increased with 170% by replacing the HCl 
salt with a H3PO4 salt. Besides a higher flux another practical advantage can be 
established when using a high donor concentration at pH 5.0. Calculations revealed 
that after 24h, maintaining a maximum flux of 135.8 nmol.cm-².h-1, the amount 
rotigotine.H3PO4 in the donor phase decreased with 35%. This decrease in donor 
concentration would result only in a decrease of 10% in steady state flux. This shows 
that with a high donor concentration a high flux can be maintained for a long time. 
Taking these results together, one must seek a balance between transport efficiency 
and donor concentration by choosing the pH of the donor solution. On one hand by 
increasing the pH it is possible to increase the transport efficiency, however the 
limited solubility of the compound at pH 6.0 prevents the use of a high 
concentration. On the other hand at pH 5.0 the transport efficiency is lower, 
nonetheless a high flux can be established for a long time due to the higher solubility 
of rotigotine.H3PO4. 
The total flux is driven by the passive, the electromigrative and the electroosmotic 
flux. The electroosmotic contribution of rotigotine.H3PO4, estimated at 5%, is higher 
than the electroosmotic contribution of rotigotine.HCl, calculated at 2.3% [2]. This is 
mainly due to the higher concentration of rotigotine.H3PO4 in the donor formulation. 
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Nonetheless the main driving force of the iontophoretic delivery of both salt forms 
remains electromigration, and in case of rotigotine.H3PO4 accounts for 
approximately 80% of the total flux at two different concentrations (Figure 3). The 
transport number of rotigotine.H3PO4 at pH 5.5 was estimated from the slope of 
relationship between the Fluxss and the current density at 0.7%. This is higher than 
the transport number of rotigotine.HCl (0.4%) at pH 5.0, which can be explained by 
a higher donor concentration of rotigotine.H3PO4 [2].  
4.3 From in vitro modeling to in vivo simulation 
After characterizing and optimizing the transdermal delivery of this promising 
compound in vitro, the potential of the iontophoretic delivery of rotigotine in vivo 
was evaluated. A series of simulations was performed, using pharmacokinetic 
modeling. The first step was to determine the parameters driving the iontophoretic 
delivery in vitro across human stratum corneum of rotigotine.H3PO4 (47 mM), 
buffered at pH 5.0. The value of the Fluxss corresponds well with the value estimated 
by the permeation lag time method (Table 3). In addition, diagnostic plots of the data 
modeling (Figure 4) confirm that this model successfully describes the in vitro 
Protocol 1:
24h 350 μA.cm-2



















5h 350 μA.cm-2 + 19h 150 μA.cm-2














Figure 5: Population prediction of the simulations of iontophoretic delivery of 
rotigotine.H3PO4 (47 mM) using different protocols: Protocol 1: 24h 350 μA.cm-2; 
Protocol 2: 5h 350 μA.cm-2 + 19h 150 μA.cm-2. The open circles are the population 
prediction of the simulated plasma concentration (Cp). 
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iontophoretic transport of rotigotine.H3PO4. In the next step the apparent 
pharmacokinetic parameters of rotigotine, reported in literature, are combined with 
the best-fit values of Fluxss, KR and tL to predict the plasma levels in vivo [11-17]. A 
comparison was made with the passive delivery of rotigotine. Neupro®, a passive 
transdermal delivery system of rotigotine, is approved by the EMEA for 
symptomatic treatment of Parkinson’s disease [24]. The patch delivers 1 to 8 mg 
rotigotine in 24h, depending on the patch size. As reported in literature, passive 
delivery of rotigotine with a patch size of 10 cm2, estimated to deliver 2 mg in 24h, 
resulted in a maximum plasma concentration (Cmax) of 215 pg.ml-1 at 16 h [16]. Two 
different protocols were used to evaluate the iontophoretic delivery of rotigotine (47 
mM, pH 5.0) during 24h. As shown in Figure 5 applying a current density of 350 
µA.cm-2 during 24h (protocol 1) is expected to result in Cmax of 630 pg.ml-1. Not only 
can a higher flux be established with iontophoresis, but more interestingly already at 
time=5h a plasma concentration of 240 pg.ml-1 can be reached. Therefore the in vivo 
iontophoretic delivery of rotigotine was simulated using protocol 2, applying initially 
a current density of 350 µA.cm-2 for 5h, after which the current density was 
decreased to 150 µA.cm-2. These simulations demonstrate two very important 
advantages of iontophoretic delivery of rotigotine in combination with iontophoresis 
over transdermal passive diffusion. Firstly, because of active transdermal delivery 
the onset time to achieve the desired level can be significantly decreased. Secondly, 
by adjusting the current density a titration of the plasma concentration is possible, 
making it feasible to individually modulate the delivery according to the desired 
dosing regimen. Both advantages can be of great benefit for symptomatic treatment 
of Parkinson’s disease.  
In conclusion despite the lipophilicity of rotigotine, high levels can be achieved with 
transdermal iontophoretic delivery with a rapid onset time, making it a very 
promising compound for symptomatic treatment of Parkinson’s disease. Thereby 
changing the salt form of a drug can improve the physicochemical properties and 
consequently the maximal transdermal transport of a therapeutic drug, without 
changing its major transport mechanisms. 
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CHAPTER 5   
Abstract  
The transdermal iontophoretic delivery of a novel series of 2-aminotetraline and 
chromanamine based dopamine agonists was investigated in vitro. Systematic 
structural modifications allowed us to investigate their effect on solubility in the 
donor phase and iontophoretic delivery across human skin. Transport profiles were 
analyzed with nonlinear mixed effect modeling, utilizing an extension to an existing 
compartmental model. Furthermore relationships between physicochemical 
properties and transport parameters were addressed. A solubility increase was 
observed: 5,6-di-OH-DPAT < 5-OH-MPAT < 5-OH-EPAT < 8-OH-DPAC. The 
structure significantly affected the iontophoretic delivery across human stratum 
corneum and dermatomed human skin with the highest flux for 5-OH-EPAT and 5-
OH-MPAT. The extended model with two skin release constants (KR1, KR2) 
describes more adequately iontophoretic transport profiles than the existing model 
with one release constant. The extended model suggests 2 parallel transport pathways 
during current application. Across human stratum corneum the electrophoretic 
mobility, measured with capillary electrophoresis, showed a linear relationship with 
the electromigrative flux and the zero order iontophoretic mass input into the skin 
(I0). Combining transport parameters (I0, KR1 and KR2), predicted from 
physicochemical properties, with compartmental modeling provides a powerful tool 
to simulate iontophoretic transport profiles for screening potential candidates and 
designing experiments. 
  
Keywords: transdermal, iontophoresis, dopamine agonists, modeling, transport 
pathway 
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Figure 1: The chemical structures of different dopamine agonists   
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1 Introduction  
Transdermal iontophoresis enhances the delivery of small charged solutes across the 
skin by application of a small current (≤0.5 mA.cm-²) across this membrane. 
Important advantages of transdermal delivery are circumvention of the hepatic first-
pass effect and a continuous administration of the drug. A particular advantage of 
iontophoresis is the possibility to adjust the rate of delivery by changing the current 
density [1]. For the symptomatic treatment of Parkinson’s disease (Pd) the current 
strategy is to administer therapeutic agents in a continuous manner to reduce the 
induction of motor fluctuations after long term use [2-4]. Most of the dopamine 
agonists have a very narrow therapeutic window, which demands for an accurate 
individualized titration, adjusted to the needs of the therapy [5-6]. For these reasons, 
the in vitro and in vivo iontophoretic delivery of dopamine agonists, such as 
apomorphine, ropinorole, 5-OH-DPAT and rotigotine, have been intensively 
investigated [7-16].  
To improve the transport efficiency and consequently the therapeutic treatment of 
Pd, a good understanding is required about the structure-transport relationship. 
However, with respect to this class of drugs little is known about the structure-
transport relationship. In the present study the in vitro iontophoretic delivery is 
investigated of a new series of dopamine agonists, which were selected based on 
their potency and their molecular structure [17-23]. The small structural differences 
allow us to investigate in detail the influence of molecular structure and related 
physicochemical properties of the dopamine agonists on the iontophoretic transport 
efficiency.  
During the years several studies have focused on selecting the key physicochemical 
properties that determine the transdermal iontophoretic delivery efficiency. It has 
been reported that the size of the solute, expressed as molecular weight (Mw) or 
molecular volume (MV), is an important descriptor with a higher transport for 
smaller molecules [24-26]. Furthermore, an increase in charge/Mw ratio results in an 
increase in transdermal electromigrative flux, as was observed for a series of 
peptides [27]. In a follow up study by Abla et al. the electrophoretic mobility, 
measured by capillary zone electrophoresis (CZE), provided an estimation of the 
electromigrative flux [28]. Finally, the lipophilicity of the transported molecules also 
affects the transdermal iontophoretic transport, however the relationship with the 
corresponding transport efficiency is not so straightforward as with passive diffusion 
[29-30].  
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Most of these physicochemical property-transport relationships use a single 
parameter to describe the transdermal iontophoretic flux. As a single end-point the 
flux at the end of the iontophoresis period or the steady state flux and lag time are 
often selected. However in these approaches, the information on the shape of the 
iontophoresis transport curve is neglected, which makes extrapolation towards the in 
vivo situation more difficult. The mathematical models, introduced by Nugroho et 
al., were designed to overcome the aforementioned disadvantages and to make the 
extrapolation from the in vitro to in vivo transport studies more reliable [16, 31-32]. 
The proposed models were based on a commonly used assumption for iontophoresis, 
namely a constant mass input into the skin during iontophoresis due to the constant 
iontophoretic driving force resulting from the application of a constant current. An 
adapted model, based on the compartmental models introduced by Nugroho et al. 
[16, 31], is presented and applied to describe the iontophoretic flux profile of this 
series of dopamine agonists. In this study the relationship between the 
physicochemical properties and the transport is addressed, using the electromigrative 
flux as single end-point and using the adapted model describing the total 
iontophoretic flux profile. 
The objectives of the present work are: (i) to investigate the transdermal 
iontophoretic delivery in vitro of a new series of dopamine agonists, (ii) to evaluate 
the adapted mathematical compartmental model to describe the in vitro iontophoretic 
delivery of these dopamine agonists and (iii) to study the relationship(s) between the 
physicochemical properties (clogP, electrophoretic mobility and molecular weight) 
of the molecules and the JEM and the parameter estimates (zero order mass input from 
donor to skin and skin release constants), using the adapted model.  
2 Materials and methods 
The 2-aminotetralines 5-Hydroxy-2-(N-ethyl,N-n-propylamino)tetralin (5-OH-
EPAT.HBr), 5-Hydroxy-2-(N-n-propylamino)tetralin (5-OH-MPAT.HBr), 5,6-di-
hydroxy-2-(N-n-propylamino)tetralin (5,6-di-OH-MPAT.HBr), 5,6-di-hydroxy-2-
(N,N-di-n-propylamino)tetralin (5,6-di-OH-DPAT.HBr), 5-hydroxy-2-(N,N,-di-n-
propylamino)tetralin (5-OH-DPAT.HBr) and the chromanamine 8-hydroxy-3-(N,N,-
di-n-propylamino)chroman (8-OH-DPAC.HBr) (Figure 1; purity > 95%, determined 
with HPLC and NMR) were synthesized at the Department of Medicinal Chemistry 
of the University of Groningen, Groningen, the Netherlands. Silver, silver chloride 
(purity >99.99%), Trypsin (Type III from bovine pancreas) and trypsin inhibitor 
(Type II-S from soybean) were obtained from Sigma-Aldrich (Zwijndrecht, The 
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Netherlands). Acetaminophen was purchased from Brocacef BV (Maarssen, the 
Netherlands) and D-Mannitol was obtained from BDH Laboratory supplies (Poole, 
UK). Spectra/Por® RC dialysis membrane disks (cut off value of 6000-8000 Da) 
were purchased from Spectrum laboratories, Inc (Rancho Dominquez, Ca, USA). 
Tetrahydrofuran (THF, stabilized, purity > 99.8%) was obtained from Biosolve 
(Valkenswaard, the Netherlands). Triethylamine (TEA, purity > 99%) was obtained 
from Acros Organics (Geel, Belgium). All other chemicals and solvents were of 
analytical grade. All solutions were prepared in Millipore water with a resistance of 
more than 18 MΩ.cm. 
2.1 Maximum solubility  
The solubility studies of the different compounds were carried out as described 
elsewhere [14]. Briefly, each compound was solubilized in citric buffer 5 mM, pH 
5.0 + 4 g.l-1 NaCl + 23.1 g.l-1 D-mannitol. Subsequently the pH in each test tube was 
adjusted to pH 5.0 with 1M NaOH or 1M HCl under continuous shaking. Each 
solution was shaken for 48h, after which the solution was centrifuged and filtered. 
The concentration in each solution was determined with HPLC.   
2.2 Stability of 5,6-di-OH-MPAT and 5,6-di-OH-DPAT 
The oxidation of 5,6-di-OH-MPAT and 5,6-di-OH-DPAT was investigated under 
various conditions. At the starting point 0.1 mg.ml-1 of 5,6-di-OH-DPAT and 5,6-di-
OH-MPAT were dissolved in the buffer solution. The solutions were continuously 
stirred and kept constant at the desired temperature, using a thermostat controlled 
water bath. If required a circular sheet of HSC (ø=18 mm) was added to the solution 
and a current of 320 µA was applied. At regular time intervals samples were taken 
from the solution and diluted in Millipore water, containing 2.86% v/v anti-oxidant 
solution (0.5% w/v ascorbic acid 0.05% w/v EDTA and 25% v/v H3PO4) to prevent 
the molecule to further oxidize. The amount of remaining drug was quantified by 
RP-HPLC (section 2.6). 
2.3 Capillary electrophoresis  
Previous studies have shown that the electrophoretic mobility at pH 7.4 is related to 
the iontophoretic mobility during transdermal transport [28, 33]. The electrophoretic 
mobility of various compounds in the current study was investigated with capillary 
electrophoresis (CE). These experiments were performed using a HPCE system 
(modelnumber: G1600OAX, Agilent Technologies, Amstelveen, The Netherlands) 
equipped with an on-column diode-array detector, an autosampler, and a 30 kV 
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power supply. CE Chemstation (Agilent Technologies) was used for CE control, data 
acquisition, and handling. The separation was performed in a 50 μm fused-silica 
capillary 48.5 cm in total length, and 40 cm to the UV detector. All experiments were 
carried out in cationic mode (the anode at the inlet and cathode at the outlet). The 
concentration of the samples was 0.5 mM in water and DMSO in water (0.5% v/v) 
was added to the solution as a marker for the electroosmotic flow. The 
electrophoretic mobility was determined using a phosphate buffer pH 7.4 (Na2HPO4: 
5.82 g.l-1; NaH2PO4: 5.1 g.l-1) as electrolyte solution (mobile phase). UV detection 
was applied at 220 and 278 nm for the detection of DMSO and the molecule, 
respectively. The capillary was preconditioned as follows: 5 min 0.1 M NaOH + 10 
min electrolyte solution. The sample was injected during 5 sec under a pressure of 50 
mbar. Every sample was measured 3 times and every analysis a fresh electrolyte 














      (1) 
with µobs and µEOF as the electrophoretic mobility of the compound and the 
electroosmotic marker DMSO, respectively. Furthermore Ltot and Leff are the total 
distance of the capillary and the distance from the inlet to the detection point, 
respectively. tobs and tEOF are the time required to reach the detection point for the 
analyte and the electroosmotic marker DMSO, respectively and V is the applied 
voltage [34-35]. 
2.4 In vitro transport studies 
The preparation of dermatomed human skin (DHS) and human stratum corneum 
(HSC) was performed according to the method described previously [15]. All 
transport experiments were carried out as described elsewhere [15]. The donor 
formulation (citric buffer 5 mM, pH 5.0, NaCl: 4 g.l-1, D-mannitol: 23.1 g.l-1), 
containing the solute, was added to the anodal chamber. The cathodal chamber was 
filled with PBS pH 7.4 (NaCl: 8 g.l-1, Na2HPO4: 2.86 g.l-1, KH2PO4: 0.2 g.l-1, KCl: 
0.19 g.l-1). The acceptor phase, maintained at 32°C, was continuously perfused with 
PBS pH 7.4 at a flow rate of 7.0 ml.h-1. The following protocol was used: 6h passive 
diffusion + 9h iontophoresis (500 µA.cm-²) + 5h passive diffusion. Samples were 
collected every hour with an automatic fraction collector (ISCO Retriever IV, Beun 
De Ronde BV, Abcoude, The Netherlands). The specific conditions of the individual 
transport studies are described below. To prevent oxidation of 5,6-di-OH-DPAT and 
5,6-di-OH-MPAT after transdermal transport and prior to analysis, 200 µl of the anti-
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oxidant solution (EDTA (Titriplex III): 0.5 g.l-1, Na2S2O5: 5 g.l-1, H3PO4 (85 wt. % in 
H2O): 294 ml.l-1) was added to every collecting tube in the fraction collector. 
2.4.1 Total iontophoretic flux  
The iontophoretic delivery of 5-OH-EPAT, 5-OH-MPAT, 5,6-di-OH-MPAT and 
5,6-di-OH-DPAT and 8-OH-DPAC across HSC was studied at 3.9 mM. Two 
additional concentrations (1.5 and 7.0 mM) of 5-OH-EPAT and 5-OH-MPAT were 
studied. Of 5-OH-EPAT, 5-OH-MPAT, 5,6-di-OH-DPAT, 5-OH-DPAT and 8-OH-
DPAC, transport studies across DHS were performed using a donor concentration of 
3.9 mM.  
2.4.2 Electroosmotic flux  
According to the Nernst-planck Equation the total flux (Jtot) consists of three 
transport mechanisms: 
PEOEMtot JJJJ ++=         (2) 
with the electromigrative flux (JEM) and the electroosmotic flux (JEO) as the principal 
driving mechanisms for iontophoresis of charged species. The passive flux (JP) is 
often negligible. The electroosmotic flux across HSC was investigated during 
iontophoretic transport of 5-OH-EPAT, 5-OH-MPAT, 5,6-di-OH-DPAT and 8-OH-
DPAC (3.9 mM). Acetaminophen (15 mM) was added to the donor phase as a 
marker for the electroosmotic flux. The electroosmotic flux was calculated, using the 







J =          (3) 
with Jace as the flux of acetaminophen and Cm and Cace as the donor concentration of 
the molecule and acetaminophen, respectively. 
2.5 Compartmental modelling 
The iontophoretic transport in vitro of different molecules was analyzed using non-
linear mixed effects modelling. The starting point of the models is a zero order mass 
transport form the donor solution into the skin during and after iontophoresis. In this 
paper an extension to the basic model is presented.  
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2.5.1 Basic model in vitro 
An extensive explanation and description of the basic model is presented elsewhere 
[31]. Briefly, the basic model assumes a constant rate of mass input from the donor 
into the skin during iontophoresis due to a constant iontophoretic driving force. 
Based on this assumption the equations, to describe in vitro iontophoretic transport 
during (Equation 4) and after current application (Equation 6) are: 











          (5) 






   (6) 
where J(t) is the flux at time t and S is the diffusion area, KR is a first order skin 
release rate constant, I0 the zero-order iontophoretic mass transfer from the donor 
compartment into the skin compartment during current application, tL is the kinetic 
lag time parameter, introduced to address the time required for drug molecules to 
enter the skin compartment, T is time of current application, Jss is the flux at steady 
state and PPI is the zero order drug input due to the passive driving force post-
iontophoresis. 
2.5.2 Extended model in vitro 
As observed from the iontophoretic flux profile of the compounds presented in this 
paper, the flux increases in time during the current application. This suggests that 
two transport routes are involved in the iontophoretic delivery, linked in parallel. The 
observed flux is the total amount of drug released in the acceptor compartment. In 
analogy to the basic model the zero order mass transfer from the donor into the skin 
remains constant, but the first order release constant from the skin to the acceptor 
will be different for both transport mechanisms. Therefore the iontophoretic flux in 
vitro during iontophoresis (t≤T) can be described by the equation: 










0*2=           (8) 
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With KR1 and KR2 as the release constants to describe both transport routes. During 
the post iontophoresis period (t>T) only one release constant appeared to be 
sufficient to describe the passive flux, resulting in the following Equation:   














⎛ −+−+−=     (9) 
2.5.3 Curve fitting and model evaluation 
Fitting the data was performed using the subroutines ADVANCE6 TRANS1 TOL=5 
from PREDPP in NONMEM (NONMEM version VI). Interindividual variability 
was modeled using an exponential model and the residual error was characterized by 
an exponential and/or additive error model. The estimation of the population 
parameters was performed using a conventional first order method [36].  
The extended model was evaluated in comparison to the basic model. The statistical 
analysis was based on the objective function, which is defined as -2 times the 
logarithm of the likelihood. If the objective function of the extended model with 2 
release constants during the current application, decreases with a value of 3.84 
(and/or more) compared to the objective function of the basic model, the extended 
model is significantly better (p<0.05; χ²-test).  
2.6 Analytical method 
Different HPLC methods were developed to analyze the respective molecule and 
acetaminophen by RP-HPLC. The aminotetralins and the chromanamine were 
detected using a scanning fluorescence detector (Waters™ 474, Millipore, Milford, 
MA, USA) and acetaminophen was detected using a UV detector (Dual λ 
Absorbance Detector 2487, Waters, Milford, USA). The column, the composition of 
the mobile phase, the volume of injection and the respective excitation and emission 
wavelengths to analyze the different compounds are depicted in Table 1. The flow 
rate was set to 1.0 ml.min-1. Calibration curves showed a linear response between 
100 and 40000 ng.ml-1 (R2>0.99). The limit of detection (LOD) and limit of 
quantification (LOQ) for these HPLC methods can also be found in Table 1.  
2.7 Data analysis 
All data are presented as mean ± standard deviation (SD) or as mean ± standard error 
of the mean (SEM). When a statistical analysis was performed comparing only 2 
groups, a Students t-test was used. When 3 or more groups were compared, a 1-way 
ANOVA statistical analysis was executed. Comparing the effect of two factors  
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Table 1: The HPLC method of the different compounds investigated in the current paper 
including column, mobile phase composition, volume of injection, excitation wavelength 
(λex), emission wavelength (λem), limit of detection (LOD) and limit of quantification (LOQ) 
 
Compound Column Mobile phase  Fluorescence 
simultaneously was performed using 2-way ANOVA. If the overall p-value was less 
than 0.05, a Bonferonni post-test was applied to compare different groups. Statistical 
tests were performed by using GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego, CA, USA). For all statistical analysis a significance level of 
p<0.05 was used.  
3 Results 
3.1 Maximum solubility  
The maximum solubility of the different compounds was determined in citric buffer 
5 mM at pH 5.0 in the presence of 68 mM NaCl and D-mannitol as this is the 
composition of the donor solution, used for transport studies. The results of the 
solubility assay can be found in Table 2. The solubility data of rotigotine.HCl and 5-
OH-DPAT, adapted from literature, were added to the table for comparison. An 
increase in solubility was observed ranking the molecules in the following order: 



















Superspher   
RP-select B 
C8 
Ace 50 mM/THF   
95/5 30 20 275 302 21.0 35.0 
5-OH-MPAT Inertsil 5ODS-2 
Ace 100 mM/ACN 
90/10 15 50 280 310 8.2 12.3 
5,6-di-OH-
DPAT 
Superspher    
RP-select B 
C8 
Ace 50 mM/THF   





Ace 50 mM/THF   
96/4 15 50 280 310 90.7 150.5 
8-OH-DPAC 
Superspher   
RP-select B 
C8 
Ace 50 mM/THF   
95/5 30 50 277 306 29.9 44.9 
Acetaminophen: mobile phase, column, limit of detection and quantification are dependent on the 
compound co-analyzed;  
UV-detection: λ=243 nm;  
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Table 2: The physicochemical properties of the various compounds investigated. The 
molecular weight (Mw) and the calculated logP (clogP) are presented together with the 
solubility in a citric buffer 5mM pH 5.0, containing 4 g.l-1 NaCl and 23.1 g.l-1 D-mannitol, 
and the electophoretic mobility, determined with capillary electrophoresis. The solubility of 
5-OH-DPAT and rotigotine, obtained from literature, are added to the table for comparison. 
 
      
 Compound Mw clogPc Solubility Electrophoretic mobility (µem) 
  (g.mol-1)  (mM) 10-4 (cm2.s-1.V-1) 
     mean ± SD 
      
      
 5-OH-EPAT 233.36 3.71 111.7 1.84 ± 0.01 
 5-OH-MPAT 205.30 2.93 93.1 1.88 ± 0.00 
 5,6-di-OH-DPAT 263.38 3.74 44.2 1.56 ± 0.01 
 5,6-di-OH-MPAT 221.30 2.5 n.d 1.61 ± 0.01 
 8-OH-DPAC 249.36 3.4 282.5 1.64 ± 0.01 
 5-OH-DPAT 247.38 4.15 56.7a 1.76 ± 0.01 
 rotigotine 315.48 4.82 7.1b 1.49 ± 0.04 
      
a,b: value adapted from literature [14, 40]  
c: cLogP was calculated using alogsP [37-39] 




rotigotine < 5,6-di-OH-DPAT < 5-OH-DPAT < 5-OH-MPAT < 5-OH-EPAT <       
8-OH-DPAC. Furthermore the relative hydrophilicity of the different analogs, 
expressed with the octanol-water partition coefficient, clogP, was 
calculated/computed using the ALOGPS 2.1 webservice [37-39]. The results are also 
 
provided in Table 2.  
3.2 Stability of 5,6-di-OH-MPAT and 5,6-di-OH-DPAT 
The catecholgroup of 5,6-di-OH-MPAT and 5,6-di-OH-DPAT is expected to be 
susceptible to photo-, auto- and chemical oxidation to ortho-semiquinone and 
subsequently to ortho-quinone, similar as apomorphine, another catecholamine [41]. 
Therefore the stability of these 2 molecules was investigated under various 
conditions, mimicking the different compartments during in vitro iontophoretic 
transport. Figure 2, evaluating the % remaining catechol after 24h and 48h, shows 
that 5,6-di-OH-MPAT remains stable at pH 5.0 at room temperature. Increasing only 
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the temperature had little influence on the stability: after 48h the remaining 5,6-di-
OH-MPAT was 95.9 % and 87.7 ± 5.6 % at room temperature and 32 °C, 
respectively. Addition of HSC and application of a current decreased the remaining 
drug from 96.2 ± 3.1% to 90.2% after 24h. In analogy to other catecholamines, the 
pH of the solution had a strong influence on the stability of the 2 compounds [41-42]. 
At pH 5.0 5,6-di-OH-MPAT and 5,6-di-OH-DPAT were more stable than at pH 6.0. 






































5,6-di-OH-MPAT  at 24 h
5,6-di-OH-MPAT at 48 h
5,6-di-OH-DPAT at 24 h











Figure 2: Bar plot of the % remaining 5,6-di-OH-MPAT after 24h (white) and 48h (grey) 
and of the % remaining 5,6-di-OH-DPAT after 24h (striped) and 48h (black) at various 
conditions. The data are presented as mean ± SD (n=2-3).  
CB=citric buffer, Current=320µA, HSC=circular sheet of human stratum corneum (ø=18 
mm), RT=room temperature. 
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Figure 3: The iontophoretic flux profile of the different aminotetralines, 5-OH-MPAT 
(star), 5-OH-EPAT (open square), 5-OH-DPAT (closed triangle), 5,6-di-OH-DPAT 
(closed square), 5,6-di-OH-MPAT (open circle) and the chromanamine 8-OH-DPAC 
(open triangle) across two different skin types HSC (A) and across DHS (B). The donor 
concentration of all the compounds was 3.9 mM.  Panel C shows the comparison of the 
iontophoretic flux vs time profile of 5-OH-MPAT (star) and 5-OH-EPAT (open square) 
across HCS at 3 different concentrations (1.5, 3.9, 7.0 mM). The data are presented as 
mean ± SD (n=4-7).
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3.3 Capillary electrophoresis 
To assess the electrophoretic mobility of the various compounds, capillary 
electrophoresis was performed. The results of the capillary electrophoresis are 
summarized in Table 2. The electrophoretic mobility of the various compounds 
increased in the following order: rotigotine    5,6-di-OH-DPAT < 5,6-di-OH-MPAT 
< 8-OH-DPAC < 5-OH-DPAT < 5-OH-EPAT < 5-OH-MPAT.  
3.4 Iontophoretic transport 
3.4.1 Total transport across HSC and DHS   
Transport studies with the dopamine agonists at 3.9 mM were performed to compare 
the iontophoretic delivery of the various compounds. The different flux profiles of 
the analogs across HSC and DHS are depicted in Figure 3A and 3B, respectively. 
The flux of the different compounds was evaluated statistically after 9h of 
iontophoresis (current density is 500 µA.cm-²). Across HSC 1-way ANOVA analysis 
showed an overall significant difference in the flux of the different compounds 
(p<0.0001). The observed flux after 9h increased in the following order: 5,6-di-OH-
MPAT (134.5 ± 12.9 nmol.cm-².h-1) < 5,6-di-OH-DPAT (175.0 ± 15.9 nmol.cm-².h-1) 
< 8-OH-DPAC (175.9 ± 18.9 nmol.cm-².h-1) < 5-OH-DPAT (207.7 ± 38.0 nmol.cm-
².h-1) < 5-OH-MPAT (219.7 ± 31.4 nmol.cm-².h-1) < 5-OH-EPAT (247.7 ± 12.1 
nmol.cm-².h-1). In a follow up study 2 additional concentrations (1.5 and 7.0 mM) of 
5-OH-MPAT and 5-OH-EPAT were investigated. Comparing the flux of 5-OH-
MPAT and 5-OH-EPAT after 9h of iontophoresis at 1.5 (99.6 ± 15.9 vs 68.7 ± 22.0 
nmol.cm-².h-1), 3.9 mM (see above) and 7.0 mM (404.9 ± 72.9 vs 354.2 ± 78.1 
nmol.cm-².h-1) showed no significant difference (2-way ANOVA; p>0.05) (Figure 
3C). A similar trend was seen for iontophoretic transport studies across DHS: 8-OH-
DPAC (168.2 ± 13.2 nmol.cm-².h-1) < 5,6-di-OH-DPAT (175.2 ± 25.9 nmol.cm-².h-1) 
< 5-OH-DPAT (193.0 ± 19.9 nmol.cm-².h-1) < 5-OH-EPAT (199.8 ± 8.0 nmol.cm-².h-
1) < 5-OH-MPAT (241.8 ± 11.2 nmol.cm-².h-1). A significant difference could be 
observed between the fluxes of the different compounds (1-way ANOVA; p<0.05).  
3.4.2 Electroosmotic contribution across human stratum corneum 
Acetaminophen (15 mM) was added to the donor solution to investigate the 
electroosmotic flow across HSC during iontophoretic transport. The resulting 
electroosmotic contribution, calculated using Equation 3, expressed as % of the total 
flux, is depicted in Figure 4. A significantly higher electro-osmotic contribution was 
observed when 5,6-di-OH-DPAT (12.1 ± 3.4 %) was transported through HSC, 
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Figure 4: bar plot of the electroosmotic contribution during iontophoretic transport across 
human stratum corneum of different compounds. The donor concentration was 3.9 mM. 
Acetaminophen (15 mM) was co-transported to determine the electroosmotic flow during 
iontophoretic transport. The data are presented as mean ± SD (n=5-6). 
compared to the other compounds 5-OH-EPAT (4.5 ± 0.9 %), 5-OH-MPAT (4.6 ± 
1.4 %) and 8-OH-DPAC (6.1 ± 0.4 %) (1-way ANOVA, Bonferroni post test; 
p<0.01).  
3.5 Model evaluation 
The iontophoretic transport of the different compounds was fitted using the basic and 
extended model. The basic model assumes a constant input during iontophoresis with 
one skin release constant KR. As an example the iontophoretic flux of 8-OH-DPAC 
(3.9 mM) across HSC is shown in Figure 5. The iontophoretic transport of 3.9 mM 8-
OH-DPAC (open circle), together with the model predictions of the basic model 
(dashed line) clearly shows that the basic model does not fit to the experimental data.  
For this reason we employed the extended model with two release constants, KR1 and  
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Figure 5: The individual iontophoretic flux (500 µA.cm-²) vs time profiles of 8-OH-DPAC 
(3.9 mM) across human stratum corneum. The data are plotted as individual observations 
(open circle), together with the individual prediction (IPRED) based on the basic in vitro
model (intermittent line) and on the extended in vitro model with two different release 
constants (solid line) 
 



































































































































































CHAPTER 5   
Table 3: The parameter estimates of data fitting the in vitro iontophoretic delivery (500 
µA.cm-2) across human stratum corneum (HSC) and dermatomed human skin (DHS) of the 
various 2-aminotetralins and chromanamine. The intrinsic driving force corrected for the 
surface area (I0/S), the skin release constants (KR1 and KR2), the passive driving force post 
iontophoresis corrected for the surface area (PPI/S;Pass) and the lag time (tL) are depicted. 
The donor concentration was 3.9 mM. Results are presented as population mean ± standard 
error of the estimate (n=4-7).  
 
 
        
skin 
type Compound  I0/S KR1 (slow) K R2 (fast) Pass tL 
   nmol.cm-².h-1 h-1 h-1 nmol.cm-².h-1 h 
  n Mean SE Mean SE Mean SE Mean SE Mean SE
             
             
HSC 5-OH-EPAT 6 176.56 9.33 0.06 0.02 1.43 0.13 3.17 0.58 n.d. n.d 
 5-OH-MPAT 5 178.13 6.36 0.02 0.02 1.63 0.09 3.33 0.23 n.d. n.d 
 5,6-di-OH-MPAT 5 133.28 5.11 n.d n.d 1.38 0.23 n.d n.d 0.08 0.13
 5,6-di-OH-DPAT 5 91.25 1.86 0.43 0.12 1.19 0.07 2.77 1.28 0.06 0.05
 8-OH-DPAC 7 113.91 2.55 0.09 0.01 1.41 0.04 8.82 1.72 0.14 0.05
 5-OH-DPATa 6 119.69 8.67 0.25 0.15 1.39 0.14 4.47 0.74 0.06 0.07
 rotigotine.HClb 6 45.31 0.42 0.32 0.10 0.96 0.06 20.30 0.39 n.d n.d 
            
             
DHS 5-OH-EPAT 6 99.22 2.25 1.27 0.69 0.46 0.04 0.02 n.d 0.27 0.01
 5-OH-MPAT 7 118.91 1.49 0.47 0.11 0.54 0.04 4.64 1.32 0.26 0.08
 5,6-di-OH-DPAT 6 116.25 2.66 0.08 0.02 0.63 0.02 10.10 1.12 0.21 0.05
 8-OH-DPAC 7 101.88 1.12 0.08 0.04 0.53 0.04 n.d n.d 0.47 0.08
 5-OH-DPAT 4 95.16 1.43 0.73 0.33 0.56 0.06 5.15 2.99 0.22 0.03
 rotigotine.HClb 6 35.31 3.33 0.03 0.02 0.28 0.04 22.70 1.62 n.d n.d 
 
            
a,b: data was adapted from literature[14, 40] 
n.d: not determined because the parameter was constrained to 0 
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KR2. The extended model describes more adequately the flux of the drug than the 
basic model (Figure 5, solid line). This graphical analysis was performed for all 
compounds across DHS and HSC. The majority of the individual fits showed an 
improvement when using the extended model. The two models were also evaluated 
statistically by comparison of the objective function of the models. Except for 
rotigotine.HCl across DHS and 5,6-di-OH-MPAT across HSC, in all cases the 
objective function decreased with a value larger than 3.84. This indicates that 
although an extra parameter (KR2) was added to the model, a clear improvement in 
fitting the iontophoretic transport across HSC and DHS was obtained (p<0.05; Chi-
square test). A model using two zero order mass input rates (I0) or an additional 
release constant (KR3) did not further improve data fitting. The estimated transport 
parameters, using the extended model with one zero order mass input rate and 2 
release constants, can be found in Table 3. 
 
4 Discussion 
In this study the transdermal iontophoretic delivery of a series of 2-aminotetralins 
and 1 chromanamine (8-OH-DPAC) is presented. The systematic structural 
differences of these compounds allowed us to investigate the effect of molecular 
structure on the solubility and on iontophoretic delivery efficiency.  
4.1 Solubility 
The differences in structure highly affected the solubility of the various compounds. 
Compared to 5-OH-DPAT, approximately a 2-fold higher solubility was observed 
for 5-OH-EPAT and 5-OH-MPAT, indicating that decreasing the length of the alkyl 
side chain on the nitrogen group improves the solubility of the compound, most 
probably due to reduction in lipophilicity and an increase in chargeability of the 
nitrogen group. Furthermore for 8-OH-DPAC almost a 5-fold higher solubility was 
observed compared to 5-OH-DPAT. This demonstrates that replacement of the 
tetrahydronaphtalene moiety, present in the structure of 5-OH-DPAT, by a chroman 
moiety (as in 8-OH-DPAC), increases the solubility. In contrast, 5,6-di-OH-DPAT 
showed a reduced solubility, which can be explained by the formation of 
intermolecular hydrogen bridges, decreasing its water solubility.  
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4.2 Efficiency of iontophoretic transport 
Small structural changes influence the transport efficiency of the different analogs 
significantly across HSC and DHS. Although steady state had not been reached yet 
after 9h of current application, already a clear difference can be observed at this time 
point. Despite the increase in hydrophilicity of 5,6-di-OH-MPAT and 5,6-di-OH-
DPAT by introducing an extra oxygen on the phenylring, the iontophoretic flux 
reduced, compared to 5-OH-MPAT and 5-OH-DPAT. It has been reported that an 
increase in molecular volume results in a decrease in total iontophoretic flux, but in 
an increase in electroosmotic contribution [24, 43]. The significantly higher 
electroosmotic contribution for 5,6-di-OH-DPAT might be due to an increased 
molecular volume, caused by intermolecular hydrogen bonds, which would also 
account for the reduced iontophoretic flux. Decreasing the alkyl length of one side 
chain on the nitrogengroup from propyl (5-OH-DPAT) to ethyl (5-OH-EPAT) or 
further to a hydrogen (5-OH-MPAT) resulted in an increased efficiency of 
iontophoretic transport. This is in agreement with the observations by Del Terzo et 
al., who obtained a similar result with ionized n-alkalanoic acids [29]. 
4.3 Transport pathways 
In literature different iontophoretic transport routes are proposed: (i) the transport 
route across the appendageal structures, such as hair follicles and sweat glands, and 
(ii) the transport route via the intercellular route in the skin [44-47]. In agreement, 
fitting the iontophoretic flux using a model with two release constants also suggests 
the presence of at least 2 different transport routes across human skin during current 
application. In the initial time period of iontophoresis transport across the more 
permeable pores, possibly the appendages, with a faster release to the acceptor phase 
(described by KR2) is the major contributor to the total iontophoretic flux. However, 
when the iontophoresis proceeds, the contribution of the second penetration route, 
suggested as the intercellular pathway, with a slower release (described by KR1) 
increases. This results in an increase in the total iontophoretic flux (Figure 5). 
Modeling transport across HSC and DHS post iontophoresis revealed that the release 
from the skin was best described by KR2. This suggests that the appendageal route 
post iontophoresis is still the predominant route. Similar observations by Turner and 
co-workers reported that the predominant transport route for the ionized calcein after 
iontophoresis pre-treatment was via the pores [47].  
Comparing the skin release constant KR2 for HSC and DHS transport, it was 
observed that KR2 was smaller during transport across DHS. This can at least partly 
be attributed by the presence of hydrophilic regions and negative charged cell 
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membranes at pH 7.4 in both the epidermis and the upper part of the dermis, slowing 
down the partitioning of the compounds from the skin to the acceptor phase. 
4.4 Physicochemical considerations for iontophoretic delivery 
In literature several in vitro methods have been proposed as first screening methods 
for transdermal iontophoretic delivery. The molecular descriptors for iontophoresis 
in these methods were charge, molecular weight/volume and ionic/electrophoretic 
mobility [28, 33, 48-49].  
As the electrophoretic mobility was reported as a good descriptor for the 
electromigrative flux (JEM) [28, 33], in the present study, JEM after 9h of 
iontophoresis was calculated using Equation 2. The passive flux was considered to 
be negligible. For the transport studies across HSC JEM correlated linearly with the 
electrophoretic mobility (R²=0.85) (Figure 6C).  
Although capillary electrophoresis to estimate the JEM at 9h is a good screening 
method for transdermal iontophoresis, this single end-point approach has some 
limitations. Firstly, this approach assumes that the end-point is representative for the 
entire iontophoretic flux, also before and after this point. However it does not 
account for the shape of the curve. Secondly, it is also important to understand the 
influence of the physicochemical properties on the different transport parameters, 
such as the zero order mass input and the release constants (Table 3). This 
information is important to make a realistic extrapolation towards in vivo. The 
iontophoretic mass transfer is driven by a potential gradient. This implies that 
besides the current density and the donor composition, which are kept constant in the 
transport studies, the zero order mass transfer is dependent on the electrophoretic 
properties of the molecule. It is observed that the zero order mass input, corrected for 
the surface area (I0/S), is linearly correlated to the electrophoretic mobility (R2=0.93) 
(Figure 6A). This also means that the steady state flux, calculated using Equation (8), 
can be predicted by the electrophoretic mobility. Previous studies demonstrated that 
the transport efficiency decreased with increasing molecular weight (Mw) [24-26]. 
For instance Lai and co-worker considered in the ionic mobility-pore model, that the 
logarithm of the permeability coefficient decreases linearly with increasing Mw [24]. 
If our interpretations are correct and KR2 describes the release during appendageal 
transport, it can be expected that the release from these pores into the acceptor phase 
is size dependent. Plotting the fast release constant KR2 against the Mw confirms this 
size dependency. The fast release constant KR2 is reduced linearly with increased Mw 
(Figure 6B; R²=0.90).  
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Figure 6: The relationships between the physicochemical properties of the compounds 
(open circle) and the transport parameters. The data of 5-OH-DPAT and rotigotine (closed 
square) were added to the graphs and included in the correlations. In all cases the donor 
concentration of the dopamine agonist was 3.9 mM. Data are presented as mean ± SD for 
the EM-flux and electrophoretic mobilty (n≥3). The parameter estimates (I0 and KR2) are 
presented as mean ± standard error of the estimate (n≥4). The regression analysis was 
performed with the mean point estimates. A: The linear correlation between the intrinsic 
driving force corrected for the surface area (I0/S) vs the mean electrophoretic mobility. B: 
The linear correlation between the KR2 and the molecular weight. C: The electromigrative 
flux (EM-flux) at 9h across human stratum corneum is plotted against the mean 
electrophoretic mobility. D: The correlation between the flux at 9h across dermatomed 
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Although not fully understood yet, the lipophilicity of the molecules can be of 
importance for the transport efficiency and transport pathway. For instance Jadoul et 
al. showed that fentanyl, a relatively lipophilic molecule, was distributed across the 
whole HSC, while the more hydrophilic thyrotropin releasing hormone was mainly 
localized in the pores after iontophoresis [50]. In analogy, our observations show that 
the relative contribution of the two different transport pathways is dependent on the 
lipophilicity of the solute. For the more lipophilic compounds, rotigotine and           
5-OH-DPAT, a relatively high KR1 value was observed, while for the more 
hydrophilic compounds KR1 remained small. For the most hydrophilic compound                     
5,6-di-OH-MPAT even a negligible value for KR1 was observed.  An exception was 
made for 5,6-di-OH-DPAT, since other mechanisms play a role in its iontophoretic 
transport.  
Due to the increased membrane complexity of DHS, the aforementioned 
relationships between the physicochemical properties (electrophoretic mobility, Mw, 
clogP) and the transport parameters (JEM, I0/S, KR2, KR1) were not so evident, 
contrasting the observations for transport across HSC. For instance across DHS, 
assuming that the relative electromigrative contribution is similar to that across HSC, 
the linear correlation between the JEM and the electrophoretic mobility was not so 
clear (Figure 6D) (R²=0.78). DHS includes HSC, the viable epidermis, and a part of 
the dermis, and therefore the complexity of the transport membrane augments. 
Further research is necessary to fully understand the underlying transport 
mechanism(s) involved in epidermal transport. A larger set of molecules, covering a 
broader range of electrophoretic mobilities presumably will increase the predictive 
value of capillary electrophoresis for the JEM across DHS, as was observed for a 
series of dipeptides [28, 33]. These dipeptides were grouped in 3 clusters, where the 
correlation within the groups was far less than the overall correlation, including all 
11 peptides. Nonetheless the electrophoretic mobility and the corresponding JEM 
across DHS, observed for the dopamine agonists in the current paper were similar to 
the values obtained for the dipeptides at pH 7.4 [28, 33]. 
Next to identifying the physicochemical-transport parameter relationships, 
compartmental modeling can be very useful for extrapolation towards the in vivo 
situation. Assuming transport across HSC in vitro is representative for transport in 
vivo in humans, combining these transport parameters with pharmacokinetic 
parameters, applying non-linear mixed effect modeling, simulations can be made of 
the iontophoretic flux in vivo. Nugroho et al. demonstrated that for transdermal 
iontophoresis such an extrapolation from in vitro to in vivo is possible in rats, 
predicting the plasma concentration and even the pharmacodynamic effect [16].  
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In conclusion, this study shows that small structural changes affect the solubility, 
electrophoretic mobility, the iontophoretic delivery efficiency and the contribution of 
the transport route during iontophoresis. Increasing the hydrophilicity by addition of 
an extra OH-group on the phenyl ring (5,6-di-OH-MPAT and 5,6-di-OH-DPAT) did 
not result in an increase in solubility nor transport efficiency. On the other hand 
solubility and iontophoretic transport can benefit from reduction in the alkyl groups 
at the nitrogen. In addition the electrophoretic mobility and the Mw can be applied to 
estimate the zero order mass input I0/S and KR2, respectively. The clogP might be 
helpful in determination of the relative contribution of the different transport 
pathways by estimation of KR1, although further research is required to define a clear 
relationship. With the estimated parameters, using the proposed compartmental 
model, it will be possible to simulate the iontophoretic flux profile across HSC in 
vitro. Simulations can be a helpful tool in designing future experiments, giving the 
opportunity to explore different flux profiles and different study designs. 
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CHAPTER 6   
Abstract 
The pharmacokinetic (PK) and pharmacodynamic (PD) properties of the active (S)-
enantiomer of the potent dopamine agonist 5-OH-DPAT were investigated in a novel 
anesthetized animal model. Firstly, the relationship between current density, in vivo 
transport and plasma profile was characterized. Secondly, the effect of the anesthetic 
mixture, transdermal iontophoresis and blood sampling on the striatal dopamine 
release (PD endpoint) was investigated. Thirdly, the PK-PD relationship following 
transdermal iontophoresis was investigated during a controlled and reversible 
pharmacological response. As pharmacodynamic effect the dopamine release in 
striatum was selected. Given that the striatal dopamine levels are unaltered during 
experimental procedures, this rat model can be used to investigate the PK-PD 
relationship. The in vivo flux was found to be linearly correlated with the current 
density, which indicates that drug delivery can carefully be titrated by the current 
density. Following both transdermal iontophoresis and IV infusion, a strong and 
reversible PD effect was observed. Compartmental modeling showed that the 
relationship between drug plasma concentration and biomarker response can be best 
characterized by an effect compartment, rather than an indirect response model. In 
addition, covariate analysis suggested that the delivery rate can affect the 
pharmacodynamic efficiency. Finally, simultaneous PK-PD analysis revealed that 
steady delivery rates are translated into continuous dopaminergic stimulation. This 
can be of great benefit for reducing side effects in the symptomatic treatment of 
Parkinson’s disease with 5-OH-DPAT. 
 
Keywords: PK-PD, compartmental modeling, iontophoresis, (S)-5-OH-DPAT, 
microdialysis
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1 Introduction  
Transdermal iontophoresis is a well established physical method to facilitate the 
percutaneous penetration of molecules [1]. By application of a small electrical 
current across the skin iontophoresis enhances the transdermal delivery of 
therapeutic agents. An important advantage of transdermal delivery is the 
circumvention of the hepatic first-pass metabolism, making it an interesting non-
invasive alternative for oral drug delivery. A particular advantage of iontophoresis is 
the possibility to tailor the delivery to the patient’s needs by adjusting the current 
density. This may allow for better therapeutic efficacy and reduction in overdosing 
and subsequent side effects. These properties make iontophoresis an excellent 
method for the transdermal delivery of drug molecules for the symptomatic treatment 
of Parkinson’s disease.  
Parkinson’s disease is a neurodegenerative disorder, which is characterized by 
tremor, akinesia, rigidity and postural instability [2]. Up to today orally dosed 
levodopa is still the most effective symptomatic treatment, but chronic use eventually 
leads to severe long-term side-effects, i.e. dyskinesia and the on-off phenomenon [3-
4]. Current strategy to prevent or delay the onset of these side-effects is to administer 
therapeutics in a constant and controlled manner [5]. Therefore, the transdermal 
iontophoretic delivery of the dopaminergic agonists R-apomorphine, ropinirole and 
5-OH-DPAT were investigated in vivo for their application in symptomatic treatment 
of Parkinson’s disease [6-9].  
Besides a constant and controlled delivery, another attractive property of 
iontophoresis is the possibility to develop a feedback system. In this approach, the 
concentration of a relevant biomarker, extracted for instance with reverse 
iontophoresis, can be used to titrate the transdermal iontophoretic delivery of the 
drug molecule. Preferably, a pharmacodynamic endpoint instead of the drug plasma 
concentration should be chosen to monitor the drug effect. Under experimental 
conditions, striatal dopamine concentration, measured by microdialysis, has been 
shown to be a biomarker for dopaminergic activity [10-11].  
In the current investigation, we have therefore characterized pharmacokinetic-
pharmacodynamic (PK-PD) relationships of the dopamine agonist following 
transdermal iontophoresis using dopamine as a measure of the pharmacological 
effect. In order to optimize the feedback system, we have also performed an 
integrated evaluation of relationship between the pharmacodynamics, 
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pharmacokinetics and the delivery rates of the compound. In a previous study, the 
PK-PD of 5-OH-DPAT was assessed, however a ceiling effect was observed, with 
dopaminergic levels not altering throughout the time frame of the experiments [7]. 
Modelling of the data was therefore difficult and demanded for a follow-up study to 
investigate the PK-PD relationship under a wider exposure range, in which 
maximum effect (ceiling) is short lasting. In addition, during the previous study 5-
OH-DPAT was administered as racemic mixture, while (S)-5-OH-DPAT is the only 
enantiomer with dopaminergic activity. In contrast to previous studies, in the present 
investigation, experiments are conducted with the active enantiomer (S)-5-OH-
DPAT [7].  
The aims of this study were three-fold. First, to examine the relationship between the 
current density, the in vivo iontophoretic transport and the (S)-5-OH-DPAT plasma 
profile. Given the requirement for the use of anaesthesia to conduct transdermal 
iontophoresis, second, to examine the effect of the anesthetic mixture, transdermal 
iontophoresis and blood sampling on the striatal dopamine release. Third, to assess 













Figure 1: The molecular structures of (S)-5-hydroxy-2-(N,N,-di-n-
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ensuring the induction of a controlled and reversible effect [7]. A comprehensive 
approach based on non-linear mixed effects modeling was used that allows us to 
characterize and predict the time course of drug action. Furthermore this approach 
enables to combine data from different experiments to obtain individual and 
population PK-PD parameter estimates [12]. Extensive PK-PD modeling is further 
applied to characterize the pharmacokinetics of (S)-5-OH-DPAT in plasma and the 
corresponding pharmacodynamic effect. The PK model to describe the plasma 
concentration was adapted from literature [7]. Given that a delay is observed 
between plasma concentrations and the onset of the pharmacological response, two 
PD models are compared to describe the DA release: the effect compartment model 
[13] vs the indirect response type I model [14]. The results of this comparison add 
value to the efforts in the optimization of drug delivery. We ultimately illustrate how 
PK-PD relationships can be used to design a delivery system for symptomatic 
treatment of Parkinson’s disease. 
2 Materials and Methods 
2.1 Chemistry 
5-hydroxy-2-(N,N,-di-n-propylamino)tetralin ((S)-5-OH-DPAT) and (R)-5-hydroxy-
2-(N-n-propyl-N-α,α-dideutero-propylamino)-tetralin ((R)-d2-5-OH-DPAT) (HBr 
salts, purity > 98%) were synthesized at the Department of Medicinal Chemistry of 
the University of Groningen, Groningen, the Netherlands (Figure 1). To synthesize 
d2-5-OH-DPAT the following deuteration strategy was employed: (+)-5-Methoxy-2-
(N-n-propylamino)tetralin was converted to the propionamide. Subsequently, the 
propionamide was reduced with lithium aluminium deuteride and after 
demethylation with 48% hydrobromic acid, the final compound d2-5-OH-DPAT 
hydrobromide was obtained with an overall yield of 13%. 
2.2 Materials 
Silver, silver chloride (puritiy >99.99%) and octanesulfonic acid were obtained from 
Sigma-Aldrich (Zwijndrecht, the Netherlands). Acetonitrile (LC-MS grade), 
ammonium acetate (LC-MS grade), acetic acid (LC-MS grade) and methanol (LC-
MS grade) were purchased from Biosolve (Valkenswaard, the Netherlands). 
Ammonium hydroxide (25% w/v; analytical grade) was obtained from Baker 
(Deventer, the Netherlands). NaCl 0.9% was purchased from the hospital pharmacy 
of LUMC (Leiden, the Netherlands). EDTA was obtained from Merck (Merck 
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KGaA, Darmstadt, Germany). All solutions were prepared in Millipore water with a 
resistivity of more than 18 MΩ.cm. 
2.3 Iontophoresis patches 
A detailed description of the iontophoresis patches, used for the transdermal 
iontophoresis studies can be found elsewhere [7]. Briefly, the iontophoresis patches 
were prepared by the Fine Mechanical Department of Leiden University from elastic 
silicon materials (silicon: Smooth-Sil 920; Smooth-on Inc., Easton, PA, USA). The 
volume of the patches was 2.3 ml and the active area was 2.5 cm². The patch was 
fixed on wound dressing film (Opsite Flexigrid, Smith&Nephew, Hoofdorp, the 
Netherlands), which can be attached to the skin during the experiment. Ag/AgCl was 
used as driver electrode pair. 
2.4 Animals 
Animal procedures were conducted in accordance with guidelines published in the 
NIH guide for the care and use of laboratory animals and all protocols were approved 
by the Institutional Animal Care and Use Committee of the University of Groningen 
and Leiden University. The pharmacokinetic (PK) and the pharmacokinetic-
pharmacodynamic (PK-PD) studies were performed in albino male Wistar rats (280-
340 g) obtained from Charles River (Maastricht, the Netherlands) and Harlan (Horst, 
the Netherlands), respectively. Prior to surgery the animals were housed at least 1 
week in Plexiglas cages, maximum 6 animals per cage with free access to water and 
standard laboratory chow. The cages were placed in a room with a controlled 
temperature at 21 °C and controlled humidity between 60-65% and a light-dark cycle 
of 12h. 
2.5 Pharmacokinetic (PK) studies 
In these experiments the relationship between the current density and the plasma 
concentration profile of (S)-5-OH-DPAT following transdermal iontophoresis was 
investigated. (S)-5-OH-DPAT was administered by transdermal iontophoresis and 
intravenous (IV) infusion to the same animals with a one week interval between 
treatments. The use of both routes of administration allowed improved 
pharmacokinetic parameter estimation. A detailed description of the experiments is 
given below. 
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2.5.1 Surgical procedures 
Prior to surgery the animals were anaesthetized with a combination of Dormicum® 
(midazolam, 5 mg.ml-1, Roche Nederland, Mijdrecht, the Netherlands) and 
Hypnorm® (fentanyl citrate 0.315 mg.ml-1 + fluanizone 10 mg.ml-1, Janssen 
Pharmaceutica, Beerse, Belgium) at a dose of 0.5 mL.kg-1 rat weight. The permanent 
cannulation was performed using Polethene tubings (Rubler BV, Hilversum, the 
Netherlands) with the diameter of 0.58 mm (I.D.) – 0.96 mm (O.D.) and 0.28 mm 
(I.D.) – 0.61 mm (O.D.), respectively for femoral vein and artery cannulation. After 
surgery the animals were housed individually and were allowed to recover during 
one week. 
2.5.2 Experimental procedures 
In the first part of the study (S)-5-OH-DPAT was administered by transdermal 
iontophoresis. Firstly the animals were anesthetized with Hypnorm® and Dormicum® 
(0.5 mL.kg-1) and the hair of the back was removed using an electrical clipper and a 
scalpel. A pair of patches was attached to the skin surface. After 15 min the patches 
were filled with (S)-5-OH-DPAT (3.9 mM) at pH 5.0 (citric buffer, 5 mM) and with 
PBS pH 7.4 (NaCl: 8 g.L-1, Na2HPO4: 2.86 g.L-1, KH2PO4: 0.2 g.L-1, KCl: 0.19 g.L-1) 
at the anodal and the cathodal side, respectively. The following protocol was used for 
the iontophoresis studies: 15 min passive diffusion + 120 min 75 µA.cm-2 + 120 min 
150 µA.cm-2. At time=255 min, the patches were removed and the skin was wiped 
using a tissue paper. Blood samples were taken at regular time intervals during the 
current application and after removal of the patch: 0, 15, 45, 75, 105, 135, 165, 195, 
225, 255, 270, 285, 315, 345, 390, 435 min. Blood samples (0.2 ml) were collected 
using lithium-heparin containing tubes (Microvette® 200 Plasma/Lithium Heparin, 
Sarsted BV, Etten-Leur, the Netherlands). Plasma was then separated by 
centrifugation at a speed of 6000 rpm during 10 min. The samples were kept at -20 
°C prior to analysis with LC-MS-MS (section 2.7).  
After 1 week of recovery in individualized housing, animals received a total dose of 
29 nmol (S)-5-OH-DPAT, dissolved in 0.9% NaCl, during a 15-min IV infusion. At 
regular time intervals blood samples were taken from the femoral artery cannula: 0, 
15, 20, 30, 45, 60, 75, 90, 105, 120, 150, 180 min. The samples were prepared in the 
same way as described above following iontophoretic delivery (see above). In all 
experiments the animals were kept in an anaesthetized condition during the 
experiment using Hypnorm® and Dormicum®. 
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2.6 On-line microdialysis studies (PK-PD studies) 
This series of experiments consisted of three parts. Firstly, the influence of 
anesthesia and iontophoresis on the striatal dopamine release (PD end point) was 
determined with on-line microdialysis. Secondly, the pharmacokinetic (PK) and 
pharmacodynamic (PD) properties following transdermal iontophoretic delivery 
were examined. Thirdly, to explore the implications of differences in delivery rate on 
the PK and PD parameters, (S)-5-OH-DPAT was administered with IV infusion. In 
all experiments the striatal dopamine level and the striatal 5-OH-DPAT 
concentration were monitored by microdialysis with simultaneous blood sampling 
for the analysis of (S)-5-OH-DPAT plasma concentrations. A detailed description of 
the experiments is given below.  
2.6.1 Surgical procedures 
Prior to surgery the rats were anaesthetized with Isofluran 2% in N2O/O2 (2/1). The 
permanent cannulations were performed using silicone catheters (inner diameter 
(I.D.): 0.5 mm; outer diameter (O.D.): 0.9 mm) (UNO BV, Zevenaar, The 
Netherlands). The catheters were inserted approximately 2 cm inside the vessels. The 
catheters were tunneled subcutaneously, externalized at the back of the head. After 
the cannulation the rats were kept under anaesthetized condition and mounted into a 
stereotaxic frame for the implementation of microdialysis probes in left and right 
striatum according to a method described previously [10-11]. After exposing and 
anesthetizing the skull with 0.5% marcaine-adrenaline, the holes for probe insertion 
were drilled. A Y-shaped dialysis probe was used for the experiments, with an 
exposed tip length of 3 mm. The dialysis cannula (I.D.: 0.24 mm; O.D.: 0.34 mm) 
was prepared from polyacrylonitrile/sodium methallyl sulfonate copolymer (AN 69, 
Hospal, Bologna, Italy). The microdialysis cannula was implanted in the striatum. 
The following coordinates were used according to the atlas of Paxinos and Watson 
[15]: AP +0.9, LM ± 3.0 relative to bregma, and Vd – 6.0 below dura. Before 
insertion into the brain, the dialysis probe was perfused successively with 70% 
ethanol, ultrapure water and Ringer solution (140 mM NaCl, 3.0 mM KCl, 1.2 mM 
CaCl2, 1.0 mM MgCl2). The dialysis probe was positioned in the burr hole under 
stereotaxic guidance. The probe was cemented in this position with dental cement. 
Thereafter the rats were housed solitary. 
2.6.2 Experimental procedures 
The PK-PD experiments were performed 15-20 h after cannulation and implantation 
of the probes. The rats were anaesthetized prior to and kept under anesthetized 
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condition during the experiment with Hypnorm® and Dormicum® at a starting dose 
of 0.5 mL.kg-1 and subsequently with hourly doses of 0.17 mL.kg-1.  
Firstly, to dismiss the potential confounding effects of anaesthesia,  an iontophoretic 
control experiment was conducted administering only citric buffer (pH 5.0, 5 mM), 
as this is the donor phase used for transdermal iontophoresis, without (S)-5-OH-
DPAT. Before the start of the experiment, the hair of the back of the anesthetized rat 
was removed with an electrical clipper and scalpel. 15 min after attaching the patches 
to the skin surface, the cathodal patch was filled with PBS pH 7.4 and the anodal 
patch was filled with the donor solution. The protocol for iontophoresis was: 15 min 
passive diffusion + 90 min current application (250 µA.cm-2). The patch was 
removed and the skin was wiped using tissue paper. To include the influence of 
blood sampling on the DA level, blood samples were taken at regular time intervals: 
0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 165, 195, 225, 255, and 285. Blood sampling 
and subsequent preparation of the samples were identical to the procedures used for 
the PK studies following transdermal iontophoresis (cf. supra).  
Secondly, a PK-PD microdialysis study following transdermal iontophoretic delivery 
of (S)-5-OH-DPAT was performed. The donor solution consisted of (S)-5-OH-
DPAT (3.9 mM), buffered with a citric buffer (pH 5.0, 5 mM). All the experimental 
procedures were identical to the control experiment, as described in the previous 
paragraph. Thirdly, a PK-PD microdialysis study was performed with a total dose of 
113 nmol 5-OH-DPAT, dissolved in NaCl 0.9%, administered as a 10-min IV 
infusion. Blood sampling and subsequent preparation of the samples were identical 
to the procedures used for the PK studies following IV infusion (cf. supra).  
In all the PK-PD studies the dopamine level and the 5-OH-DPAT concentration were 
monitored in the left and right striatum, respectively, with microdialysis. The 
microdialysis probes in the striata were perfused with Ringer solution at a flow of 2 
μL.min-1 (CMA/102 Microdialysis Pump, Sweden). Every 15 min a sample was 
collected for analysis with a total volume of 30 µl. The analysis of the microdialysate 
samples is described below (section 2.7.2). 
2.7 Sample analysis 
2.7.1 Blood samples of (S)-5-OH-DPAT 
The blood samples of 5-OH-DPAT were analyzed with an on-line solid-phase 
extraction-liquid-chromatography-mass spectrometry/mass spectrometry (SPE-LC-
MS/MS) method. 5 µl of the internal standard (d2-5-OH-DPAT; 5 ng.ml-1) was added 
to 35 µl of the collected plasma and 350 µl acetonitrile was added to precipitate the 
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proteins. The mixture was vortexed and centrifuged at a speed of 8000 rpm during 10 
min at 10 °C. The supernatant was dried and redissolved in 50 µl MilliQ and 3 µl 
was injected on to the SPE cartridge. An external binary HPLC pump (Gynkotek, 
Munich, Germany) and an external Agilent 1200, 2/6 switch valve (Agilent 
Technology, Santa Clara. CA, USA) were used for the SPE sample trapping. The 
samples were trapped on a Hysphere Resin C8, endcapped, 10 x 4 mm, 10 μm SPE 
cartridge (Spark Holland B.V, Emmen, The Netherlands). Prior to injection, the SPE 
cartridge was conditioned with 50mM ammonium acetate buffer pH 9.0, after the 
injection the sample was trapped with 10mM ammonium acetate buffer pH 9.0/ACN 
(4:1 v/v) during 1 min with a flow of 0.4 ml.min-1. Subsequently, the valve was 
switched placing the SPE cartridge in-line with the LC system for elution onto the 
analytical column. Elution of 5-OH-DPAT and its internal standard was 
accomplished by flushing the SPE column with H2O/ACN (1:9 v/v) during 4 min 
with a flow of 0.05 ml.min-1 and 1 min with 1 ml.min-1. Finally, the cartridge was 
switched off-line again and re-conditioned using a 50mM ammonium acetate buffer 
at pH 9.0 during 2 min with a flow of 1 ml.min-1. To analyze the extracted sample an 
Agilent 1200 HPLC system with autosampler (Agilent Technology, Santa Clara. CA, 
USA) was coupled online with an Agilent 6460 Triple Quadrupole mass 
spectrometer (Agilent Technology, Santa Clara. CA, USA). The samples were 
analyzed by μPLC-MS/MS using an Altima HP C18 column (150X 1.0 mm; 5 µm) 
(Grace Davison Discovery Sciences, Lokeren, Belgium). The mobile phase consisted 
of 10 mM ammonium acetate buffer pH 3.7: Acetonitril (2.3:1 v/v) was used. The 
total analysis time was 11 min, the flow-rate was 100 μl.min-1, the temperature of the 
autosample tray was set to 4 ºC and the column temperature was set to room 
temperature. The detection was performed with a triple quadrupole mass 
spectrometer in the positive-ion electrospray mode and all analytes were monitored 
with Multiple Reaction Monitoring (MRM). 5-OH-DPAT and the internal standard 
d2-5-OH-DPAT were ionized to produce the protonated molecules at m/z 248 and 
m/z 250, respectively. Upon collision (collision energy 15 eV; fragmentor enenergy 
120 V) the pre-cursor ions of both of 5-OH-DPAT and d2-5-OH-DPAT produced the 
same product-ion at m/z 147, corresponding to 5-hydroxy-aminotetraline. System 
operation and handling the acquired data was performed using Agilent MassHunter 
data acquisition software (version, B.02.00; Agilent). Calibration curves showed a 
linear response when using concentrations of compounds between 0.2 and 50 ng.ml-1 
(R2>0.999). The recovery, limit of detection (LOD) and limit of quantification 
(LOQ) were experimentally determined at 93.9 ± 2.9 %, 0.07 and 0.2 ng.ml-1, 
respectively.  
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2.7.2 Microdialysate samples of (S)-5-OH-DPAT  
To analyze the striatal 5-OH-DPAT concentration the dialysate from the probe in the 
right striatum was collected every 15 min, resulting in a total volume of 30 μL per 
sample. Subsequently, 70 μL of a 7.15 nM solution of (R)-d2-5-OH-DPAT as 
internal standard was added to yield final concentrations of 5 nM internal standard in 
a 100 μL mixture of water + 0.1% formic acid and Ringer (1:1). The solution was 
analyzed using LC-MS/MS. The HPLC system consisted of a Shimadzu LC 20 AD 
binary system with a Shimadzu SIL 20AC autosampler. The samples were injected 
on a Grace Alltech Alltima HP C18 EPS reverse-phased column (3 μm, length 150 x 
2.1 mm I.D.) (Grace Alltech, Lokeren, Belgium). The mobile phase consisted of a 
mixture of 0.1% formic acid in water (solvent A) and 0.1% formic acid in 
acetonitrile (solvent B). The gradient was programmed as follows: 1 minute 
isocratically at 15% B, increase in 7.5 min to 95% B, 2.5 min isocratically at 95% B, 
decrease in 1 minute to 15% B and isocratically for 5 min at 15% B. The total 
runtime was 17 min. The flow was set at 0.4 mL.min-1 and the analysis was 
performed at room temperature. The injection volume was 20 μL (partial loop fill) 
and the compounds were detected on a SCIEX API3000 triple quadrupole mass 
spectrometer (Applied Biosystems/MDS SCIEX, Foster City, CA, USA) equipped 
with a Turbo Ion Spray interface. The mass spectrometer was operated in the positive 
ion mode with MRM, quantifying transition pairs of m/z 248.2/147.1 and 
250.2/147.1 for 5-OH-DPAT and d2-5-OH-DPAT, respectively. Instrument 
parameters were as follows: Ion spray voltage 5000 V, nebulizer gas 13, curtain gas 
13, TIST (Turbo Ion Spray Temperature) 500 °C, collision activated dissociation 
(CAD) gas 4, declustering potential (DP)=35 V, focusing potential (FP)=130 V, 
entrance potential (EP)=10 V. The detection limit of 5-OH-DPAT was 1 fmol which 
is 0.25 pg (5 x 10-11 M, 20 μL injection volume). 
2.7.3 Striatal concentration of dopamine (DA) and metabolites 
The dialysate contents of dopamine (DA) and its metabolites were quantified from 
the probe implanted at the left striatum by an on-line HPLC with electrochemical 
detection with the detection limit of 1 fmol/sample. A HPLC pump (LC-10AD vp, 
Shimadzu, Kyoto, Japan) was used in conjunction with an analytical cell (5011A, 
ESA,  Chelmsford, MA, USA) and a electrochemical detector (Coulochem II, ESA, 
Chelmsford, MA, USA) working at +300 mV for DOPAC and HIAA and -300 mV 
for DA. The analytical column was a Supelco Supelcosil™ LC-18-DB column (150 
mm x 4.6 mm, 3 μm) (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). 
The mobile phase consisted of a mixture of 4.1 g.L-1 sodium acetate (Merck), 215 
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mg.L-1 octane sulphonic acid, 186 mg.L-1 EDTA, 7% methanol  and ultrapure water 
(pH=4.2 with glacial acetic acid). Data were converted into percentage of basal 
levels. The basal levels were determined from four consecutive samples (less than 
20% variation), and set to 100%. After the experiments the rats were sacrificed and 
the brains were removed. The brains were kept in 4% paraformaldehyde solution 
until they were sectioned to control the location of the dialysis probes. 
2.8 Data analysis 
A non-linear mixed effects modeling approach was used to describe the 
pharmacokinetics of (S)-5-OH-DPAT in plasma and the dopamine levels (PD 
endpoint) in the striatum. The in vivo data following transdermal and IV infusion 
were combined for analysis.  
2.8.1 PK model 
A detailed description of the pharmacokinetic model for (S)-5-OH-DPAT has been 
reported elsewhere [7]. Briefly, the PK model is based on compartmental mass 
transfer to describe the iontophoretic transport in vivo. Data fitting was performed 
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With dt
dX i t)(  as the rate of change in the amount of the drug in compartment i, Xi as 
the amount of the drug in compartment i, which refers to the skin compartment (i=1), 
the plasma compartment (i=2) and the peripheral compartment (i=3). I0 is defined as 
the zero order mass input during iontophoresis, KR as the first order release rate 
constant from skin to plasma, k as the first order elimination rate constant, k23 and k32 
as the first order distribution rate constants from plasma to tissue and tissue to 
plasma, respectively. N is a flag in the model to indicate that the input rate I0 is only 
valid during the iontophoresis period.  
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Following intravenous administration, data was modeled using Equation 4, which 
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With Rate as the zero order intravenous infusion rate and M as a flag to indicate that 
the Rate only applies during the duration of the infusion. Equation 3 was used to 
describe the rate of change in the peripheral compartment.  
2.8.2 PD model 
Two PD models were compared to fit the data of the dopamine release in the 
striatum during and after transdermal iontophoresis and intravenous infusion. The 
first model was the indirect response (IDR) type I model in analogy to the model 
proposed by Nugroho et al. [7]. The levels of 5-OH-DPAT in the plasma (Cp) were 
directly linked to the dopaminergic effect. The equations of the model to describe the 
rate of change in the dopamine concentration 
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With Imax as the maximum inhibition of the dopamine production, IC50 is the plasma 
concentration of 5-OH-DPAT at which 50% of maximum inhibition is observed, H is 
the slope of the curve (Hill coefficient), k0in is the zero order rate constant for the 
production of response, kout is the first order rate constant for the loss of response, 
CDA(0) is the baseline values of dopamine (i.e., dopamine concentration prior to the 
inhibiting effect of 5-OH-DPAT). 
In the second model, an extra hypothetic compartment was introduced to account for 
the delay between plasma concentration and the response, i.e., the effect 
compartment. The rate of change of drug concentration dt
tdCe )(
 in the effect 
compartment can be described as follows: 
( )()(.)( 20 tCtCkdt
tdC
ee
e −= )         (7) 
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With ke0 as the first order distribution rate constant from plasma to effect 
compartment and the elimination rate constant from the effect compartment. The 





















max        (8) 
With Ce as the drug concentration in the effect compartment.  
2.8.3 Model parameters 
A detailed description of the PK and PD modeling steps is presented elsewhere [7]. 
In short, the data analysis was performed using NONMEM version VI (NONMEM 
project group, University of California, San Francisco, USA), using the ADVAN6 
TRANS1 TOL=5 from PREDPP, as subroutines. The fixed effect parameters (θ) 
included: I0, KR, clearance (CL), inter compartmental clearance (Q), volume of the 
central compartment (V2), volume of the peripheral compartment (V3), kout, Imax, IC50 
and ke0. Variability in pharmacokinetic parameters was assumed to be log-normally 
distributed in the population. Inter-individual variability was modeled by an 
exponential error model as written in Equation 9: 
)exp(. iiP ηθ=           (9) 
in which θ is the population value for the fixed effect parameter P, Pi is the 
individual estimate and ηi is the normally distributed interindividual random variable 
with mean zero and variance ω². The coefficient of variation (CV %) of the structural 
model parameters is expressed as percentage of the root mean square of the 
interindividual variability term. The residual error was modeled by a proportional 
error model as written in Equation 10: 
)1.( 1,,, ijijpredijobs CC ε+=                  (10) 
where Cobs,ij is the jth observed concentration in the ith individual, Cpred,ij is the 
predicted concentration, and εij is the normally distributed residual random variable 
with mean zero and variance σ². The estimation of the final population parameters 
was performed using the conventional first order estimation method (FOCE). The PK 
model parameters were estimated independently and subsequently used as input for 
the PD analysis. During model building, goodness-of-fit was based on statistical and 
graphical diagnostic criteria. Model selection and identification was based on the 
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likelihood ratio test, coefficient of variation of parameter estimates, parameter 
correlations and goodness-of-fit plots. For the likelihood ratio test, the significance 
level for the inclusion of one parameter was set at p<0.05, which corresponds with a 
decrease of 3.84 points in the minimum value of the objective function (MVOF) 
under the assumption that the difference in MVOF between two nested models is χ2 
distributed. Non-nested models are evaluated using the Aikaike Information 
Criterion (AIC), which is the MVOF plus two times the number of parameters. The 
following goodness-of-fit plots were subjected to visual inspection to detect systemic 
deviations from the model fits: individual observed versus population and individual 
predicted values. Finally, the performance of the population PK and PK-PD models 
were assessed by simulating 100 data sets with the final model parameter estimates. 
The evaluation of model performance also included visual predictive check (VPC), 
as implemented in Xpose 4 (R version 2.7.0, R-foundation) [16].  
 
3 Results 
Three series of in vivo experiments were conducted to investigate the controllability 
of transdermal iontophoresis and to explore the potential impact of delivery rate on 
the PK-PD relationship of (S)-5-OH-DPAT. In the first study, the influence of the 
current density on drug pharmacokinetics in plasma profile was assessed. Two 
current densities were applied consecutively for 2h (75 and 150 µA.cm-2). In 
addition, (S)-5-OH-DPAT was administered as an IV infusion to the same animals to 
discriminate delivery-related properties from intrinsic pharmacokinetic properties. 
The crossover design also allowed higher precision of the parameter estimates. In the 
second study, the influence of the anesthetics, iontophoresis and blood sampling on 
the striatal dopamine level (PD endpoint) was investigated as a validation procedure 
for this experimental model. In the third study, the PK-PD relationship was 
investigated across a range of exposures, with maximum effects being attained for a 
short period followed by return of DA levels back to baseline conditions. For this 
reason, transdermal iontophoresis (250 µA.cm-2) was applied up to 1.5h. In analogy 
to the first study presented above, (S)-5-OH-DPAT was also administered with IV 
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Figure 2: The observed data (filled circles) of the plasma concentration (Cp) of the 
individual rats during and after transdermal iontophoretic delivery of (S)-5-OH-DPAT (3.9 
mM) together with the population model prediction (solid line) and the individual model 
prediction (dashed line). The following protocol was used: 120 min current density of 75 
µA.cm-²+ 120 min current density of 150 µA.cm-2. The patch was removed after 240 min 
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Figure 3: A: (S)-5-OH-DPAT concentration-time profiles in blood plasma following 
transdermal iontophoresis of (S)-5-OH-DPAT (3.9 mM). Depicted are the observed data 
(filled circles) together with simulated median (50%, solid line) and the upper and lower 
limit of the model-simulated interquantile concentration range (97.5%-5%, dashed lines). 
B: (S)-5-OH-DPAT concentration-time profiles in striatum following transdermal 
iontophoresis of (S)-5-OH-DPAT (3.9 mM). Depicted are the observed data together with 
the mean.  
 
3.1 PK properties following iontophoresis and IV infusion 
In these studies two different current densities (75 and 150 µA.cm-2) were applied 
consecutively during 2h to investigate the impact of flux on plasma profiles. 
Moreover it was of interest to determine the time to reach steady state conditions. 
The results of the pharmacokinetic studies are depicted in Figure 2. After 15 min of 
passive diffusion prior to iontophoresis no detectable amount was transported into 
the plasma (data not shown). In contrast, drug plasma levels increase immediately 
when switching on the current. In almost all the animals steady state plasma levels 
were achieved after 2h of 75 µA.cm-2 current application, with an average plasma 
concentration (Cp) of 4.1 ± 1.9 ng.ml-1. By further increasing the current density to 
150 µA.cm-2, Cp increased to 9.4 ± 4.8 ng.ml-1 after 2h approximately. In parallel, 
following IV infusion, Cp reached a maximum of 5.3 ± 0.5 ng.ml-1 after 15 min (data 
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not shown). After the discontinuation of infusion or upon termination of the current 
application, the Cp declined according to a 2-compartment disposition model. 
3.2 Validation of the rat model to investigate the PD effect 
The potential effects of anaesthesia (fentanyl+fluanisone and midazolam), of blood 
sampling and of transdermal iontophoresis on the striatal levels of dopamine (PD 
end-point) were investigated. The results of this control experiment are presented in 
Figure 4A. Dopamine levels remained stable in the period immediately before 
attaching the patch (-60 to -15 min) and in the 15 minute period of passive diffusion 
before iontophoresis (-15 to 0 min). The DA levels, which were set to 100% showed 
a non-significant small increase from 97 ± 3% to 100 ± 4% during iontophoresis, 
followed by a stronger increase to 114 ± 6% during 115 min after the end of 
iontophoresis. These results indicate the suitability of the anesthetized rat model for 
monitoring of DA levels to evaluate the properties of transdermal iontophoretic 
delivery or IV infusion of (S)-5-OH-DPAT. 
3.3 PK-PD relationships following iontophoresis and IV infusion 
The pharmacokinetics and pharmacodynamics of (S)-5-OH-DPAT were assessed 
following transdermal iontophoresis and IV infusion. With regard to the PK, no 
detectable plasma concentration could be observed after 15 min passive diffusion 
(data not shown). When starting the current application (250 µA.cm-2) the plasma 
concentration increased immediately and tended towards steady state after 90 min of 
current application (Figure 3A). The average concentration after 90 min of 
iontophoresis was 20.4 ± 3.7 ng.ml-1. Following IV infusion, Cp reached a maximum 
of 29.9 ± 2.4 ng.ml-1 after 10 min (data not shown). The decline in plasma 
concentration post (S)-5-OH-DPAT administration was best described by a 2-
compartment disposition model. Following transdermal iontophoresis, (S)-5-OH-
DPAT concentrations in the striatum were also monitored. As shown in Figure 3B, 
5-OH-DPAT concentrations increased to 0.96 ± 0.18 ng.ml-1 during current 
application, but this effect occurred after a small delay (between 7.5 and 22.5 min) in 
relation to the beginning of iontophoresis. The concentrations decreased again with 
the same delay upon discontinuation of the iontophoretic current.  
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Figure 4: The dopamine release, expressed as % of baseline vs time. A: transdermal 
iontophoresis of only buffer (control experiment) B, D: transdermal iontophoresis of (S)-5-
OH-DPAT (3.9mM).C, E: IV infusion of (S)-5-OH-DPAT (113 µM).  
A: depicted is the mean ± SD. B-E: depicted are the observations (filled circles) together 
with the model simulated interquantile DA% range (2.5 %-97.5%, dashed lines) and the 
simulated median (50%, solid line). A number of 100 samples were simulated based on the 
final parameter estimates.  
B, C: the visual predictive check without including a covariate of route of administration on 
IC50. D, E: the visual predictive check including a covariate of route of administration on 
IC50. In all panels the average dopamine release of 4 consecutive points prior to 
administration (time=-60 to -15 min) was set to 100%. 
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Table 1: The population estimates obtained from fitting the plasma profile and/or the 
pharmacological response following transdermal iontophoresis. During the PK study, two 
different current densities (75 and 150 µA.cm-2) were applied consecutively for 2h. During 
the PK-PD study, a current density of 250 µA.cm-2 was applied for 1.5h. 
 
    
  PK study PK-PD study 
      








      
parameter unit mean RSE% mean 
RSE





          
          
V2 L 0.5 6   0.5 18 0.100 71 
V3 L 1.7 16 0.189 46 0.7 16 0.109 42 
CL L.h-1 2.6 13 0.194 45 2.0 6 0.027 29 
Q L.h-1 2.5 9   1.9 23 0.218 44 
Jss 75 nmol.cm-2.h-1 24.7 29     
Jss 150 nmol.cm-2.h-1 51.3 30     
Jss 250 nmol.cm-2.h-1   87.3 8 0.000  / 
KR h-1 2.2 21   5.5 26 0.000  / 
          
          
ke0 h-1 3.9 10 0.192  77 
IC50 IONTO ng.ml-1 4.4 13 0.162 50 
IC50 IV ng.ml-1 1.9 11   
N  3.2 10 0.000  / 
IMAX DA% 
 
41.6 8 0.045 36 
          
          
Sigma  PK  0.037 12   0.0246 20   
Sigma PD       0.0120 22   
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The striatal dopamine release (PD endpoint) was monitored on-line simultaneously 
with plasma and striatal concentrations of (S)-5-OH-DPAT. These results are 
presented in Figure 4. Firstly, the pharmacodynamic effect was monitored following 
iontophoresis (15 min passive diffusion + 90 min of iontophoresis 250 µA.cm-2) 
(Figure 4B). During passive diffusion (-15 to 0 min) no change in DA levels were 
observed. Subsequently, dopamine levels gradually decreased to a minimum of 48.8 
± 5.1% of basal values within 94.5 ± 16.4 min after the start of the iontophoresis. DA 
levels returned to baseline values within 79.4 ± 11.3 min after the end of 
iontophoresis. In contrast, IV infusion of (S)-5-OH-DPAT resulted in an immediate 
decrease in the DA level. Maximum inhibition of 38.3 ± 8.4 % relative to baseline 
values was achieved after 42.1 ± 2.5 min (tmax) after start of IV infusion (Figure 4C). 
DA levels returned to baseline values within 120.4 ± 20.5 min after the end of 
infusion. A slight rebound effect was observed at the end of the experiment. DA 
level further increased to 119 ± 22 and 120 ± 23% relative to baseline after 
transdermal delivery and IV infusion, respectively. 
3.4 PK-PD analysis following transdermal iontophoretic delivery and IV 
infusion 
The pharmacokinetic data following transdermal iontophoresis was analyzed 
simultaneously with the PK data following intravenous infusion. The objective of the 
integrated analysis was to facilitate discrimination between delivery-specific 
parameters (I0, KR) and drug-specific parameters (V2, V3, CL, Q). The larger sample 
size also allowed for more precise estimation of model parameters. The resulting 
parameters are provided in Table 1. The low relative standard error (RSE) for all the 
fixed effect parameters (RSE ≤ 30%) indicates high precision of estimates. 
Moreover, as observed in Figure 2 and in Figure 5A, the model accurately describes 
the time course of plasma concentration during and after current application.  
An integrated approach was also applied to the PK-PD experiments. The analysis of 
the PK PD data following IV administration and iontophoresis was performed 
simultaneously. In analogy to the PK study, the plasma concentration profile could 
be described by the proposed compartmental model. In Figure 3A, the VPC depicts 
the goodness of fit, with observed data randomly distributed within the 95% 
confidence interval (C.I.). In addition, the diagnostic plots (Figure 5B) show a good 
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Figure 5: Diagnostic plots of the plasma and striatum analysis using the integrated PK-PD 
model. A: Analysis of plasma concentration (Cp) of (S)-5-OH-DPAT following IV infusion 
and iontophoresis during the PK study. B: Analysis of plasma concentration (Cp) of (S)-5-
OH-DPAT following IV infusion and iontophoresis during the microdialysis study.               
C: Analysis of dopamine (DA) release in striatum, expressed as % of baseline values, 
following IV infusion and iontophoresis. In every panel the population prediction (left 
graph) and individual prediction (right graph) vs the measured value is displayed. 
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The effect of (S)-5-OH-DPAT (striatal dopamine release) was assessed by two 
pharmacodynamic models. The first model consisted of a turnover model, i.e., with 
indirect response type I [14], and the second model consisted of an effect 
compartment and a sigmoid Imax model [13]. The AIC of the effect compartment 
model was lower than the turnover model. In addition, an improved distribution of 
the observations in the 95% C.I. of the VPC and a lower residual standard error 
(RSE) of the parameter estimates were observed when fitting the data with the effect 
compartment model (comparison not shown). Therefore the effect compartment 
model was selected for further evaluation of the PK-PD relationship of (S)-5-OH-
DPAT. Given the small bias observed in the simulated median profiles of DA 
(Figure 4B and 4C), a covariate analysis was performed, which revealed differences 
in IC50 depending upon the administration route. Incorporation of the route of 
administration as covariate into the model improved the VPC (Figure 4D and 4E) 
and the objective function decreased significantly (χ²-test; p<0.05). The resulting 
parameters are summarized in Table 1. PK and PD parameters were estimated with 
good precision, as indicated by a relatively low RSE of the parameters (≤26 %).  
Figure 4D and 4E depict the 95 C.I. together with the simulated median response 
when including route of administration as covariate in the model. It can be observed 
that the model slightly under- and overpredicts the median of the DA release 
following transdermal iontophoresis and IV infusion, respectively. Nonetheless, 95% 
of the observations can be found within the boundaries of the confidence interval. 
Finally, goodness-of-fit plots for the dopamine release (Figure 5C) show that the 
model accurately predicts the observed DA release for both administration routes. 
4 Discussion 
The present study provides novel information on the pharmacokinetic and 
pharmacodynamic properties of the active enantiomer of the potent dopamine agonist 
(S)-5-OH-DPAT. Specifically, the present investigation focused on the 
controllability of the transdermal iontophoretic delivery of this compound with 
regard to the plasma concentration and the dopaminergic activity in the striatum.  
4.1 Relationship between current density and plasma profile 
With regard to the controllability of the plasma concentration, the relationship 
between the applied current density and the corresponding plasma profile was 
investigated. Three different current densities (75, 150 and 250 µA.cm-²) were 
applied in 2 different studies. A comparison of the pharmacokinetic parameters of 
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the PK-study (using two current densities 75, 150 µA.cm-²) and the PK-PD study 
(applying 250 µA.cm-²) revealed a difference in peripheral volume of distribution 
(V3), central (CL) and peripheral clearance (Q). The difference in these 
pharmacokinetic parameters can be attributed to the difference in recovery period 
after surgery of the animals in the two studies, rather than due to differences in 
transport/delivery. For the PK-studies, the animals were allowed to recover for at 
least 1 week, whereas the PK-PD studies were executed 15-20h post surgery. Similar 
results were found by Torres-Molina and co-workers, who demonstrated that the 
placement of a permanent cannula in the jugular vein influences the PK parameters 
of amoxycilin and antipyrin in rats. The PK parameters depended on the time of 
execution of the experiment after placement of the cannula [17]. This should be 
taken into account when designing new experiments, especially with a cross-over 
design.   
Despite the difference in PK parameters between the two studies, a clear linear 
dependency (R²=0.999) was observed (Figure 6) between the applied current density 
and the in vivo steady state flux, calculated from the zero order mass input using the 
following equation [18]:  
S
IFluxss 0=                    (11) 
In literature, similar results were reported for the iontophoretic delivery in vivo of 
hydromorphone and ropinirole [6, 19]. Moreover, Patel et al. recently demonstrated 
the controllability of the plasma concentration profiles by the current density for 
zolmitriptan [20]. These results show that, despite differences in PK properties, the 
drug input into the skin can be controlled very carefully by adjusting the current 
density. This can be very useful in initiating therapeutic treatment with dopamine 
agonist, adjusting the dose to the demand of the individual patient. 
Based on this relationship between the in vivo flux and the current density, the in 
vivo flux, applying a current density of 500 µA.cm-², was estimated at 174.9 
nmol.cm-².h-1. Despite the interspecies differences, this value differs only 21% from 
the in vitro flux across human stratum corneum (211.9 ± 11.1 nmol.cm-².h-1), when 
applying a current density of 500 µA.cm-2 [21]. This indicates that in vitro transport 
parameters can be used to predict drug delivery properties in vivo, even across 
species. Regarding the rat skin, iontophoretic transport is frequently comparable with 
human skin, in which iontophoresis may diminish interspecies variations in in vitro 
skin permeation studies [22-23].   
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Figure 6:  In vivo flux vs current density. Each data point represents the parameter estimate, 
determined with compartmental modeling, with the standard error of the parameter estimate. 
In each experiment 4-6 rats were used. 
Our findings suggest the possibility of further refinement of future experiments for 
the evaluation of drug delivery by iontophoresis. In fact, a model-based approach can 
be used to to provide guidance for optimal sampling and dose selection as well as by 
allowing a more quantitative assessment of safety margins. This is one of the reasons 
why PK-PD modeling is gaining a more prominent place in the different stages of 
drug development [24].  
4.2 PK-PD relationship  
Next to a controlled plasma concentration the second aim of our investigation was to 
characterize the PK-PD relationship of (S)-5-OH-DPAT. A previous study showed 
that 5-OH-DPAT, administered with transdermal iontophoresis can cause a very 
strong pharmacodynamic effect. However it was observed that even after 3h post-
iontophoresis the dopamine level (PD end-point) did not recover to its initial state 
[7]. In addition, during these studies choral hydrate was used as anesthetic [7]. 
Chloral hydrate is not considered the optimal choice for anesthesia of small animals, 
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like rodents. Moreover several studies showed that choral hydrate influences the 
striatal DA turnover [25-27] and enhances the suppressive effects of several DA 
agonists [28]. Therefore our studies were performed following IV infusion and 
iontophoresis to explore the implications and validate the use of new anesthetic 
procedures in conjunction with on-line brain microdialysis [10-11]. In addition, we 
assessed the PK-PD relationship under a wider range of exposures, ensuring 
reversibility of the PD effect. 
A mixture of fentanyl, fluanisone and midazolam was chosen to anesthetize the 
animals. However, it has been reported in literature that these anesthetics 
individually also can affect the striatal DA metabolism. Fentanyl and fluanisone can 
increase the DA turnover in the striatum [29-31], while midazolam has been reported 
to decrease the DA levels in a dose dependent manner [32]. Besides the effect of the 
combination of anesthetics, the effect of iontophoresis and blood sampling on the 
dopamine level was also investigated. As shown in Figure 4A, the stimulating effect 
of fentanyl and fluanisone and the inhibiting effect of midazolam on the dopamine 
release were balanced during iontophoresis. After iontophoresis the dopamine release 
increased slightly, which could indicate a dominating effect of fentanyl. Nonetheless 
a rat model was established with stable dopamine release levels during anesthesia, 
which enabled us to investigate the dopaminergic effect of (S)-5-OH-DPAT 
following intravenous infusion and transdermal iontophoresis.  
For both administration routes a decrease in striatal DA level can be observed which 
returns to baseline within 2h after ending the administration. This demonstrates that a 
controlled reversible effect can be obtained. Moreover, DA levels seem to reach 
steady state following transdermal iontophoresis, in parallel to time course of 
concentrations in plasma. These results suggest that steady state concentrations of 
(S)-5-OH-DPAT translate into a steady state decrease of the dopamine level. Given 
that dopamine synthesis is indirectly controlled by presynaptic dopamine receptors, 
these findings suggest a continuous stimulation of the dopamine receptors [33-34]. 
Likewise, it has been shown that stable plasma levels of rotigotine, another potent 2-
aminotetralin, also result into continuous dopaminergic stimulation [35]. This could 
be of great benefit for symptomatic treatment of Parkinson’s disease. It is generally 
believed that continuous dopaminergic stimulation is currently the best strategy to 
reduce motor complications after long-term use of dopaminergic agents [5]. 
However, further investigations are required applying current for a longer time 
period with different doses to confirm the applicability of transdermal iontophoresis 
of dopamine agonists like (S)-5-OH-DPAT.  
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4.3 PK-PD modeling  
The plasma profile and the DA release following IV infusion and transdermal 
iontophoresis were analyzed using compartmental modeling. Plotting the DA release 
vs the plasma concentration showed a counter clock-wise hysteresis (data not 
shown). This indicates a time delay between the plasma concentration and the 
pharmacological response. To account for this delay an effect compartment model 
[13] was compared with an indirect response model type I [14]. In the present study, 
it is shown that the DA release is best described by an effect compartment in 
conjunction with the sigmoidal Imax model. This suggests that the delay between 
plasma concentration and pharmacological response is attributed to the distribution 
from plasma to site of action, rather than because of a slow onset of the effect. This 
is further supported by the delayed increase in striatal 5-OH-DPAT concentration 
following transdermal iontophoresis in Figure 3B. These findings shed light into the 
mechanisms underlying delay reported by Nugroho et al., who described the DA 
release, following transdermal iontophoresis of 5-OH-DPAT with an indirect 
response model type I [7].  
As observed in Table 1, the IC50 is approximately 2.3 times lower when 
administering (S)-5-OH-DAT with IV infusion compared to the IC50 with 
transdermal administration. This raises an important question regarding the role of 
the delivery rate: Do differences in delivery rate alter the response profiles of (S)-5-
OH-DPAT? This question can be addressed by estimating the pharmacodynamic 
efficiency (EFF), defined as the pharmacological response per unit of concentration, 
as shown in the following equation: 
AUC
AAECEFF =                             (12) 
Where AUC (ng.ml-1.min) is the area under the plasma 5-OH-DPAT concentration 
curve and AAEC (DA%.min) is the area above the effect curve (normalized for 
baseline dopamine levels). For the IV infusion EFF was 9.2 ± 2.3 ml.ng-1, which is 
approximately 1.9 ± 0.8 times higher than the EFF following transdermal 
iontophoresis, estimated at 4.8 ± 1.7 ml.ng-1. Given that the delivery rate during IV 
infusion was approximately 3.5 times higher than during transdermal iontophoresis, 
these observations suggest that a high delivery rate may improve the 
pharmacodynamic efficiency. In this respect. transdermal iontophoresis can be a 
suitable delivery technique, since the delivery rate can easily be adjusted using 
different current densities (Figure 6). For instance a loading dose, by applying a 
higher current density at the start of the iontophoretic delivery, can be combined with 
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a maintenance dose, by gradually decreasing the current density to a certain level. 
Follow-up studies based on drug administration with different delivery rates should 
be performed to confirm these findings.   
The use of an integrated PK-PD approach, simultaneously monitoring drug 
concentrations in plasma and pharmacodynamic effects, has several benefits over 
experimental designs in which Cp or the PD effect are evaluated independently. 
Firstly, it was shown that a steady state plasma concentration may result in a 
continuous stimulation of the dopamine receptor. Secondly, PK-PD modeling 
contributes to further understanding of the mechanisms and time course of drug 
action. Thirdly, PK-PD model parameters can be used to support the design of future 
experiments. Furthermore, the assessment of PK-PD relationships enables 
discrimination between delivery-specific and drug-specific parameters. This 
distinction is critical in drug delivery research, in that it warrants the identification of 
the factors which may ultimately determine treatment response in vivo.   
In conclusion, these studies demonstrate that transdermal iontophoresis can be an 
excellent delivery route for continuous controlled administration of (S)-5-OH-DPAT 
and other potent dopamine agonists for the symptomatic treatment of Parkinson’s 
disease. PK-PD modeling suggests that target distribution causes the delay between 
plasma concentration and drug effect. In addition, modulation of the delivery rate 
seems to have a direct impact on the pharmacodynamics. These results are very 
important for understanding of the mechanisms underlying drug transport and 
disposition following transdermal iontophoresis. This information will be crucial for 
designing a self-controlled delivery device, guided by a feedback system.   
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CHAPTER 7   
Abstract 
The feasibility of transdermal iontophoretic transport of 4 novel ester prodrugs of 5-
OH-DPAT (glycine-, proline-, valine- and β-alanine-5-OH-DPAT) was investigated 
in vitro and in vivo. Based on the chemical stability of the prodrugs, the best 
candidates were selected for in vitro transport studies across human skin. The 
pharmacokinetics and pharmacodynamic effect of the prodrug with highest transport 
efficiency, was investigated in a rat model. The in vitro transport, plasma profile and 
pharmacological response were analyzed with compartmental modeling. Valine- and 
β-alanine-5-OH-DPAT were acceptably stable in the donor phase and showed a 4-
fold and 14-fold increase in solubility compared to 5-OH-DPAT. Compared to 5-
OH-DPAT, valine- and β-alanine-5-OH-DPAT were transported less and more 
efficiently across human skin, respectively. Despite a higher in vitro transport, lower 
plasma concentrations were observed following 1.5 h current application (250 
μA.cm-2) of β-alanine-(S)-5-OH-DPAT in comparison to (S)-5-OH-DPAT. However 
the prodrug showed higher plasma concentrations post-iontophoresis, explained by a 
delayed release due to hydrolysis and skin depot formation. This resulted in a 
pharmacological effect with the same maximum as 5-OH-DPAT, but the effect lasted 
for a longer time. The current findings suggest that β-alanine-5-OH-DPAT is a 
promising prodrug, with a good balance between stability, transport efficiency and 
enzymatic conversion. 
 
Keywords: prodrugs, stability, iontophoresis, PK-PD 
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Figure 1: Molecular structure of 5-OH-DPAT and the 4 synthesized prodrugs, glycine-5-
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1 Introduction  
Transdermal delivery has been explored thoroughly as an alternative for oral delivery 
and injections. However, the main hurdle for transdermal delivery is the barrier 
function of the skin located in the outermost layer of the skin, the stratum corneum. 
An attractive approach to overcome this main barrier for drug delivery is 
iontophoresis. By applying a small current across the skin it is possible to enhance 
the transport of low molecular weight molecules across the skin. One of the 
interesting properties of this technique is the possibility to modulate the transport rate 
into and through the skin. This is an important advantage for drugs with a narrow 
therapeutic window, such as dopamine agonists (e.g. rotigotine, apomorphine, 
pergolide, 5-OH-DPAT). Most of the dopamine agonists are considered moderate 
lipophillic and have a relative low solubility in aqueous solutions [2-4]. For this 
reason, besides a low efficiency in iontophoretic transport, the low solubility of 
dopamine agonists can be a limitation for application with transdermal iontophoresis. 
Increasing the maximum solubility in the donor phase can be achieved by adjusting 
the donor phase (co-solvent, surfactant, source of Cl--ions) or by changing the salt 
form. Another approach is the use of prodrugs with the desired physicochemical 
properties to overcome the problem of solubility and increase the efficiency in 
iontophoretic transport [5]. The principle goal of synthesizing prodrugs is to  
chemically modify an existing pharmacologically active drug in a form that can be 
reversed to the parent drug in vivo, with the aim to change the physicochemical 
and/or pharmacokinetic properties. Moreover for transdermal delivery a prodrug 
should be enzymatically metabolized in a controllable and predictable manner once it 
has penetrated the main barrier, the stratum corneum [6-8].  
The main focus of the present study is to identify a prodrug that is transported 
efficiently with transdermal iontophoresis and is hydrolyzed during transport through 
the skin. This implies a good balance between the transport rate and the rate of 
enzymatic conversion of the prodrug. Previous studies showed that transdermal 
iontophoretic delivery of 5-OH-DPAT resulted in a strong pharmacological response, 
which is believed to meet the requirements for symptomatic therapy with a 
reasonable patch size and acceptable current density [1, 9]. However further 
improving the iontophoretic delivery could merely enhance the clinical applicability 
of this potent dopamine agonist by reduction of the patch size and more importantly 
minimization of the current density. Therefore 5-OH-DPAT, a dopamine agonist 
with limited aqueous solubility, was esterified with 4 different natural occurring 
amino acids (Figure 1). These amino acids contain an extra chargeable aminogroup, 
providing the possibility to investigate the influence of an additional charge on the 
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iontophoretic delivery of 5-OH-DPAT. The stability of these 4 prodrugs is 
investigated and the most stable compounds are selected for transdermal 
iontophoretic transport. Depending on the iontophoretic transport efficiency of the 
selected prodrugs in vitro across human stratum corneum and dermatomed human 
skin, the in vivo transport of the most promising candidate is further investigated. The 
plasma profile and the pharmacodynamic effect are monitored simultaneously in an 
animal model under anaesthetized conditions. Both in vitro and in vivo transport 
profiles are analyzed using compartmental modeling. Taking the hydrolysis of the 
prodrug into account, an adaptation to existing kinetic models is made to describe the 
transdermal iontophoretic delivery in vivo [1, 9].  
2 Materials and Methods 
2.1 General synthesis of the glycine, L-proline, β-alanine and L-valine esters 
of 5-OH-DPAT 
The full description of the synthesis of the 4 prodrugs of 5-OH-DPAT is described 
elsewhere [10]. Briefly, 5-OH-DPAT was esterified to the N-protected amino acid 
with the carbodiimide coupling reagent N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide (EDC). 1-Hydroxybenzotriazole (HOBt) was added to suppress 
racemisation. The deprotection of the Boc-protected compound was carried out in 4N 
HCl in dioxane. After removal of the solvent and evaporation in vacuo, the solid 
hygroscopic foams were reprecipitated from dry methanol with dry ether to remove 
excess dioxane. The prodrugs were obtained as white hygroscopic dihydrochloride 
salts with a purity of >95% (HPLC). 
2.2 Materials 
5-OH-DPAT and 5-hydroxy-2-(N-n-propyl-N-α,α-dideutero-propylamino)-tetralin 
(d2-5-OH-DPAT) (HBr salts, purity >98%) were synthesized at the Department of 
Medicinal Chemistry of the University of Groningen, Groningen, the Netherlands.  
Silver, silver chloride (purity >99.99%), trypsin (Type III from bovine pancreas) and 
trypsin inhibitor (Type II-S from soybean) were obtained from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Acetaminophen was purchased from Brocacef BV 
(Maarssen, the Netherlands) and D-Mannitol was obtained from BDH Laboratory 
supplies (Poole, UK). Spectra/Por® RC dialysis membrane disks (cut off value of 
6000-8000 Da) were purchased from Spectrum laboratories, Inc (Rancho 
Dominquez, Ca, USA). Tetrahydrofuran (THF, stabilized, purity >99.8%) was 
obtained from Biosolve (Valkenswaard, the Netherlands). Triethylamine (TEA, 
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purity >99%) was obtained from Acros Organics (Geel, Belgium). All other 
chemicals and solvents were of analytical grade. All solutions were prepared in 
Millipore water with a resistance of more than 18 MΩ.cm. 
2.3 Stability of glycine-, proline-, valine- and β-alanine-5-OH-DPAT 
The stability of the prodrugs was investigated under various conditions. At the 
starting point 1 mg.ml-1 of proline- and glycine-5-OH-DPAT and 0.02 mg.ml-1 of 
valine- and β-alanine-5-OH-DPAT were dissolved in the buffer solution. The buffer 
solution was citric buffer (5 mM, pH 5.0 + 4 g.L-1 NaCl + 23.1 g.L-1 D-mannitol), 
PBS pH 6.2 (NaCl: 8 g.l-1, KCl: 0.19 g.l-1, Na2HPO4.2H2O: 0.43 g.l-1, KH2PO4: 0.97 
g.l-1) or PBS pH 7.4 (NaCl: 8 g.l-1, Na2HPO4: 2.86 g.l-1, KH2PO4: 0.2 g.l-1, KCl: 0.19 
g.l-1). The solutions were continuously stirred and kept constant at the desired 
temperature, using a thermostat controlled water bath. If required a circular sheet of 
human stratum corneum (HSC) (ø=18 mm) was added to the solution and a current 
of 320 µA was applied. At regular time intervals samples were taken from the 
solution and diluted in Millipore water, containing 0.1% trifluoroacetic acid [11] to 
stop degradation. Both the amount of remaining prodrug and the parent drug 5-OH-
DPAT were quantified by RP-HPLC. The amount of remaining prodrug was plotted 
as a function of time to calculate the first order rate constant of hydrolysis and the 
corresponding half life. 
2.4 Maximum solubility of valine-5-OH-DPAT and β-alanine-5-OH-DPAT 
The solubility studies of the different compounds were carried out as described 
elsewhere [3]. Briefly, each compound was solubilized in citric buffer 5 mM, pH 5.0 
+ 4 g.L-1 NaCl + 23.1 g.L-1 D-mannitol. Subsequently the pH in each test tube was 
adjusted to pH 5.0 with 1M NaOH or 1M HCl under continuous shaking. Each 
solution was shaken for 48h, after which the solution was centrifuged and filtered. 
The concentration in each solution was determined with HPLC. Due to the limited 
availability of the compound and the relative high solubility, this assay was 
performed in monoplicate (n=1). 
2.5 In vitro transport studies 
The preparation of dermatomed human skin (DHS) and human stratum corneum was 
performed according to the method described previously [12]. All transport 
experiments were carried out as described elsewhere [12]. The donor formulation 
(citric buffer 5 mM, pH 5.0, NaCl: 4 g.L-1, D-mannitol: 23.1 g.L-1), containing the 
solute, was added to the anodal chamber. The cathodal chamber was filled with PBS 
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pH 7.4. Unless described differently, the acceptor phase, maintained at 32°C, was 
continuously perfused with PBS 7.4 at a flow rate of 7.0 ml.h-1. The following 
protocol was used: 6h passive diffusion + 9h iontophoresis (500 µA.cm-²) + 5h 
passive diffusion. Samples were collected every hour with an automatic fraction 
collector (ISCO Retriever IV, Beun De Ronde BV, Abcoude, The Netherlands). To 
stop the hydrolysis after transport through the skin and before analysis TFA (0.1% 
v/v) was added to each sample. The specific conditions of the individual transport 
studies are described below.  
2.5.1 Iontophoretic delivery of valine-OH-DPAT and β-alanine-5-OH-DPAT 
The iontophoretic delivery of valine-5-OH-DPAT across HSC and DHS was studied 
at a concentration of 3.9 mM.  
Iontophoretic delivery of β-alanine-5-OH-DPAT across HSC was studied at 3 
different concentrations (1.5 mM, 3.9 mM or 7.0 mM). For the transport study with 
1.5 mM as donor phase the current was only applied for 7h, after which the 
experiment was stopped. Transport studies across DHS were performed with a donor 
concentration of 3.9 mM. For all experiments PBS pH 7.4 was used as acceptor 
phase. 
2.5.2 Electroosmotic flux across HSC 
The electroosmotic flux across HSC was investigated during iontophoretic transport 
of valine- and β-alanine-5-OH-DPAT (3.9 mM), buffered at pH 5.0. Acetaminophen 
(15 mM) was added to the donor phase as a marker for the electroosmosis. PBS pH 
7.4 was used as acceptor phase.  
2.6 Hydrolysis during transport across HSC and DHS 
The prodrugs valine-5-OH-DPAT and β-alanine-5-OH-DPAT are expected to 
hydrolyze during transdermal transport. Although stratum corneum is considered as 
the main barrier of the skin, the majority of the enzymes, such as esterases can be 
found in the epidermis [13]. Therefore the hydrolysis of the prodrugs (donor conc: 
3.9 mM) was determined during iontophoresis across HSC and DHS. In case of 
valine-5-OH-DPAT, PBS pH 6.2 was used as acceptor phase and for β-alanine-5-
OH-DPAT PBS pH 7.4 was used. The remaining prodrug was determined in the 
acceptor phase every hour after transport, taking the degradation in the donor phase 
and acceptor phase into account. 
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2.7 PK-PD studies 
In the following studies the pharmacokinetic (PK) and pharmacodynamic (PD) 
properties of β-ala-(S)-5-OH-DPAT following transdermal iontophoretic delivery 
were determined simultaneously by taking blood samples (PK) and using on-line 
microdialysis (PD). For these studies, the active enantiomer (S)-5-OH-DPAT, was 
esterified with β-alanine. Animal procedures were conducted in accordance with 
guidelines published in the NIH guide for the care and use of laboratory animals and 
all protocols were approved by the Institutional Animal Care and Use Committee of 
the University of Groningen. The surgical, experimental and analytical procedures 
were identical to the methods used for PK-PD studies performed with the parent drug 
(S)-5-OH-DPAT [1]. A brief description is outlined below.  
2.7.1  Animals 
The pharmacokinetic-pharmacodynamic (PK-PD) studies were performed in albino 
male wistar rats (280-340 g) obtained from Harlan (Horst, the Netherlands). Prior to 
surgery the animals were housed at least 1 week in plexiglas cages, maximum 6 
animals per cage with free access to water and standard laboratory chow. The cages 
were placed in a room with a controlled temperature at 21 °C and controlled 
humidity between 60-65% and a light-dark cycle of 12h.  
2.7.2 Surgical procedures 
Prior to surgery the rats were anaesthetized with Isofluran 2% in N2O/O2 (2/1). The 
permanent cannulations in the femoral vein and femoral artery were performed using 
silicone catheters (inner diameter (I.D.): 0.5 mm; outer diameter (O.D.): 0.9 mm) 
(UNO BV, Zevenaar, The Netherlands). After the cannulation the rats were kept 
under anaesthetized condition and mounted into a sterotaxic frame for the 
implementation of the microdialysis probes. A Y-shaped dialysis probe was used for 
the experiments, with an exposed tip length of 3 mm. The dialysis canulla (I.D.: 0.24 
mm; O.D.: 0.34 mm) was prepared from polyacrylonitrile/sodium methallyl 
sulfonate copolymer (AN 69, Hospal, Bologna, Italy). The microdialysis canulla was 
implanted in the striatum. The following coordinates were used according to the atlas 
of Paxinos and Watson [14]: AP +0.9, LM ± 3.0 relative to bregma, and Vd – 6.0 
below dura. The dialysis probe, filled with Ringer solution (140 mM NaCl, 3.0 mM 
KCl, 1.2 mM CaCl2, 1.0 mM MgCl2), was positioned and fixed in the burr hole 
under stereotaxic guidance. Thereafter the rats were housed solitary. 
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2.7.3 Experimental procedures 
The PK-PD studies were performed 15-20 h after permanent cannulation and 
implementation of the probes. The rats were anaesthetized prior to and kept under 
anesthetized condition during the experiment with Hypnorm® and Dormicum® at a 
starting dose of 0.5 mL.kg-1 and subsequent 1h doses of 0.17 mL.kg-1. 
The donor solution consisted of β-ala- (S)-5-OH-DPAT (3.9 mM), buffered in citric 
buffer 5 mM at pH 5.0. Before the start of the experiment, the hair of the back of the 
anesthetized rat was removed with an electrical clipper and scalpel. 15 min after 
attaching the patches to the skin surface, the cathodal patch was filled with PBS pH 
7.4 and the anodal patch was filled with donor solution. The volume of the patches 
was 2.3 ml and the active area was 2.5 cm². The protocol for the transdermal 
iontophoretic PK-PD studies was: 15 min passive diffusion + 90 min current 
application (250 µA.cm-2). The patch was removed and the skin was wiped using 
tissue paper. Blood samples were taken at regular time intervals: 0, 15, 30, 45, 60, 
75, 90, 105, 120, 135, 165, 195, 225, 255, 285 min. The blood samples (0.2 ml) were 
collected using lithium-heparin containing tubes (Microvette® 200 Plasma/Lithium 
Heparin, Sarsted BV, Etten-Leur, the Netherlands) and subsequently the plasma 
samples were separated from the blood cells by centrifugation. The samples were 
kept at -20 °C prior to analysis with LC-MS/MS. The microdialysis probes in the 
striata were perfused with Ringer solution at a flow of 2 μL.min-1 (CMA/102 
Microdialysis Pump, Sweden). The analysis of the microdialysate samples are 
described below. 
2.8 Analytical method 
2.8.1 in vitro samples 
Different HPLC methods were developed, in order to analyze simultaneously the 
respective prodrug, the parent drug 5-OH-DPAT and, if required, acetaminophen by 
RP-HPLC using a Superspher® 60 RP-select B, 75 mm-4 mm column (Merck KGaA, 
Darmstadt, Germany). The prodrugs of 5-OH-DPAT and acetaminophen were 
detected using a UV detector (Dual λ Absorbance Detector 2487, Waters, Milford, 
USA). The absorption wavelengths for the prodrugs and acetaminophen were 220 
nm and 243 nm respectively. 5-OH-DPAT was detected using a scanning 
fluorescence detector (Waters™ 474, Millipore, Milford, MA, USA) with excitation 
wavelength and emission wavelength of 276 nm and 302 nm, respectively. The 
composition of the mobile phase for analyzing the respective prodrug together with 
5-OH-DPAT is presented in Table 1. The flow rate was set to 1.5 ml.min-1 and the 
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volume of injection was 200 µl. Calibration curves showed a linear response when 
using concentrations of compounds between 0.1 and 40 µg.ml-1 (R2>0.999). The 
limit of detection (LOD) and limit of quantification (LOQ) for these HPLC methods 
can also be found in Table 1.  
2.8.2 Blood samples of (S)-5-OH-DPAT 
Since the hydrolysis of β-ala-(S)-5-OH-DPAT to (S)-5-OH-DPAT is occuring very 
rapidly in human blood plasma (t1/2=0.24 min in 80% human blood plasma), only 
(S)-5-OH-DPAT was analyzed in plasma [10]. Blood samples of 5-OH-DPAT were 
analyzed with an on-line solid-phase-extraction-liquid-chromatography-mass 
spectrometry/mass spectrometry (SPE-LC-MS/MS) method, described elsewhere [1]. 
Briefly, after addition of the internal standard (d2-5-OH-DPAT; 5 ng.ml-1) to the 
collected plasma, acetonitrile was added to precipitate the proteins. The mixture was 
vortexed, centrifuged, after which the supernatant was dried and redissolved in 
MilliQ and injected on the SPE cartridge (Hysphere Resin C8, endcapped, 10 x 4 
mm (ID), 10μm SPE cartridge (Spark Holland B.V, The Netherlands). An external 
 
 
Table 1: Physicochemical properties of the different molecules investigated 
(Mw, charge/Mw ratio and cLogP) and the composition of the mobile phase with the 
corresponding limit of detection (LOD) and limit of quantification (LOQ) 
       
Compound Mw Charge/ Mw clogP
a Mobile phase LOD LOQ 
  (x103)  Composition TEA    
 (g.mol-1) (mol.g-1)  (v/v) (mM) (µg.ml-1) (µg.ml-1) 
        
        
gly-5-OH-DPAT 304.4 6.6 3.6 Ace 50 mM/ACN    85/15 0 n.d n.d 
pro-5-OH-DPAT 344.5 5.8 4.1 Ace 50 mM /ACN   74/26 0 n.d n.d 
val-5-OH-DPAT 346.5 5.8 4.8 Ace 100 mM /THF   95/5 30 0.25 0.41 
β-ala-5-OHDPAT 318.4 6.3 3.8 Ace 100 mM/THF  97.5/2.5 30 1.6 2.7 
5-OH-DPAT 247.4 4.0 4.3 *  1.4.10-3 2.4.10-3
acetaminophen 151.2 0.0 n.d *  0.9.10-3 1.4.10-3
        
Ace: acetatebuffer pH 3.6; nd: not determined; * :mobile phase is dependent on the prodrug investigated 
acLogP was calculated using ACD/Chemsketch [15-17]; n.d.: not determined 
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binary HPLC pump (Gynkotek, Germany) and an external Agilent 1200, 2/6 switch 
valve (Agilent Technology, USA) were used for the SPE sample trapping. First the 
SPE cartridge was conditioned, then the injected sample was trapped, consequently 
the valve was switched placing the SPE cartridge in-line with the LC system for 
elution on to the analytical column, after which the SPE cartridge was cleaned. 
Finally the cartridge was conditioned again. To analyze the extracted sample an 
Agilent 1200 HPLC system with autosampler (Agilent Technology, USA) was 
coupled online with an Agilent 6460 Triple Quadrupole mass spectrometer (Agilent 
Technology, USA). The samples were analyzed by μPLC-MS/MS using an Altima 
HP C18 column (150X 1.0 mm; 5 µm) (Grace Davison Discovery Sciences, 
Belgium). The detection was performed with a triple quadrupole mass spectrometer 
in the positive-ion electrospray mode and all analytes were monitored with Multiple 
Reaction Monitoring (MRM). System operation and handling the acquired data was 
performed using Agilent MassHunter data acquisition software (version, B.02.00; 
Agilent). Calibration curves showed a linear response when using concentrations of 
compounds between 0.2 and 50 ng.ml-1 (r2>0.999). The recovery, limit of detection 
(LOD) and limit of quantification (LOQ) were experimentally determined at 93.9 ± 
2.9 %, 0.07 and 0.2 ng.ml-1, respectively. 
2.8.3 Microdialysate samples 
To analyze the striatal 5-OH-DPAT concentration the dialysate from the probe in the 
left striatum was collected every 15 min resulting a total volume of 30 μL per 
sample. The solution was analyzed using LC-MS/MS method, described elsewhere 
[1]. Briefly, d2-5-OH-DPAT.HBr was added as internal standard to a 100 μL mixture 
of water + 0.1% formic acid and Ringer (1:1). The HPLC system consisted of a 
Shimadzu LC 20 AD binary system with a Shimadzu SIL 20AC autosampler. The 
samples were injected on a Grace Alltech Alltima HP C18 EPS reverse-phased 
column (150 x 2.1 mm (ID), 3 µm). The compounds were detected on a SCIEX 
API3000 triple quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX) 
equipped with a Turbo Ion Spray interface. The mass spectrometer was operated in 
the positive ion mode with MRM. The detection limit of 5-OH-DPAT was 12.5 
pg.ml-1. 
The dialysate contents of dopamine (DA) and its metabolites were quantified from 
the probe implanted at the right striatum by an on-line HPLC with electrochemical 
detection with the detection limit of 1 fMol per sample. An HPLC pump (LC-10AD 
vp, Shimadzu, Japan) was used in conjunction with an analytical cell (5011A, ESA,  
Chelmsford, MA, USA) and an electrochemical detector (Coulochem II, ESA) 
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working at +300 mV for DOPAC and HIAA and -300 mV for DA. The analytical 
column was a Supelco Supelcosil™ LC-18-DB column (150 mm x 4.6 mm (I.D.), 
3μm). Data were converted into percentage of basal levels. The basal levels were 
determined from four consecutive samples (less than 20% variation), and set at 
100%. After the experiments the rats were sacrificed and the brains were removed. 
After removal, the brains were kept in 4% paraformaldehyde solution until they were 
sectioned to control the location of the dialysis probes. 
2.9 Data modeling  
The data of the in vitro transport of valine-, β-alanine-5-OH-DPAT and 5-OH-DPAT 
and the PK-PD data following transdermal iontophoresis of β-alanine-(S)-5-OH-
DPAT were analyzed using non-linear mixed effects modeling.  
in vitro model 
Previous studies suggested that two transport routes are involved in the iontophoretic 
delivery, linked in parallel [18]. Therefore to describe the iontophoretic transport 
across the skin, one zero order mass input I0 from donor compartment into the skin 
during current application and two first order release constants KR1 and KR2 from skin 
to acceptor are used (Figure 2). The iontophoretic flux in vitro during iontophoresis 
can be described with the following equations: 










I            (2) 
where J(t) is the flux at time t and S is the diffusion area and tL is the kinetic lag time 
parameter, introduced to address the time required for drug molecules to enter the 
skin compartment and Jss as the flux at steady state.  
During the post iontophoresis period only one release constant is sufficient to 
describe the passive flux, resulting in the following equation:   













⎛ −+−+−=   (3) 
where T is time of current application and PPI is the zero order drug input due to the 
passive driving force in the post iontophoretic period. 
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Figure 2: Overview of the compartmental models, used to fit the in vitro iontophoretic flux 
profiles during the iontophoresis period (in vitro model) and the model, used to fit the 
plasma profile during the iontophoretic period (PK model).  
I0: the zero order drug input during time of current application  
KR1 and KR2: first order release constants from the skin to the acceptor phase (in vitro) 
KR: the first order release constants from the skin to the plasma (in vivo) 
k: the elimination rate constant  
k14: the first order skin-hydrolysis compartment distribution rate constant  
k42: the first order hydrolysis compartment-plasma distribution rate constant  
k23: the first order plasma-peripheral distribution rate constant   




Since the hydrolysis of β-ala-(S)-5-OH-DPAT to (S)-5-OH-DPAT is occurring very 
rapidly in the blood, only the plasma concentration of the parent drug S-OH-DPAT 
was monitored. To account for the hydrolysis of β-ala-(S)-5-OH-DPAT to (S)-5-OH-
DPAT during transport, an adaptation was made to the basic PK model, developed 
by Nugroho et al. to describe the plasma concentration following transdermal 
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iontophoresis [19]. It is believed that during transport of the prodrug into and through 
the skin 2 effects occur: hydrolysis and depot formation. The resulting effect of both 
mechanisms is described with the addition of an extra compartment, as illustrated in 
Figure 2. The differential equations to describe the plasma concentration of (S)-5-





















−=         (7) 
With  
dt
 as the rate of change in the amount of the drug in compartment i, XtdX i )(
 model to indicate that the 






the amount of the drug in compartment i, which refers to the skin compartment (i=1), 
the plasma compartment (i=2), the peripheral compartment (i=3) and the hydrolysis 
compartment (i=4). I0 is defined as the zero order mass input, KR as the first order 
release rate constant from skin to plasma, k as the first order elimination rate 
constant, k23 and k32 as the first order distribution rate constants from plasma to tissue 
and tissue to plasma, respectively. k14 and k42 are the rate constants for the mass 
transfer from the skin to hydrolysis compartment and from the hydrolysis 
compartment to the systemic circulation. N is a flag in the
input rate 
An effect compartment model was used to describe the dopamine release following 
transdermal iontophoresis of β-ala-(S)-5-OH-DPAT. The rate of change 
dt
e tdC )(  in the effect compartment can be described as follows: 
))()(.( 2 tCtCkdt eeo
e −=
)(tdC          (8) 
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With ke0 as the rate constant from plasma to the effect compartment and the 
elimination rate constant from the effect compartment. The striatal dopamine release 
CDA, which is the pharmacodynamic end-point, is described by the sigmoid Imax 





















duce 50% of Imax, H is the Hill-slope coefficient, 
meters was assumed to be log-
normally distributed in the population. Inter-individual variability was modeled by 
an exponential er
max is the maximum inhibition of the dopamine production, IC50 is the plasma 
concentration of 5-OH-DPAT to pro
CDA(0) is the baseline values of dopamine (i.e., dopamine concentration prior to the 
inhibiting effect of 5-OH-DPAT).  
PK-PD data following IV infusion and transdermal delivery of (S)-5-OH-DPAT, 
obtained from literature, were included in the data set to obtain more reliable 
parameter estimates [1]. In analogy to the PK-PD model of (S)-5-OH-DPAT a 
covariate of route of administration for IC50 was added [1]. The fixed effect 
parameters (θ) included: I0, KR, clearance (CL), inter compartmental clearance (Q), 
volume of the central compartment (V2), volume of the peripheral compartment (V3), 
ke0, Imax, and IC50. Variability in pharmacokinetic para
ror model as written in Equation 10: 
)exp(. iiP ηθ=            
in which θ is the population value for the fixed effect parameter P, P
       (10) 
ral 
ntage of the root mean square of the 
interindividual variability term. The residual error was modeled by a proportional 
error model as written in Equation 11: 
i is the 
individual estimate and ηi is the normally distributed interindividual random variable 
with mean zero and variance ω². The coefficient of variation (CV %) of the structu
model parameters is expressed as perce
2,1,,, )1.( ijijijpredijobs CC εε ++=           
where Cobs,ij is the jth observed concentration in the ith individual, Cpred,ij is the 
predicted concentration, and εij is the normally distributed residual random variable 
with mean zero and variance σ². The estimation of the final population parameters 
was performed using the conventional first order estimation method (FOCE). The PK 
model parameters were estimated independently and subsequently used as input for 
(11) 
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the PD analysis. During model building, goodness-of-fit was based on statistical and 
graphical diagnostic criteria. Model selection and identification was based on the 
likelihood ratio test, coefficient of variation of parameter estimates, parameter 
correlations and goodness-of-fit plots. For the likelihood ratio test, the significance 
level for the inclusion of one parameter was set at p<0.05, which corresponds with a 
decrease of 3.84 points, in the minimum value of the objective function (MVOF) 
under the assumption that the difference in MVOF between two nested models is χ2 
distributed. The following goodness-of-fit plots were subjected to visual inspection 
to detect systemic deviations from the model fits: individual observed versus 
population and individual predicted values. Finally, the performance of the 
population PK and PK-PD models were assessed by simulating 100 data sets with 
the final model parameter estimates. The evaluation of model performance also 
included visual predictive check (VPC), as implemented in Xpose 4 (R version 2.7.0, 
verall p-value was less than 0.05, a bonferonni post-test was 
applied to compare different groups. For all statistical analysis a significance level of 
ed.  
R-foundation) [20].  
2.10 Data analysis 
All data are presented as mean ± standard deviation (SD). When a statistical analysis 
was performed comparing only 2 groups, a Students t-test was used. When 3 or more 
groups were compared, a 1-way ANOVA statistical analysis was executed. 
Comparing effect of two factors simultaneously was performed using 2-way 
ANOVA. If the o
p<0.05 was us
3 Results 
3.1 Stability of prodrugs of 5-OH-DPAT in different conditions  
A series of prodrugs of 5-OH-DPAT were synthesized by esterification of 5-OH-
DPAT with different amino acids [10]. Because ester bounds are known to be 
susceptible to hydrolysis, the chemical stability of prodrugs was investigated. The 
various conditions were selected to mimic the conditions in the different 
compartments during iontophoretic transport. Apparent first order rate constants for 
hydrolysis were determined from the slopes of various plots of percent remaining 
prodrug vs time. The corresponding half lives are presented in Figure 3. Glycine-5-
OH-DPAT and proline-5-OH-DPAT show a limited chemical stability in a citric 
buffer pH 5.0 at room temperature with a half life of 9.6 and 7.5 h, respectively. 
Valine-5-OH-DPAT and β-alanine-5-OH-DPAT are stable under this condition with 
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a half life of 318 and 692h, respectively. However increasing the pH from 5.0 to 6.2 
at room temperature (RT) decreases the half life of both valine- and β-alanine-5-OH-
DPAT to 7.6 h and to 64.2h, respectively. Further increasing the pH to 7.4 decreases 
the half life of the prodrugs to 0.7 and 4.5h for valine- and β-alanine-5-OH-DPAT, 
respectively. Increasing the temperature from RT to 32 °C, the skin temperature, 
decreased the stability of glycine-, valine- and β-alanine-5-OH-DPAT. For instance 
the half life of valine-5-OH-DPAT at pH 6.2 decreases from 7.6 to 5.1h when 
increasing the temperature. Current application and the presence of HSC however do 
not affect the stability of the prodrugs. Since valine- and β-alanine-5-OH-DPAT are 
the most stable prodrugs, these 2 compounds were selected for further investigations, 








































Figure 3: The half life (t1/2) of the hydrolysis of the prodrugs glycine-5-OH-DPAT 
(striped bar), proline-5-OH-DPAT (blocked bar), valine5-OH-DPAT (white bar) and β-
alanine-5-OH-DPAT (black bar) under various conditions. The data are presented as 
estimate + the upper limit of the estimate. CB: citric buffer 5 mM; RT: room 
temperature; HSC: human stratum corneum; Cur: current 320 µA. 
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Figure 4: In vitro flux profiles of valine-5-OH-DPAT (closed triangle), β-ala-5-OH-DPAT 
(star) and 5-OH-DPAT (open circle). A: Iontophoresis of valine-5-OH-DPAT (only 3.9 mM 
(intermittent line)) and β-ala-5-OH-DPAT and 5-OH-DPAT at 3 different concentrations 
(1.5 (solid line), 3.9 (intermittent line), 7.0 mM (thick solid line)) across stratum corneum. 
B: Iontophoresis of 3.9 mM valine-5-OH-DPAT, β-ala-5-OH-DPAT and 5-OH-DPAT 
across dermatomed human skin. PBS pH 7.4 was used in all experiments as acceptor phase. 
 
3.2 Solubility of valine- and β-alanine-5-OH-DPAT  
The maximum solubility was determined in citric buffer 5 mM pH 5.0 as this is the 
donor solution, used for transport studies. The maximum solubility of valine-5-OH-
DPAT is 232.2 mM. With respect to β-alanine-5-OH-DPAT the maximum solubility 
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is expected to be higher than 832.2 mM. At this concentration the maximum 
solubility of β-alanine-5-OH-DPAT is not yet reached. However, the study was 
discontinued due to the limited availability of the compound.  
3.3 In vitro iontophoresis of the two prodrugs in comparison to 5-OH-DPAT 
Figure 4 illustrates the iontophoretic flux profiles of the prodrugs at different 
concentrations under various conditions. The flux profiles of the parent drug, 
adapted from literature, were added to the graphs for comparison [21]. In case of the 
prodrugs the non-hydrolyzed and the hydrolyzed fraction of the prodrug are added 
and the resulting total flux is displayed in Figure 4. The iontophoretic transport 
across HSC of the two prodrugs was evaluated in comparison to each other and their 
parent drug 5-OH-DPAT, using PBS pH 7.4 as acceptor phase (Figure 4B). The flux 
after 9h current application of β-alanine-5-OH-DPAT (238.0±26.1 and 329.6±41.9 
nmol.cm-².h-1) across HSC is not significantly different from the flux of the parent 
drug 5-OH-DPAT (207.7±38.0 and 407.7±37.0 nmol.cm-².h-1) at 3.9 and 7.0 mM 
donor concentrations (p>0.05; 2-way ANOVA). Since the assay of iontophoretic 
delivery of 1.5 mM β-alanine-5-OH-DPAT was stopped after 7h of current 
application this time point was chosen to compare the flux of prodrug and parent 
drug. A similar flux was observed for β-alanine-5-OH-DPAT (84.1±5.6 nmol.cm-².h-
1), compared to 1.5 mM 5-OH-DPAT (78.2±6.2 nmol.cm-².h-1) (p<0.05; t-test).  
The results of the transport studies across DHS, with PBS pH 7.4 as acceptor phase, 
are depicted in Figure 4C. 2-way ANOVA was performed to analyze the Flux after 
9h of current application (Flux9h) across HSC and DHS for all the compounds at 3.9 
mM. An overall significant difference could be observed between the Flux9h of the 
different compounds, which was due to compound variation and not due to the use of 
the different skin types (p<0.05). Bonferonni’s post-test demonstrated that the Flux9h 
of the prodrug β-alanine-5-OH-DPAT is significantly higher compared to the Flux9h 
of valine-5-OH-DPAT across DHS and HSC. In addition only across DHS the Flux9h 
of β-alanine-5-OH-DPAT is significantly higher than the Flux9h of the parent drug, 
5-OH-DPAT. Furthermore the Flux9h of valine-5-OH-DPAT was significantly lower 
compared to the Flux9h of the parent drug across HSC and DHS.  
Acetaminophen (15 mM) as electroosmotic marker was added to the donor 
concentration to quantify the electroosmotic flux. 1-way ANOVA, with a bonferonni 
post test showed that the electroosmotic flux during transport of valine-5-OH-DPAT 
(7.8±1.9 nmol.cm-².h-1) is significantly lower than the electroosmotic flux of 5-OH-
DPAT (13.7±3.4 nmol.cm-².h-1) (p<0.05), however not significantly different from 
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Figure 5: Resulting graphs of the PK-PD study with β-ala-(S)-5-OH-DPAT (open circle) 
together the results of (S)-5-OH-DPAT (closed triangle), adapted from literature. The 
observed plasma concentration (Cp) of (S)-5-OH-DPAT, following transdermal 
iontophoresis of β-ala-(S)-5-OH-DPAT (A) and (S)-5-OH-DPAT (B) are presented 
together with the population prediction (PRED) (full line).  
C:  The striatal concentration of (S)-5-OH-DPAT (Cs), presented as mean ± SD, following 
iontophoretic delivery of β-ala-(S)-5-OH-DPAT and (S)-5-OH-DPAT.  
D: The dopamine (DA) release in the striatum, as % baseline, presented as mean ± SD, 
following iontophoretic delivery of β-ala-(S)-5-OH-DPAT and (S)-5-OH-DPAT. 
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β-alanine-5-OH-DPAT (11.7±4.2 nmol.cm-².h-1) (p>0.05). Also the electroosmotic 
flux of 5-OH-DPAT and β-alanine-5-OH-DPAT are not significantly different 
(p>0.05). 
The iontophoretic transport profile across HSC and DHS of 3.9 mM β-alanine-5-OH-
DPAT was modeled using Equations 1 and 3. The resulting parameters are displayed 
in Table 2. The estimated steady state flux, calculated with Equation 2, is higher for 
DHS, compared to HSC. The lag time (Tlag) and passive driving force post 
iontophoresis (Pass=PPI /S) are also higher for DHS, whereas the release constants 
KR1 and KR2 are lower compared to HSC. 
3.4 Hydrolysis during transport through HSC and DHS  
Approximately 19.8±2.6% and 55.4±15.1% of β-alanine-5-OH-DPAT is hydrolyzed 
in 5-OH-DPAT when transported across HSC and DHS, respectively, using PBS pH 
7.4 as acceptor phase. A similar observation is found for val-5-OH-DPAT, using 
PBS pH 6.2 as acceptor phase: 26.8±5.4% and 100% valine-5-OH-DPAT is 
converted into 5-OH-DPAT when transported through HSC and DHS, respectively.  
3.5 In vivo iontophoretic delivery of β-ala-(S)-5-OH-DPAT 
The PK and PD of the active S-enantiomer of the most promising prodrug β-ala-(S)-
5-OH-DPAT following transdermal delivery were investigated simultaneously. For 
comparison the plasma-, striatum profile and the dopamine release following 
transdermal iontophoresis of the parent drug (S)-5-OH-DPAT, adapted from 
literature, are added to the resulting graphs (Figure 5B-D) [1].  
3.5.1 Plasma profile 
The prodrug is rapidly hydrolyzed to (S)-5-OH-DPAT in blood plasma, since the 
half life is 0.24 min in 80% human blood plasma [10]. Therefore the plasma 
concentration of the parent drug (S)-5-OH-DPAT was monitored during the PK-PD 
study. No detectible amount of (S)-5-OH-DPAT was observed after 15 min of 
passive diffusion (data not shown). Current application starts at t=0 min, as depicted 
in Figure 5A. As can be observed current application results in immediate increase in 
plasma concentration. After 90 min of current application, the plasma profile tends 
towards a steady state situation. The resulting plasma concentration at time=90 min 
is 18.2±0.8 ng.ml-1. After current application is discontinued and the patch is 
removed, the profile shows a decline in plasma concentration, which is best 
described with a 2-compartmental model.  
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Table 2: The resulting population estimates of simultaneous modeling the plasma 
concentration and dopamine release following transdermal iontophoresis of β-ala-(S)-5-
OH-DPAT (3.9 mM) in male wistar rats. The resulting parameters of fitting the in vitro 
transdermal iontophoretic transport of β-ala-5-OH-DPAT (3.9 mM) across human stratum 
corneum (HSC) and dermatomed human skin (DHS) is depicted. PBS pH 7.4 was used as 
acceptor phase for the in vitro experiments 
        








        
        
parameter unit mean RSE% mean
RSE





            
            
PK-PD      HSC (in vitro)     
            
V2 L 0.46 18 0.13 97 Jss 500 * 272.5 4   
V3 L 0.78 16 0.07 52 KR1 h-1 0.278 28 0.516 82 
CL L.h-1 2 6 0.02 38 KR2 h-1 1.69 8 0.035 23 
Q L.h-1 1.96 21 0.16 73 Tlag h 0.005    
Jss 250 * 110.6 8   Pass * n.d.    
KR h-1 0.31 23         
k14 h-1 5.06 23   Sigma 1  0.019 17   
k42 h-1 4.79 21   Sigma 2  1.93 36   
keo h-1 3.79 12 0.19 48       
IC50 ng.ml-1 4.50 12 0.07 35       
N  3.12 9   DHS (in vitro)     
Imax  40.9 7 0.03 39 Jss 500 * 381.3 7   
      KR1 h-1 0.069 35 0.212 23 
      KR2 h-1 0.588 5 0.3 51 
      Tlag h 0.22 10   
      Pass * 29.1 14 0.045 33 
            
Sigma 1  PK 0.02 24   Sigma 1  0.002 67   
Sigma 1 PD 0.01 20   Sigma 2  18.4 59   
 
*: unit of Jss and Pass is: nmol.cm-².h-1 
Sigma 1: proportional error; Sigma 2: additive error 
n.d.: not determined because the parameter value was constrained to 0 
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3.5.2 Striatum profile 
The 5-OH-DPAT concentration of the microdialysate samples of the left striatum 
was analyzed following transdermal iontophoresis of β-ala-(S)-5-OH-DPAT. With a 
delay of approximately 7.5 min, the striatal 5-OH-DPAT concentration (Cs) 
increased when starting iontophoresis to a maximum level of 0.88±0.18 ng.ml-1. This 
maximum was reached 22.5 min after switching off the current (t=112.5 min). After 
this time point Cs declines again. 
3.5.3 Pharmacodynamic effect 
With on-line microdialysis the DA concentration (the pharmacodynamic end-point) 
in the right striatum was monitored. The resulting DA release profile (mean ± SD) is 
depicted in Figure 5D. Prior to iontophoresis the DA level was monitored and the 
average DA level from 4 consecutive points was set to 100%. As can be observed, 
when starting iontophoresis the DA level decreases with a lag time between 7.5 and 
22.5 min. The DA level decreases to near steady state level of 48.6±8.2% baseline, 
94.5 min after the start of iontophoresis. After removal of the patch, the DA level 
recovers again to its initial state (DA release=100%) at time=189.2±12.1 min 
following prodrug iontophoresis.  
3.6 Non-linear mixed effects modeling:  model evaluation 
The in vitro transport flux profiles, the plasma profile and the pharmacodynamic 
effect are modeled with non linear mixed effects modeling, using compartmental 
models. The resulting parameter estimates are depicted in Table 2. A relatively low 
Residual Standard Error (RSE%) for the fixed in vitro (≤ 35%) and in vivo 
parameters estimates (≤ 23%) indicates a reliable prediction of the estimates. 
Moreover Figure 6A and B, displaying the visual predictive check (VPC), 
demonstrates that the in vivo observations are well distributed between the 2.5th and 
the 97.5th percentiles. This indicates that the variability, predicted by the PK-PD 
model, corresponds with the observed variability. In addition the diagnostic plots of 
the PK and PD profile, shown in Figure 6C-F, indicate that the proposed PK-PD 
model adequately describes the plasma profile and pharmacodynamic effect.   
4 Discussion 
The general aim of the present study is to evaluate different prodrugs and select the 
best candidate(s) for transdermal iontophoretic delivery. The presence of enzymes in 
the skin, such as esterases and amidases, makes the use of prodrugs an interesting 
 171
CHAPTER 7   
approach for transdermal delivery. The prodrugs can be tailored to improve drug 
delivery and during transport across the skin, the enzymes hydrolyze the prodrugs to 
their active parent drug [8].  
4.1 Chemical stability and solubility 
Ester prodrugs, as presented in this paper, are not only susceptible to enzymatic, but 
also to chemical hydrolysis. The stability of the prodrugs in different aqueous 
solutions is highly dependent on the side chain, esterified with 5-OH-DPAT 
(stability: glycine < proline < valine < β-alanine). Based on these results valine- and 
β-alanine-5-OH-DPAT were selected for further investigating the transdermal 
iontophoretic transport across human skin. Esterification of 5-OH-DPAT with valine 
and β-alanine improved its solubility tremendously. The solubility of valine- and β-
alanine-5-OH-DPAT was respectively 4 and more than 14 times higher, compared to 
its parent drug 5-OH-DPAT [21]. A higher solubility enables reduction of the patch 
volume, while keeping sufficient amount of drug in the patch. Presumably addition 
of an extra chargeable amine group contributes substantially to the solubility of the 
prodrugs. 
4.2 Transdermal iontophoresis in vitro 
At pH 5.0 both prodrugs have an additional charge compared to 5-OH-DPAT. When 
increasing the charge from monovalent to bivalent, this affects in several ways the 
transport: (i)  bivalent ions have a larger hydrated volume, as suggested by Lai and 
Roberts, which can result in a reduced flux [22], (ii) bivalent ions interact more with 
charged sites in SC, which according to Phipps et al. will result in a reduced flux 
[23] and (iii) an increase in the charge/molecular weight ratio results in an equivalent 
higher electromigrative flux [24]. It is suggested that the lipophilicity, indicated by 
the cLogP (Table 1), of the prodrugs influences the balance between these three 
factors and therefore affects the transport efficiency [15-17]. Only for the more 
hydrophilic prodrug β-alanine-5-OH-DPAT with a charge/Mw ratio which is 1.5 
times higher compared to 5-OH-DPAT, resulted in almost in an equivalent increase 
(1.4 times) in the total flux after 9h of current application across DHS. The flux of β-
alanine-5-OH-DPAT is less affected by the increased hydrated volume and the skin 
interaction. In contrast valine-5-OH-DPAT with a hydrophobic prodrug moiety is 
retained more by the skin and shows a decreased flux compared to 5-OH-DPAT. 
This hypothesis is strengthened by the decreased electroosmotic flux during transport 
of valine-5-OH-DPAT. Valine-5-OH-DPAT is retained more strongly and the two 
positive charges cause a neutralization of the skin negative charges, resulting in a  
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Figure 6: Diagnostic plots of simultaneous fitting the plasma concentration (A, C, D) and the 
dopamine release (B, E, F) following the transdermal iontophoresis of β-ala-(S)-5-OH-DPAT. 
Depicted are the observations (open circles) together with the interquantile concentration 
range (2.5%-97.5%, intermittent line) and the median (50%, solid line) of the plasma profile 
(A) and the dopamine release profile (B). A number of 100 samples were simulated based on 
the final parameter estimates. C,E: population predicted vs the observed data. D,F: individual 
prediction vs the observed data.  
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reduced electroosmotic flux. Furthermore, the transport of valine-5-OH-DPAT is less 
affected by the charge/molecular weight ratio. These results are in agreement with 
the computational studies performed by Schuetz et al., who predicted with a 3D 
quantitative structure-permeation relationship that iontophoresis was favored by 
peptide hydrophilicity and hindered by voluminous localized hydrophobicity [25].  
Besides the transport efficiency it is also important to determine the rate of 
hydrolysis during iontophoretic transport across human skin in order to be able to 
predict the amount of prodrug and parent drug that will taken up by the blood stream. 
In analogy to the chemical stability, β-alanine-5-OH-DPAT is the more stable 
prodrug. For both prodrugs an increased hydrolysis is observed when transported 
across DHS. This increased hydrolysis rate is the result of 2 mechanisms. Firstly the 
presence of enzymes, such as esterases, is more abundant in the epidermis [13]. 
Secondly the increased migration time through DHS and the slower release from the 
DHS, reflected by KR1 and KR2 (Table 2), results in a possibly longer interaction of 
enzymes with the prodrugs augmenting the hydrolysis rate. The remaining prodrug 
that is not hydrolyzed during transdermal transport is expected to be hydrolyzed 
rapidly when taken up by the blood stream, since the enzymatic half life of valine- 
and β-alanine-5-OH-DPAT in 80% human blood plasma was 0.22 and 0.24 min, 
respectively [10]. 
4.3 PK-PD properties  
The pharmacokinetic and pharmacodynamic properties of β-alanine-(S)-5-OH-
DPAT, the more stable and soluble prodrug with improved in vitro transport 
efficiency, were investigated in an animal model. Under anesthetized conditions 
blood samples were taken and the dopamine level in the striatum (pharmacodynamic 
end-point) was monitored on-line with microdialysis. This animal model is identical 
to the animal model used to investigate the PK-PD properties of (S)-5-OH-DPAT, 
which enables us to compare the prodrug to its parent drug [1]. The plasma 
concentration profile of (S)-5-OH-DPAT (Cp) following transdermal iontophoresis of 
the prodrug differs on 3 aspects from the profile following (S)-5-OH-DPAT 
administration, as can be observed in Figure 5A-B. (i) The increase in plasma 
concentration during current application is slower for the prodrug than for the parent 
drug. This is reflected by a decreased skin release constant KR for the prodrug (Table 
2) [1]. (ii) After 90 min of current application the population predicted Cp is lower 
for β-ala-(S)-5-OH-DPAT (19 ng.ml-1) than for (S)-5-OH-DPAT (23.5 ng.ml-1). (iii) 
During the elimination phase the Cp profile is different following administration of 
prodrug vs parent drug. It is hypothesized that these 3 differences can be partially 
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attributed to the hydrolysis of the prodrug during transdermal transport, assuming the 
hydrolysis in blood plasma is occurring instantaneously. Furthermore it is believed 
that after penetration through the stratum corneum depot formation of the prodrug in 
the viable epidermis also delays the release to the systemic circulation. The resulting 
effect was included in the PK-model by adding an extra compartment between the 
skin and the central compartment (Figure 2). This model adequately described the 
plasma profile following transdermal administration of the prodrug (Figure 6).  
In addition the resulting parameter estimates corresponded very well with the 
parameters of (S)-5-OH-DPAT obtained for the PK-PD study [1]. It can be observed 
in Figure 5C that in analogy to Cp the increase in Cs during the absorption phase is 
faster and that the striatal clearance is going more rapidly following iontophoresis of 
the parent drug (S)-5-OH-DPAT. Finally the difference in Cp and Cs profile 
following prodrug vs parent drug administration resulted also in a different striatal 
DA release profile (Figure 5D). During the iontophoretic period no difference was 
observed in DA release with the same maximum. This suggests that despite a lower 
steady state plasma concentration the same maximum effect can be achieved. Post-
iontophoresis however the time for the DA release to recover to baseline values post-
iontophoresis was significantly longer for the prodrug (99.2±12.1 min) compared to 
(S)-5-OH-DPAT (79.4±1.3 min) (t-test; p<0.05). This can be attributed to higher Cp 
values after removal of the patch due to delayed skin release. On the one hand, this 
prolonged effect can be a drawback to initiate therapy to treat Parkinson’s disease, 
since rapid changes in delivery schemes may be required. On the other hand, the 
prolonged effect of the prodrug can be beneficial for patients who suffer from 
nocturnal disturbances. Nocturnal disturbances are one of the most common non-
motor complications in patients with Parkinson’s disease [26]. It is believed that 
continuous stimulation of the DA receptor during the night can reduce the occurrence 
of nocturnal disturbances [27]. 
4.4 in vitro-in vivo correlation  
Fitting in vitro and in vivo transport using compartmental modeling allowed us to 
compare both iontophoretic transports. Different kinetic models were used to 
describe the in vitro and in vivo transport of the prodrug β-alanine-(S)-5-OH-DPAT. 
This suggests that different transport mechanisms can be involved in vitro and in 
vivo. These differences can at least partially be attributed to 3 factors. Firstly, the 
structure of human skin differs from the structure of rats. Mainly the thickness of the 
different skin layers, the stratum corneum lipid composition and the density of hair 
follicles will contribute to the difference [28]. But previous studies showed that 
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iontophoresis under constant current conditions diminishes the interspecies variations 
[29] and that rat skin has comparable permeation kinetic parameters with human skin 
[28]. Secondly the clearance of the penetrant by the acceptor flow may be different 
from the clearance in vivo by the microcirculation in the skin [28]. Thirdly, the 
activity of the esterase in vivo may be different from the esterase activity in freshly 
excised skin. Despite these differences a good correlation was observed between the 
steady state flux in vitro and in vivo. Assuming that there is a linear correlation in 
vivo between the flux and the current density [1], applying a current density of 500 
µA.cm-² would result in an in vivo steady state flux (Jss=I0/S) of 221.2 nmol.cm-2.h-1. 
This flux corresponded best with the in vitro Jss across HSC (272.5 nmol.cm-2.h-1) 
compared to the Jss across DHS (381.3 nmol.cm-2.h-1). This suggests that transport 
across HSC can provide valuable information for prediction towards the in vivo 
situation for this particular compound. Whether this is also the case for other drugs, 
remains to be established.   
In conclusion this study demonstrates the potential of improving solubility, 
iontophoretic transport and changing the plasma profile and the PD effect of the 
promising dopamine agonist 5-OH-DPAT with the use of prodrugs. A good balance 
was found between an efficient transport rate and enzymatic conversion to the parent 
drug during transdermal transport. Of the synthesized prodrugs, presented in this 
research, β-alanine-5-OH-DPAT is the most promising prodrug and is a potential 
candidate for further investigation. This sufficiently stable prodrug shows a 
tremendous increase in solubility, which can be beneficial for manufacturing and 
practical use. The increased in vitro flux of β-alanine-5-OH-DPAT across human 
skin did not result in higher steady state plasma concentrations, but in a prolonged 
effect which reached the same maximum level as was observed with the parent drug.  
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CHAPTER 8   
1 Summary  
For more than 45 years orally dosed levodopa (L-DOPA) has been regarded as the 
gold standard therapy for symptomatic treatment of Parkinson’s disease (Pd) [1]. 
However its possible neurotoxicity and more importantly the induction of movement 
disorders after chronic use of L-DOPA, demand for alternative therapies [2]. One of 
the most important alternatives is the use of dopamine agonists, such as 
apomorphine, ropinorole, rotigotine and 5-OH-DPAT, which directly activate the 
post synaptic receptor [3]. Dopamine agonists are generally less associated with 
motor complications after long term use [4-5]. In addition continuous stimulation of 
the dopamine receptors is believed not only to reduce dyskinesia and motor 
complications, but also can be beneficial for other non-motor symptoms of Pd [6]. 
This emphasizes the need for controlled delivery that provides continuous 
dopaminergic stimulation. An attractive non-invasive delivery technique is 
transdermal iontophoresis.  
By application of a low current across the skin it is possible to enhance the delivery 
of small charged molecules. At steady state conditions a constant delivery can be 
provided. In addition by modulation of the current density it is possible to adjust the 
administration rate and thus the dose to the demand of the therapy [7]. This can be of 
great benefit in early stage Pd, because initiation of therapy demands rapid dose 
adjustments. Therefore in the last decade the transdermal iontophoretic delivery of 
several dopamine agonists has been investigated: apomorphine, ropinirole, 5-OH-
DPAT and rotigotine. These non-ergot dopamine agonists showed promising results 
in vitro and in vivo, demonstrating the feasibility of transdermal iontophoretic 
delivery of dopamine agonist for the symptomatic treatment of Parkinson’s disease, 
as discussed in CHAPTER 1. But further optimization and improvement of the 
iontophoretic delivery of dopamine agonist is required to achieve a strong 
therapeutic effect. Higher transport efficiency can also lead to a reduction of the 
patch size and minimization of the applied current density. This can merely enhance 
the clinical applicability of transdermal iontophoresis.   
The general objective of the presented research is the optimization of the transdermal 
iontophoretic delivery of dopamine agonists and its prodrugs for the symptomatic 
treatment of Parkinson’s disease. To achieve this goal, the following specific items 
are considered: 
1. Optimizing the transdermal iontophoretic delivery in vitro of a series of potent 
dopamine agonists, including rotigotine, 5-OH-DPAT and other potent 
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structural analogs. In addition the mechanisms driving the iontophoretic 
transport are addressed. 
2. Synthesis of novel dopaminergic prodrugs of 5-OH-DPAT with an extra 
chargeable group for transdermal iontophoretic delivery. Subsequently the 
chemical and enzymatic stability are examined. This part of the investigations 
was performed by Jeroen De Graan and will result in a dissertation at the 
Rijks Universiteit Groningen, Groningen, The Netherlands 
3. In vitro iontophoresis of selected prodrugs of 5-OH-DPAT to investigate the 
feasibility for transdermal iontophoretic delivery  
4. Pharmacokinetic-pharmacodynamic (PK-PD) studies in an animal model with 
the most promising candidates with a special focus on controlling the plasma 
concentration and the pharmacodynamic effect with transdermal iontophoresis 
5. Evaluation and optimization of the kinetic models, developed by Nugroho et 
al. for the characterization of transdermal iontophoretic transport in vitro and 
in vivo [8-10] 
 
Part I-Optimizing the transdermal iontophoretic delivery of 
dopaminergic drugs in vitro 
Previous studies showed the feasibility of transdermal iontophoretic delivery of 5-
OH-DPAT in vitro [11] and in vivo [10]. But a thorough mechanistic characterization 
is still missing. Elucidating transport mechanisms driving the iontophoretic delivery 
is crucial to understand and optimize the iontophoretic delivery in vivo.  
In CHAPTER 3, the transdermal iontophoretic delivery in vitro of 5-OH-DPAT was 
investigated from a mechanistic point of view. Especially the electroosmotic flow 
and the influence of the composition of the donor and acceptor phase were 
addressed. Acetaminophen as marker for the electroosmotic flow was also evaluated 
and approved in this chapter. The total flux is the sum of the passive, electroosmotic 
and electromigrative flux. The contribution of the passive flux was negligible. The 
main driving force for the iontophoretic delivery of 5-OH-DPAT is electromigration. 
Electromigration contributes for more than 85% to the total flux. Furthermore 
decreasing the pH of the donor phase from 6.0 to 5.0 did not affect the total flux at 
steady state (Fluxss) situation. The Fluxss increased 2.5- to 3-fold when the amount of 
Na+ in the donor phase decreased from 78 mM to 10 mM. The Fluxss showed a non-
linear hyperbolic correlation with the donor concentration of 5-OH-DPAT and 
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reached a plateau towards the maximum solubility of 5-OH-DPAT in the donor 
phase. Together with the observed linear correlation between the Fluxss and the 
current density, this shows that the administered dose can easily be adjusted with 
transdermal iontophoresis by changing the donor concentration and/or the current 
density.  
The flux of 5-OH-DPAT decreased with decreasing pH of the acceptor phase from 
7.4 to 6.2. This phenomenon was explained by an alteration of the permselective 
properties of the skin. At pH 6.2 the skin is less negatively charged, resulting in a 
reduced electroosmotic flow and increased competition of the counterions (mainly 
Cl- ion) from acceptor to donor phase. This comprehensive study demonstrates the 
high transport efficiency of 5-OH-DPAT and elucidates different transport 
mechanisms during iontophoretic delivery. 
A structurally related compound, rotigotine, is the first dopamine agonist in a passive 
patch (Neupro®, UCB pharma) that is on the market in Europe for early and 
advanced Parkinson’s disease [12-13]. In vitro investigations of rotigotine.HCl 
showed that with transdermal iontophoresis a higher transport rate with a shorter lag 
time can be achieved compared to passive delivery [14]. However in follow up 
studies, the maximum solubility in the donor phase was a limiting step to further 
enhance the iontophoretic transport [15].  
One of the possibilities to change the physicochemical properties of a compound is 
the use of a different salt form. Therefore, in CHAPTER 4, passive and transdermal 
iontophoretic studies were conducted with a different salt form of rotigotine, 
rotigotine.H3PO4. The results were compared to those obtained for rotigotine.HCl 
[14-15]. Prior to the transport studies, solubility studies showed that the solubility of 
rotigotine.H3PO4 was 2, 6 and 10-fold higher than the solubility of the HCl-salt at pH 
6.0, 5.0 and 4.0, respectively. Moreover, because of the absence of a common ion 
effect, the amount of NaCl did not affect the maximum solubility in the donor phase. 
At low donor concentrations the transdermal passive and iontophoretic flux of 
rotigotine.H3PO4 and rotigotine.HCl were not significantly different. Due to the 
increase in maximum solubility of rotigotine the maximal iontophoretic transdermal 
transport of this compound however was almost twice when using rotigotine.H3PO4 
(135.8±12.5 nmol.cm-2.h-1) instead of rotigotine.HCl (80.2±14.4 nmol.cm-2.h-1). 
Subsequently, the potential of the iontophoretic delivery of rotigotine in vivo was 
evaluated in a series of simulations. In a first step the transport parameters of the 
iontophoretic delivery in vitro across human stratum corneum (HSC) were estimated 
using the compartmental kinetic models proposed by Nugroho et al. [8]. These 
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models were based on the assumption of a zero-order mass transfer from the patch to 
the skin and a first order release from the skin to the acceptor phase (in vitro) or the 
systemic circulation (in vivo). The transport parameters were the zero-order mass 
input (I0), the skin release constant (KR) and the lag time [16]. The kinetic model 
described the in vitro flux adequately. In the next step the apparent pharmacokinetic 
parameters, reported in literature [17-21], were combined with the estimated 
transport parameters to simulate the plasma levels in vivo. It was assumed that 
iontophoretic transport in vivo is the same as iontophoretic transport in vitro across 
HSC. The simulations demonstrated two important benefits of iontophoretic over 
passive transdermal delivery. Firstly, the onset time to achieve the desired level can 
be significantly reduced. Secondly, the plasma concentration can easily be titrated by 
modification of the current density to obtain a desired profile. 
Next to 5-OH-DPAT and rotigotine, also other members of the 2-aminotetraline 
group and structural analogs are regarded as potent agonists at the D1- and/or D2-
receptor in the striatum. 5 candidates were selected based on their potency and 
molecular structure: 8-OH-DPAC, 5-OH-EPAT, 5-OH-MPAT, 5,6-di-OH-MPAT 
and 5,6-di-OH-DPAT [22-28]. Except for 8-OH-DPAC, which is a chromanamine, 
all compounds are 2-aminotetralins. In CHAPTER 5 the following properties of 
these 5 therapeutic agents were investigated: solubility, electrophoretic mobility, 
lipophilicity and in vitro transport across HSC and dermatomed human skin (DHS). 
The results of rotigotine and 5-OH-DPAT, adapted from literature, were added for 
comparison. Solubility studies ranked these molecules in the following order: 
rotigotine < 5,6-di-OH-DPAT < 5-OH-DPAT < 5-OH-MPAT < 5-OH-EPAT <       
8-OH-DPAC. In vitro transport studies demonstrated that small structural changes 
can affect the iontophoretic transport significantly. Across HSC and DHS 5-OH-
EPAT and 5-OH-MPAT showed a significant higher flux, compared to the other 
compounds investigated.  
During current application the observed flux of all compounds did not reach steady 
state but gradually increased. Therefore to describe the in vitro iontophoretic 
transport a novel kinetic model was introduced. Instead of 1 first order release 
constant (KR) to describe the release from the skin to the acceptor phase, as was 
proposed previously [8], 2 release constants (KR1 and KR2) were introduced. This 
model confirms the presence of at least two transport routes as suggested in 
literature: (i) transport route across the appendageal structures and (ii) the transport 
route via the intercellular route in the skin [29-33]. Besides describing the flux 
profile during and after iontophoresis it is also important to identify the 
physicochemical properties that are related to the different transport parameters. Our 
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results demonstrate that the electrophoretic mobility and the molecular weight of the 
molecules can be used to predict the zero-order mass input into the skin (I0) and the 
release constant KR2, respectively. In addition KR1 is related to the lipophilicity, 
although further research is required to establish a clear relationship. With these 
parameters it will be possible to simulate the flux profile, using the proposed kinetic 
model, even when no steady state has reached yet. This approach can be of great 
interest for screening a series of new candidates. 
 
Part II-In vivo investigations of the controlled iontophoretic delivery 
of (S)-5-OH-DPAT  
Optimization of the iontophoretic delivery of 5-OH-DPAT in vitro (CHAPTER 3) 
showed the great potential of this dopamine agonist and gave rise for investigating 
the controllability in an in vivo setting.  
In CHAPTER 6, the controlled release following transdermal iontophoresis of     
(S)-5-OH-DPAT, the active enantiomer of 5-OH-DPAT, was investigated in a rat 
model under anesthetic conditions. Firstly, in analogy to the in vitro flux, the in vivo 
flux was linearly correlated with the applied current density. This confirms that the 
administered dose can easily be titrated by altering the current density. Next to a 
controlled plasma profile, the second aim of these studies was to investigate the PK-
PD during a controlled and reversible pharmacological response following 
transdermal iontophoresis. Before conduction these PK-PD studies, an animal model 
under anesthetic conditions was developed. In a control experiment it was 
demonstrated that anesthesia (fentanyl, fluanisone and midazolam), current 
application with transdermal iontophoresis and blood sampling had no influence on 
the striatal dopamine release (pharmacodynamic end point). Thereafter the plasma 
profile and the striatal dopamine release were monitored simultaneously in the 
validated rat model following transdermal iontophoresis and intravenous (IV) 
infusion of (S)-5-OH-DPAT. For both administration routes a strong decrease in 
striatal dopamine release was observed, that returns to its initial state within 2h after 
the end of the administration.  
The experimental data were extensively analyzed using non-linear mixed-effect 
modeling. To facilitate discrimination between delivery-specific parameters (I0, KR) 
and drug specific parameters (Cl, Q, V2, and V3), the data following transdermal 
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iontophoresis and intravenous (IV) infusion were analyzed simultaneously. The 
kinetic models to describe the plasma profile following transdermal iontophoresis, 
adapted from literature, were based on the zero-order mass input from the donor 
phase into the skin and the first order release from the skin to the systemic 
circulation [9]. In contrast to in vitro iontophoresis, one first order release constant 
(KR) was sufficient to adequately describe the plasma profile following 
iontophoresis. To describe the striatal dopamine release, two models were compared: 
(i) indirect response model type I with inhibition of the production of response vs (ii) 
effect compartment model with sigmoidal Imax model. Based on the Akaike’s 
information criterion (AIC) and the visual predictive check, it can be concluded that 
the effect compartment model describes more adequately the striatal dopamine 
release. Furthermore covariate analysis suggested that the delivery rate can be 
important for establishing a desired effect. The use of an integrated PK-PD model 
suggested that the steady state plasma concentrations can be translated to continuous 
dopaminergic stimulation. This can be of great benefit for symptomatic treatment of 
Parkinson’s disease. It is generally believed that continuous stimulation of the 
dopamine receptor reduces motor fluctuations after chronic use and can be beneficial 
for non-motor complications, such as nocturnal disturbances [6]. 
 
Part III-Transdermal iontophoretic delivery of ester prodrugs of     
5-OH-DPAT: from synthesis to in vivo studies 
The promising results of the iontophoretic delivery in vitro and in vivo encouraged us 
to further improve the applicability of 5-OH-DPAT. Therefore 5-OH-DPAT, which 
has limited aqueous solubility, was esterified with four natural occurring amino 
acids: glycine-, proline-, valine- and β-alanine. The four resulting prodrugs all 
contain an extra chargeable amine group, compared to the parent drug.  
In CHAPTER 7 a thorough investigation is presented addressing the following 
properties of these prodrugs: chemical stability, solubility and transdermal 
iontophoretic transport. Stability studies investigated the influence of pH, 
temperature, current application and presence of skin on the stability of the prodrugs. 
Increasing the pH and temperature decreased the stability of all prodrugs, while 
current application and the presence of HSC did not affect the stability. Based on 
these results, valine- and β-alanine-5-OH-DPAT, with acceptable stability, were 
selected to conduct solubility and iontophoretic transport studies with. Compared to 
187 
CHAPTER 8   
the parent drug 5-OH-DPAT, valine- and β-alanine-5-OH-DPAT showed a 4- and 
more than 14-fold increase in maximum solubility in the donor phase (citric buffer, 
pH 5.0 with 68 mM NaCl), respectively. This enables to reduce significantly the 
patch size, without reducing the substantial amount of drug present in the patch. 
Iontophoretic transport studies in vitro across HSC and DHS, demonstrated that 
valine-5-OH-DPAT, a more lipophilic drug, was transported less efficiently than 5-
OH-DPAT across both skin types. In contrast, β-alanine-5-OH-DPAT, a more 
hydrophilic prodrug, was transported with the same efficiency across HSC, but 40% 
more efficient across DHS compared to 5-OH-DPAT. It was also observed that both 
prodrugs during iontophoresis are substantially hydrolyzed to the parent drug 5-OH-
DPAT, with a higher hydrolysis rate across DHS compared to HSC.  
Based on the in vitro results, β-alanine-5-OH-DPAT was selected for in vivo 
iontophoretic transport studies in the novel validated animal model, presented in 
CHAPTER 6. The results of the active enantiomer of the prodrug, β-alanine-(S)-5-
OH-DPAT, were compared to the results of (S)-5-OH-DPAT, presented in the 
previous chapter. Despite a higher in vitro transport, lower plasma concentrations 
were observed following 1.5h current application (250 μA.cm2) of β-alanine-(S)-5-
OH-DPAT in comparison to (S)-5-OH-DPAT. However the prodrug showed higher 
plasma concentrations post-iontophoresis, explained by a delayed release due to 
hydrolysis and skin depot formation. This resulted in a pharmacological effect with 
the same maximum as 5-OH-DPAT, but the effect lasted for a significant longer 
time. In analogy to (S)-5-OH-DPAT, the plasma profile and dopamine release 
following transdermal iontophoresis of β-alanine-(S)-5-OH-DPAT were analyzed 
using an integrated PK-PD model. To account for hydrolysis and depot formation, an 
extra compartment was integrated in the PK model for transdermal iontophoresis 
(CHAPTER 6) between the skin and the plasma concentration in parallel. Similar to 
(S)-5-OH-DPAT, an effect compartment model was used to describe the striatal 
dopamine release.  The current findings show the possibility to tailor the 
physicochemical properties, the pharmacokinetic profile and pharmacological 
response with the use of prodrugs. The prodrug β-alanine-5-OH-DPAT with a 
balanced stability and high transport efficiency is a promising candidate for 
symptomatic treatment of Parkinson’s disease.  
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2 Conclusions and future perspectives 
Transdermal iontophoretic delivery of dopamine agonists has great potential for the 
symptomatic treatment of Parkinson’s disease. It can be of  benefit for reducing or 
replacing L-DOPA therapy, certainly in the initial stage of treatment, since 
continuous administration of dopamine agonists is less associated with motor 
complications [2]. The results of the studies presented in this thesis, together with 
previous studies, show that 2-aminotetralins (5-OH-MPAT, 5,6-di-OH-MPAT, 5-
OH-EPAT, 5-OH-DPAT, 5,6-di-OH-DPAT, rotigotine) and 8-OH-DPAC can be 
transported across the skin with high efficiency [10-11, 15]. One of the advantages of 
transdermal iontophoresis is the possibility to achieve continuous plasma 
concentrations, leading to constant dopaminergic stimulation, as was demonstrated 
for (S)-5-OH-DPAT in CHAPTER 6 and β-alanine-(S)-5-OH-DPAT in 
CHAPTER 7. These observations give rise for further developing an iontophoretic 
transdermal delivery device, with ultimately the possibility to design a feedback 
control system. This could result in a self-controlling delivery device, facilitating its 
therapeutic use. Such a self-controlling iontophoretic delivery device should have the 
following properties: (i) Drug: the device should contain a potent dopamine agonist 
which elicits a strong dopaminergic effect with a relatively small dose. Additionally, 
the dopamine agonist should have a good aqueous solubility, should be transported 
efficiently across the skin and should have excellent blood-brain barrier 
permeability. (ii) Delivery: besides an efficient delivery, that enables reducing the 
applied current density, the transdermal delivery should also be easily adjustable. As 
demonstrated for (S)-5-OH-DPAT in CHAPTER 6, the drug input and plasma 
concentration can easily be controlled by adjusting the current density. (iii) 
Biomarker: there should be a valid and sensitive surrogate endpoint available to 
monitor the drug effect. Preferably a pharmacodynamic biomarker is monitored 
instead of the drug plasma concentration. This poses quite a challenge for 
Parkinson’s disease, since the biomarkers used up to today to monitor the 
dopaminergic effect in animals are measured intracranially. For humans, researchers 
are restricted to pharmacodynamic end-points such as tapping scores, walking time 
[34] and categorical rating scales [35-36]. All these end-points require active and 
conscious involvement of the patients. This underscores the need for novel 
biomarkers to monitor the dopaminergic effect in patients. (iv) monitoring: Such 
biomarkers are preferably monitored non-invasively, for instance with reverse 
iontophoresis. The utility of reverse iontophoresis has been demonstrated for the 
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treatment of diabetes: the Glucowatch® monitors with reverse transdermal 
iontophoresis the glucose level in plasma [37]. (v) Biosensor, that analyses the 
biomarker: should be small, preferably on nano or micro scale and therefore be very 
sensitive. 
The development of such a self-controlling delivery device constitutes an enormous 
challenge, which requires the development and optimization of the chemical 
structure, the delivery and the detection. This involves an excellent understanding of 
Peripheral
Figure 1: Schematic representation of the compartmental model of the iontophoresis in vitro, 
the pharmacokinetic and pharmacodynamic model following transdermal iontophoresis.  
I0: zero order drug input during time of current application  
KR1 and KR2: first order release constants from the skin to the acceptor phase (in vitro) 
KR: first order release constants from the skin to the plasma (in vivo) 
k: elimination rate constant  
k14: first order skin-hydrolysis compartment distribution rate constant  
k42: first order hydrolysis compartment-plasma distribution rate constant  
k23: first order plasma-peripheral distribution rate constant   
k32: first order peripheral-plasma distribution rate constant 
ke0: first order distribution rate constant from plasma to effect compartment and elimination rate 
constant from effect compartment  
 
*The inclusion of a hydrolysis compartment in the model is only used following transdermal iontophoresis of 
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the relationships between the molecular properties, the iontophoretic transport, the 
pharmacokinetics and the pharmacodynamics. To obtain a better understanding of 
these relationships, a powerful analytical tool or method is required that can describe 
and predict the time course of the iontophoretic transport, the plasma concentration 
and the drug effect. The compartmental models, as used in CHAPTER 5-7, allow 
such type of analysis. The models describe in a comprehensive manner the time 
dependent transport, plasma and drug effect profiles. With regard to the 
characterization of the iontophoretic transport this offers major advantages over the 
use of methods based on the estimation of single parameters (e.g. permeation-lag 
time method). In addition compartmental modeling is able to connect the rate of 
iontophoretic delivery to the pharmacokinetic and pharmacodynamic properties and 
ultimately system behavior.  
In this thesis the iontophoretic transport of a series of molecules, with small 
iles. 
As can be observed, KR1 affects the time to steady state during the current 
structural differences, were investigated in CHAPTER 5. This allowed investigating 
the influence of the physicochemical properties on the transdermal iontophoretic 
transport. The transport parameter I0, which is the zero-order mass input during 
iontophoresis from donor to skin, could be related not only to the donor 
concentration and applied current density, but also to the electrophoretic mobility of 
the compound. Furthermore the two first order release constants from skin to 
acceptor phase, KR1 and KR2 are related to the lipophilicity and molecular weight, 
respectively. Based on these property-transport relationships, simulations were 
conducted with the kinetic models presented in CHAPTER 5 to investigate the 
impact of the different transport parameters on the transport profile (Figure 1). The 
results of the simulations are displayed in Figure 2. As expected, I0 affects 
tremendously the value of the steady state flux, but it does not affect the shape of the 
flux profile (Figure 2A). The value of the zero-order mass input is influenced by 
three factors, the donor concentration, the current density and the electrophoretic 
mobility. To diminish skin irritation, the current density should be kept as low as 
possible. Therefore electrophoretic mobility and aqueous solubility for a high donor 
concentration are the key parameters to increase the iontophoretic transport. 
Screening different compounds with capillary electrophoresis to determine the 
electrophoretic mobility is useful to select appropriate candidates for transdermal 
iontophoresis. In addition improving solubility with the use of prodrugs 
(CHAPTER 7) or by selecting an alternative salt form (CHAPTER 4) can merely 
help to reduce the patch size, without reducing the amount of drug  in the patch.  
Figure 2B shows the influence of the release constant KR1 on the transport prof
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Figure 2: Simulations of iontophoretic transport profiles in vitro, changing the zero-order 
mass input I0 (A), the first order release constants, KR1 (B) and KR2 (C). The full thick line 
is the simulated profile with the transport parameters of 5-OH-DPAT, the intermittent 
lines and the full lines are the profiles with lower and higher values than of 5-OH-DPAT, 
respectively. Depicted in every graph are also the values of the parameter used for the 
simulations. Underlined are the values of transport parameters of 5-OH-DPAT. These 
values were kept constant when simulations were conducted, changing another transport 
parameter.  
         
 
application. The higher KR1, the faster steady state is reached. Therefore a high KR1 
could be favorable, but KR1 is related to the lipophilicity of the compound. 
Compounds with a higher lipophilicity are less soluble in an aqueous environment 
and are therefore transported less efficiently with transdermal iontophoresis, as was 
observed for instance for rotigotine (CHAPTER 4). This should be taken into 
account when screening new compounds. The value of KR2 affects the time to steady 
state and the post-iontophoretic decline of the transport rate (Figure 2C). A lower 
KR2, attributed to a higher molecular weight, results in a slower release from the skin 
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into the acceptor phase. Figure 2C, shows also that for KR2 values, higher than 1.30, 
no large differences in transport profiles are observed. This value can be considered 
as a minimum threshold value for a relatively rapid transport through and a rapid 
release from the skin. These simulations show that multiple parameters should be 
taken into account to optimize the iontophoretic transport profile. 
A next step is to evaluate the influence of transport parameters KR and I0 on the drug 
profile in vivo. Based on the obtained results and using the PK-PD models (Figure 1), 
as presented in CHAPTER 6 and 7, in vivo simulations were performed. The results 
are depicted in Figure 3. The intrinsic zero-order mass driving force I0 tremendously 
affects the PK profile as shown in Figure 3A. In a linearly dependent manner the 
steady-state plasma concentration is augmented with increasing I0. The 
corresponding simulations performed to investigate the PD effect with changing I0 
are shown in Figure 3C. From an I0 value of 50 µg.h-1 the maximum response 
remained unchanged when increasing the intrinsic driving force I0. With increasing 
dose the duration of maximum effect after patch removal increases. This was also 
observed for β-ala-(S)-5-OH-DPAT in CHAPTER 7, where a higher value of I0, 
compared to its parent drug resulted in a prolonged effect. This means that the time 
to recover to basal dopamine levels increases with increasing dose. On the one hand 
the prolonged effect can be beneficial for patients who suffer from nocturnal 
disturbances. Nocturnal disturbances are one of the most common non-motor 
complications in patients with PD [38]. It is believed that continuous stimulation of 
the DA receptor during the night can reduce the occurrence of nocturnal disturbances 
[6]. On the other hand this prolonged effect can be a drawback to initiate therapy to 
treat Parkinson’s disease, since rapid changes in delivery schemes may be required. 
In addition one should also take into account that with increasing plasma 
concentrations there is an increasing risk of side effects, such as nausea, vomiting 
and hallucinations [2]. Therefore it is imperative to achieve constant dopaminergic 
stimulation with optimized plasma concentrations, based on an understanding of the 
PK-PD relationship and driven by an acceptable current density. The delivery rate 
also affects the pharmacodynamic efficiency (EFF), as was observed in 
CHAPTER 6. EFF is defined as the pharmacological response per unit of 
concentration and calculated with the following equation: 
 
AUC
AAECEFF =           (1) 
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parameters. A: the plasma concentration profile, simulated with different values of the zero-
order mass input I0. B: the plasma concentration profile, simulated with different values of 
the first order release constants KR. C-D: the corresponding dopamine release (PD 
endpoint) profile, simulated with different values of I0 and KR. The full thick line is the 
simulated profile with the transport parameters of 5-OH-DPAT, the intermittent lines and 
the full lines are the profiles with lower and higher values then of 5-OH-DPAT, 
respectively. Underlined are the values of transport parameters of 5-OH-DPAT. These 
values were kept constant when simulations were conducted, changing another transport 
parameter.  
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Where AUC (ng.ml-1.min) is the area under the plasma concentration curve and 
 
 
AAEC (DA%.min) is the area above the effect curve (normalized for baseline 
dopamine levels). Within the range of delivery rates, investigated in CHAPTER 6, it 
was suggested that a higher delivery rate is favorable. By adjusting the current 
density, the delivery rate can easily be titrated. Therefore with transdermal 
iontophoresis the design of complicated dosing regimens is possible. For instance, a 
high initial dose, obtained with a high current density, can be followed by a lower 
maintenance dose by gradually decreasing the current density. Next to I0, the release 
constant KR also affects the PK-PD profiles. Figure 3B shows that KR affects the 
entire plasma profile during and after iontophoresis. KR values of 3.9 and higher do 
not change the profile dramatically. If KR drops below a value of 2.1 h-1 however, the 
PK profile starts to show a slower time to steady state and also a slower decline of 
the transport post iontophoresis. These profile changes are also found in the PD 
profile as shown in Figure 3D. Again a KR value of 3.9 h-1 can be considered as the 
threshold KR value. 5-OH-DPAT has a KR of 5.5 and small structural changes, 
resulting in relative small differences in KR would not affect the PK and PD profile.  
The similarity of the compartmental modeling of the in vitro and in vivo transport
allowed us to examine the in vitro – in vivo correlation specifically. For both the 
analysis of the in vitro transport and the in vivo plasma profiles kinetic models were 
used, based on the zero-order mass input from donor patch to skin (I0) and the first 
order release constant(s) (KR) from skin to acceptor (in vitro) or plasma (in vivo). 
However, to describe in vitro transport 2 release constants were required for all the 
compounds investigated. In contrast, to describe in vivo iontophoretic transport of  
5-OH-DPAT 1 release constant was sufficient. In addition, an extra (hydrolysis) 
compartment was included in the in vivo PK model to adequately describe the 
transport of β-ala-(S)-5-OH-DPAT. This suggests that different transport 
mechanisms govern the transdermal iontophoretic transport in vitro and in vivo. 
These differences can at least partially be attributed to the following factors. Firstly, 
the structure of human skin differs from the structure of rats. Especially the density 
of hair follicles will contribute to the difference. Previous studies showed that the 
appendageal route is believed to be the predominant route during iontophoresis and 
post-iontophoresis [33]. Therefore it is suggested that that the higher density of hair 
follicles in rat skin results in a much higher contribution of the appendageal route, 
reflected by a higher KR2. In vivo across rat skin the contribution of KR1 might 
therefore become negligible. This could explain why one KR is sufficient to describe 
the skin release in vivo. Secondly the clearance of the penetrant by the acceptor flow 
may be different from the clearance in vivo by the microcirculation in the skin [39]. 
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Thirdly, concerning the hydrolysis of β-ala-5-OH-DPAT, the activity of the esterase 
in vivo may be different from the esterase activity in freshly excised skin. Despite 
these differences the transport parameters in vitro and in vivo corresponded relatively 
well.  
The estimated in vivo steady state flux (Jss vivo) is compared with the estimated in 
vitro steady state flux (Jss vitro) (Table 1). The absolute value of Jss vivo in rats 
corresponds most closely with the Jss vitro across dermatomed human skin for          
5-OH-DPAT and to the Jss vitro across human stratum corneum for β-ala-5-OH-
DPAT. Since KR2 describes the release constant post iontophoresis in vitro, this 
 





and β-ala-5-OH-DPAT across rat skin in vivo and human skin in vitro. 
 
   
   5-OH-DPAT β-ala-5-OH-DPAT 
Para eter unit mean RSE% mean RSE% 
 
     
 m
  
Jss vivo nmol.cm-².h-1 174.6 8 221.2 8 Rat skin 
KR h 2.2 -5.5b 21-26 0.31 -4.8d 23-21 
Jss vitro nmol.cm-².h-1 239.4 9 272.5 4 HSC  
i KR2 h 1.39 10 1.69 8 
Jss vitro nmol.cm-².h-1 190.3 1 381.3 7 DHS  
i KR2 h 0.56 11 0.588 5 
 
 
in vivo -1 a c
n vitro -1  
n vitro -1
      
in vivo are normalized to a current density of 500 µA.cm-². The donor Note: The transport rates 
concentration was 3.9 mM and pH was 5.0. aThis value was obtained from the PK study; bThis value 
was obtained from the PK-PD study; cThis value is the first order release constant KR value from the 
skin to central compartment; dThis value is the first order release constant k42 value from the 
hydrolysis to central compartment  
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release constant was compared to the in vivo release constant. As can be observed, 
the in vivo release constant was more closely related to the in vivo release constant 
in vivo studies and to get a better 
across HSC. For both 5-OH-DPAT and the prodrug β-ala-5-OH-DPAT these 
differences between the in vitro and in vivo transport parameters are relatively small, 
certainly considering the interspecies differences. Nugroho et al. showed comparable 
differences between the in vitro and in vivo transport parameters using the same 
species [10]. Furthermore in the same study it was demonstrated that by combining 
the in vitro transport parameters with the in vivo PK-PD parameters, it was possible 
to predict the pharmacokinetic transport profile and even the pharmacodynamic 
effect [10]. In addition, previous studies showed that iontophoresis diminishes the 
interspecies variations [40]. This emphasizes that in vitro transport studies across 
human skin can provide valuable information for extrapolation towards the in vivo 
situation, even in other species like rats. Modeling and simulations can therefore be 
very helpful in designing novel experiments. 
In conclusion, this thesis presents various potential candidates for the symptomatic 
treatment of Parkinson’s disease with the use of transdermal iontophoresis. Thereby 
a large framework is constructed to screen new potential candidates for transdermal 
iontophoretic delivery from physicochemical properties via in vitro transport studies 
towards in vivo application. This framework is supported by the application of novel 
kinetic models to describe the transport profiles during and after iontophoresis. These 
models can be used to simulate and design new 
comprehension about the in vitro-in vivo and the PK-PD relationships. Ultimately 
these models constitute a scientific basis to design a closed-loop self controlled 
delivery system. 
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Samenvatting 
Levodopa (L-DOPA) wordt al 45 jaar beschouwd als de gouden standaard voor de 
symptomatische behandeling van de ziekte van Parkinson [1]. De eigenschappen van 
L-DOPA en de pulsatiele stimulatie van de dopamine receptoren bij orale toediening 
leiden tot bewegingsstoornissen bij chronisch gebruik van dit geneesmiddel [2]. 
Daarom wordt er gezocht naar andere geneesmiddelen, zoals dopamine agonisten 
(voorbeelden zijn apomorphine, ropinorole, rotigotine en 5-OH-DPAT). Deze 
geneesmiddelen activeren rechtstreeks de post-synaptische dopamine receptoren en 
worden beschouwd als een belangrijk alternatief voor L-DOPA, aangezien dopamine 
agonisten in mindere mate bewegingsstoornissen veroorzaken na langdurig gebruik 
[3]. Meer nog, een continue toediening van deze dopamine agonisten zou kunnen 
zorgen voor een onafgebroken stimulatie van dopamine receptoren. Dit kan leiden tot 
een verdere afname van bewegingsstoornissen bij chronisch gebruik en kan 
voordelig voor andere symptomen van deze ziekte, die niet geassocieerd zijn met 
beweging (o.a. slaapstoornissen) [4-6]. Een continue toediening van dopamine 
agonisten kan bereikt worden door gebruik te maken van transdermale iontoforese.  
Bij transdermale iontoforese wordt door middel van een potentiaalverschil over de 
huid een zwakke stroom opgewekt, die het mogelijk maakt om de toediening van 
kleine geladen moleculen via de huid te bevorderen. De toedieningsnelheid en dus de 
dosis van het geneesmiddel kan nauwkeurig aangepast worden door de stroom te 
veranderen [7]. Dit kan een groot voordeel zijn bij het opzetten van een behandeling, 
omdat vaak snelle dosisaanpassingen nodig zijn. Daarom is gedurende de laatste 10 
jaar onderzoek verricht naar de haalbaarheid van transdermale iontoforese van 
verschillende dopamine agonisten: apomorphine, ropinorole, 5-OH-DPAT en 
rotigotine. Veelbelovende resultaten werden behaald in vitro en in vivo, zoals 
beschreven staat in HOOFDSTUK 1. Echter om een optimaal therapeutisch effect te 
bereiken, moet iontoforetische toediening van dopamine agonisten verder 
geoptimaliseerd en verbeterd worden. Een verdere optimalisatie is vooral gericht op 
een efficiënter transport. Dit heeft als voordeel dat een kleinere pleister gebruikt kan 
worden en/of een lager potentiaalverschil over de huid. De klinische toepasbaarheid 
van transdermale iontoforese kan hiermee aanzienlijk worden verbeterd.  
Het doel van het onderzoek, beschreven in dit proefschrift, was het optimaliseren van 
de transdermale iontoforetische toediening van dopamine agonisten voor de 
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symptomatische behandeling van de ziekte van Parkinson. Meer specifiek werden de 
volgende onderwerpen onderzocht: 
1. Optimaliseren van transdermale iontoforese in vitro van een reeks 
dopamine agonisten, waaronder rotigotine, 5-OH-DPAT en structureel 
analoge verbindingen. Ook werden de transport mechanismen onderzocht, 
die ten grondslag liggen aan iontoforese. 
2. Synthese van nieuwe prodrugs van 5-OH-DPAT, met één of meerdere 
extra positieve ladingen. De chemische en enzymatische stabiliteit van 
deze verbindingen werd ook onderzocht. Dit deel van het onderzoek werd 
uitgevoerd door Jeroen De Graan en zal leiden tot een proefschrift aan de 
Rijks Universiteit Groningen, Groningen, Nederland. 
3. In vitro transportstudies met geselecteerde prodrugs om te onderzoeken of 
deze prodrugs geschikt zijn voor toediening met transdermale iontoforese.  
4. Farmacokinetiek-farmacodynamiek (PK-PD) studies in een dierenmodel 
met de meest belovende geneesmiddelen. Tijdens iontoforese werden 
zowel de plasmaconcentratie alsook het farmacologisch effect gemeten. 
Deze studies werden uitgevoerd in samenwerking met Jeroen De Graan.  
5. Evaluatie en verdere optimalisatie van de kinetische modellen, die 
ontwikkeld werden door Kharis Nugroho et al. voor het beschrijven van 
transdermaal iontoforetisch transport in vitro en in vivo [8-10]. 
Deel I- Optimalisatie van de transdermale iontoforetische toediening 
van dopaminerge geneesmiddelen in vitro 
Eerdere studies toonden aan dat transdermale iontoforetische toediening van 5-OH-
DPAT zowel in vitro [11] als in vivo [10] veelbelovend was. Een volledige 
karakterisatie van de transport mechanismen tijdens iontoforetisch transport ontbrak 
echter. Het bepalen van de verschillende mechanismen, die een rol spelen bij 
iontoforese is belangrijk om iontoforetische toediening in vivo te begrijpen en verder 
te verbeteren.  
Eerst werden de mechanismen die een rol spelen bij transdermale iontoforese van 5-
OH-DPAT in vitro onderzocht. Dit is beschreven in HOOFDSTUK 3. Er werd 
vooral gefocusseerd op de elektro-osmose en de invloed van de samenstelling van de 
donor- en acceptorfase op het transport van 5-OH DPAT tijdens iontoforese. De 
mogelijkheid om paracetamol (acetaminophen) te gebruiken als een marker voor 
elektro-osmose werd ook onderzocht. Het totale transport is de som van passief 
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transport en transport als gevolg van elektro-osmose en elektromigratie. 
Elektromigratie, het transport als gevolg van het potentiaalverschil en de lading van 
het geneesmiddel, draagt meer dan 85% bij aan het totale transport, terwijl electro-
osmose, het transport als gevolg van de negatieve lading in de huid, ongeveer 15% 
bijdraagt. Passief transport is nagenoeg te verwaarlozen. Een verlaging van de pH 
van de donoroplossing van 6.0 naar 5.0 had geen invloed op het totale transport 
onder stationaire condities (Fluxss). Een vermindering van de hoeveelheid Na+-zout 
van 78 naar 10 mM in de donorfase resulteerde in een 2.5- tot 3-voudige verhoging 
van de Fluxss. Er was een hyperbolische correlatie tussen de Fluxss en de 
donorconcentratie van 5-OH-DPAT. Dicht bij de maximale oplosbaarheid van 5-OH-
DPAT benaderde het transport een plateauwaarde. Ook vertoonde de Fluxss een 
lineair verband met de stroomdichtheid. Deze twee factoren tonen aan dat de 
toegediende dosis heel nauwkeurig getitreerd kan worden met transdermale 
iontoforese door de donorconcentratie en de stroomdichtheid aan te passen. Het 
verlagen van de pH van de acceptorfase van 7.4 naar 6.2 zorgde ook voor een afname 
van de 5-OH-DPAT flux. Dit kan verklaard worden door een verandering van de 
doorlaatbaarheid van de huid. Bij pH 6.2 is de huid minder negatief geladen, 
waardoor het elektro-osmotisch transport verlaagd wordt en de competitie van 
tegenionen (vnl. Cl-), die migreren van acceptor- naar donorfase, verhoogd wordt. 
Deze studie toont aan dat 5-OH-DPAT efficiënt door de huid getransporteerd kan 
worden. Tevens zijn verschillende transportmechanismen die ten grondslag liggen 
aan deze efficiëntie ontrafeld. 
Rotigotine, structureel verwant aan 5-OH-DPAT, is de eerste dopamine agonist, die 
geformuleerd in een passieve transdermale pleister (Neupro®, UCB Pharma), op de 
markt is gebracht in Europa [12-13]. Uit in vitro studies met rotigotine.HCl bleek, 
dat in vergelijking met passief transport, door middel van iontoforese een hoger 
transport met een kortere vertragingstijd kon worden bereikt [14]. In een 
vervolgstudie werd echter duidelijk dat de oplosbaarheid van rotigotine.HCl in de 
donoroplossing de beperkende factor was om het transport verder te verhogen.  
Eén van de mogelijkheden om de oplosbaarheid van een molecule aan te passen is 
het gebruik van een ander tegenzout. In HOOFDSTUK 4 werden transportstudies 
uitgevoerd onder passieve en iontoforetische condities met een andere zoutvorm van 
rotigotine, namelijk rotigotine.H3PO4. Het transport werd vergeleken met het 
transport van rotigotine.HCl [14-15]. De oplosbaarheid van rotigotine.H3PO4 was 
respectievelijk 2, 6 en 10 maal hoger dan de oplosbaarheid van het HCl-zout bij pH 
6.0, 5.0 en 4.0. Bovendien had de hoeveelheid NaCl geen invloed op de maximale 
oplosbaarheid bij rotigotine H3PO4. Uit de daaropvolgende transportstudies bleek dat 
  205
Appendix     
 
er bij lage concentraties geen verschil was in transport efficiëntie. Echter door de 
toegenomen maximale oplosbaarheid werd een hoger maximaal transport bereikt met 
rotigotine.H3PO4 (138±12.5 nmol.cm-2.h-1) vergeleken met rotigotine.HCl (80.2± 
14.4nmol.cm-2.h-1). Tenslotte werd er met behulp van simulaties onderzocht of 
iontoforese geschikt is voor rotigotine-toediening in vivo. Eerst werd het 
transdermale transport door humaan stratum corneum (HSC) tijdens iontoforese 
beschreven met behulp van de kinetische modellen, ontwikkeld door Nugroho et al. 
[8]. Deze modellen zijn gebaseerd op de veronderstelling dat er een 0de orde transport 
optreedt van het donorcompartiment naar de huid en een 1ste orde transport van de 
huid naar het acceptorcompartiment (in vitro) of de bloedcirculatie (in vivo). Het 
kinetisch model beschreef het iontoforetisch transport nauwkeurig. Daarna werden 
deze in vitro transport parameters gecombineerd met de farmacokinetische 
parameters, die in de literatuur zijn beschreven [16-21], om de rotigotine 
plasmaspiegels te simuleren in mensen. Uit de simulaties kon geconcludeerd worden 
dat toediening met behulp van iontoforese in vergelijking met passieve toediening, 
twee belangrijke voordelen heeft. Ten eerste was de periode om een bepaalde 
plasmawaarde te bereiken significant verkort. Ten tweede kon de plasmaconcentratie 
gemakkelijk getitreerd worden door een aanpassing van de stroomdichtheid. Dit 
laatste biedt de mogelijkheid om snel en gemakkelijk verschillende 
toedieningsprofielen te ontwikkelen, aangepast aan de behoefte van de patient. 
Naast 5-OH-DPAT en rotigotine zijn andere 2-aminotetralines en structurele analoge 
verbindingen ook potente agonisten van de D1- en/of D2-receptoren in het striatum. 
Op grond van potentie en moleculaire structuur werden 5 kandidaten geselecteerd: 8-
OH-DPAC, 5-OH-EPAT, 5-OH-MPAT, 5,6-di-OH-MPAT and 5,6-di-OH-DPAT 
[22-28]. Alle verbindingen behoren tot de 2-aminotetralinegroep, behalve 8-OH-
DPAC, een chromanamine. In HOOFDSTUK 5 werden de volgende eigenschappen 
van deze 5 therapeutische moleculen onderzocht: maximale oplosbaarheid in de 
donoroplossing, electroforetische mobiliteit, lipofiliteit, en in vitro iontoforese 
transport door HSC en gedermatomiseerde humane huid (DHS). De resultaten 
werden vergeleken met die van rotigotine en 5-OH-DPAT [11, 14-15]. Hieronder 
zijn de verbindingen met toenemende oplosbaarheid gerangschikt: rotigotine < 5,6-
di-OH-DPAT                      < 5-OH-DPAT < 5-OH-MPAT < 5-OH-EPAT < 8-OH-
DPAC. Uit de daaropvolgende in vitro transportstudies bleek dat kleine structurele 
veranderingen een significante invloed kunnen hebben op de efficiëntie van het 
transport. 5-OH-EPAT en 5-OH-MPAT hebben een significant hogere flux dan de 
andere verbindingen door zowel HSC als DHS. Bij alle onderzochte verbindingen 
bleek dat de flux tijdens iontoforese geen constante waarde bereikte, maar dat de flux 
gradueel toenam in de tijd. Om dit te beschrijven werd een nieuw kinetisch model 
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geïntroduceerd. In plaats van 1 afgiftesnelheidsconstante (KR), zoals eerder gebruikt 
[8], werden 2 afgiftesnelheidsconstantes (KR1, KR2) geïntroduceerd. Dit model 
suggereert dat er ten minste 2 transport routes door de huid zijn: 1) een transport 
route via de haarzakjes, zweet- en talgklieren en 2) een transport route via het 
stratum corneum [29-33]. Het is daarnaast ook belangrijk om de fysisch-chemische 
eigenschappen, die verbonden zijn met de verschillende transportparameters, te 
identificeren. Uit onze studies bleek dat de electroforetische mobiliteit en het 
moleculair gewicht van de verbindingen gebruikt kunnen worden om het 0de orde 
massatransport in de huid (I0) en de afgiftesnelheidsconstante KR2 te voorspellen. 
Ook bleek dat KR1 gerelateerd was aan de lipofiliteit, maar verder onderzoek is nodig 
om deze relatie te bevestigen. Met deze parameters is het mogelijk om flux profielen 
te simuleren. Bij het selecteren van nieuwe kandidaten kunnen soortgelijke 
simulaties een grote hulp zijn. 
Deel II- De gecontroleerde iontoforetische toediening van (S)-5-OH-
DPAT in vivo 
Uit de in vitro transportstudies (HOOFDSTUK 3) bleek dat 5-OH-DPAT een 
geschikte kandidaat is om verder te onderzoeken in vivo.  
In HOOFDSTUK 6 werd de gecontroleerde transdermale iontoforetische toediening 
van het actieve S-enantiomeer van 5-OH-DPAT onderzocht. Deze studies werden 
uitgevoerd in een rattenmodel. Uit de farmacokinetiek studies bleek dat het 
iontoforetisch transport in vivo een lineair verband vertoonde met de gebruikte 
stroomdichtheid. Dit komt overeen met de in vitro resultaten en bevestigt dat de 
toegediende dosis gemakkelijk kan worden getitreerd door een aanpassing van de 
stroomdichtheid. Naast het controleren van de plasmawaarden door middel van 
iontoforese, was het tweede doel van deze studie om de PK-PD relatie te 
onderzoeken tijdens een gecontroleerd en omkeerbaar farmacologisch effect. Om de 
PK-PD relatie te onderzoeken werd eerst een rattenmodel ontwikkeld. Een controle 
experiment toonde aan dat anesthesie, een potentiaalverschil over de huid en 
bloedafname geen of slechts een kleine invloed hadden op de dopamine afgifte in het 
striatum (farmacodynamisch eindpunt). De plasma concentraties en de dopamine 
afgifte in het striatum werden simultaan in het gevalideerde rattenmodel onderzocht. 
(S)-5-OH-DPAT werd in de ratten toegediend met transdermale iontoforese of 
intraveneuze infusie. Intraveneuze en iontoforetische toediening van (S)-5-OH-
DPAT resulteerde in een sterke daling van de dopamine afgifte. Dit wijst op een 
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sterke farmacologische respons. Binnen een periode van 2 uur na het stopzetten van 
de toediening bereikte de dopamine afgifte weer zijn oorspronkelijke waarde. De 
experimentele data van deze studies werden uitgebreid geanalyseerd met niet-lineair 
mixed-effect modellering. De farmacokinetische en farmacodynamische data na 
transdermale iontoforese en intraveneuze toediening werden simultaan geanalyseerd 
om de precisie van de schatting van de PK-PD parameters te verhogen. Deze 
simultane analyse werd ook gebruikt om een onderscheid te maken tussen transport 
parameters (I0 en KR) en geneesmiddel specifieke parameters (V2, V3, Cl, Q). De 
plasmaprofielen tijdens en na iontoforetisch transport werden beschreven met 
kinetische modellen, ontwikkeld door Nugroho et al. [9]. Zoals beschreven voor de 
in vitro situatie, zijn deze modellen ook in vivo gebaseerd op de 0de orde massa 
transfer van donorfase naar de huid en een 1ste orde afgifte van de huid naar de 
bloedcirculatie. Het bleek dat, in tegenstelling tot de in vitro modellen, 1 
afgiftesnelheidsconstante (KR) volstaat om de afgifte van de huid naar de 
bloedcirculatie nauwkeurig te beschrijven. Wat betreft het farmacodynamische 
model, werd er een vergelijking gemaakt tussen 2 modellen om de dopamine afgifte 
in het striatum te beschrijven: 1) indirecte response model type I vs 2) effect 
compartiment model met een sigmoïdaal Imax model. Op basis van het Akaike’s 
Information Criterion (AIC) en de visueel voorspellende controle bleek dat het effect 
compartiment model de dopamine afgifte in het striatum beter beschrijft. Daarnaast 
bleek uit de covariaat analyse dat de toedieningsnelheid ook een bepalende factor is 
voor het farmacologisch effect. Het gebruik van een geïntegreerd PK-PD model 
suggereert dat de plasmaconcentratie vertaald kan worden in een continue stimulatie 
van de dopamine receptoren in het striatum. Dit kan zeer voordelig zijn voor de 
symptomatische behandeling van de ziekte van Parkinson. Er wordt namelijk 
algemeen aangenomen dat continue stimulatie van striatale dopamine receptoren de 
motor fluctuaties bij chronisch gebruik van dopaminerge geneesmiddelen kan 
verminderen. Daarnaast kan continue stimulatie ook voordelig zijn voor non-motor 
complicaties, zoals slaapstoornissen [2].  
Deel III- Transdermale iontoforetische toediening van ester prodrugs 
van 5-OH-DPAT: van synthese tot in vivo studies 
Door de veelbelovende resultaten van de in vitro en in vivo studies, uitgevoerd met 
5-OH-DPAT, besloten we te onderzoeken of de toepasbaarheid van dit geneesmiddel 
verder verbeterd kon worden. 5-OH-DPAT werd veresterd met 4 natuurlijk 
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voorkomende aminozuren: glycine, proline, valine en β-alanine. In vergelijking met 
het moedermolecule 5-OH-DPAT, bevatten de prodrugs een extra amine-groep. 
Hierdoor kunnen deze prodrugs in een geselecteerd pH-gebied twee positieve 
ladingen bezitten. 5-OH-DPAT heeft maximaal slechts 1 positieve lading. 
In HOOFDSTUK 7 werden de volgende eigenschappen van deze prodrugs 
nauwkeurig onderzocht: chemische stabiliteit, oplosbaarheid en transdermaal 
iontoforetisch transport. De invloed van pH, temperatuur, iontoforese en HSC op de 
stabiliteit van de prodrugs werd onderzocht. Een verhoging van de pH en van de 
temperatuur verminderde de stabiliteit van de prodrugs. Iontoforese en de 
aanwezigheid van HSC in de oplossing hadden echter geen meetbare invloed op de 
stabiliteit. Op basis van deze resultaten, werden de meest stabiele verbindingen 
geselecteerd om verder te onderzoeken: valine- en β-alanine-5-OH-DPAT. Ten 
opzichte van 5-OH-DPAT, was de maximale oplosbaarheid in de donorfase van 
valine- en β-alanine-5-OH-DPAT, respectievelijk 4 en meer dan 14 maal groter. 
Hierdoor kan de pleister aanzienlijk worden verkleind zonder de hoeveelheid 
beschikbaar geneesmiddel voor iontoforese te verminderen. Uit iontoforetische in 
vitro transportstudies door HSC en DHS bleek dat het lipofielere valine-5-OH-DPAT 
minder efficiënt door iontoforese werd getransporteerd dan 5-OH-DPAT. De 
hydrofielere prodrug, β-alanine-5-OH-DPAT werd met dezelfde efficiëntie als 5-
OH-DPAT door HSC getransporteerd. Echter wanneer DHS werd gebruikt, werd de 
prodrug β-alanine-5-OH-DPAT 40% efficiënter getransporteerd. Tijdens 
transdermaal transport werden beide prodrugs aanzienlijk afgebroken tot het 
moedermolecule 5-OH-DPAT. De afbraak was prominenter tijdens transport door 
DHS. Op basis van deze in vitro resultaten werd β-alanine-5-OH-DPAT gekozen om 
verder te onderzoeken in vivo. Een reeks iontoforese transportstudies werden 
uitgevoerd met het actieve S-enantiomeer van β-alanine-5-OH-DPAT en de 
resultaten van deze studie werden vergeleken met de resultaten van (S)-5-OH-DPAT 
(HOOFDSTUK 6). Ondanks een efficiënter transport in vitro, werden lagere 
plasmawaarden waargenomen tijdens iontoforetische toediening van β-alanine-(S)-5-
OH-DPAT dan tijdens de toediening van (S)-5-OH-DPAT. Echter de plasmawaarden 
post iontoforese waren hoger na toediening van de prodrug. Dit kan wellicht 
verklaard worden door een vertraagde afgifte van het actief bestanddeel vanuit de 
huid naar de bloedcirculatie veroorzaakt door hydrolyse en ophoping in de huid. 
Ondanks dit verschil in farmacokinetiek, bereikte het farmacologisch effect na 
toediening van β-alanine-(S)-5-OH-DPAT een zelfde maximale waarde, maar het 
farmacologisch effect hield wel langer aan. De plasma concentraties en de dopamine 
afgifte werden geanalyseerd met een geïntegreerd PK-PD model. Er werd in het 
model rekening gehouden met hydrolyse en ophoping van de prodrug in de huid 
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tijdens iontoforetisch transport. Hiervoor werd een additioneel parallel compartiment 
geïntroduceerd tussen de huid en het centrale compartiment. Net als bij (S)-5-OH-
DPAT werd een effect compartiment model gebruikt om de dopamine afgifte in het 
striatum te beschrijven. Deze resultaten tonen aan dat met behulp van prodrugs-
synthese de fysisch-chemische eigenschappen, het plasma profiel en het 
farmacologisch effect aangepast kunnen worden. De prodrug β-alanine-(S)-5-OH-
DPAT bezit een gebalanceerde stabiliteit en een hoge transportefficiëntie en kan 
daarom beschouwd worden als een veelbelovende kandidaat voor de symptomatische 
behandeling van de ziekte van Parkinson.  
Conclusie 
In dit proefschrift worden verschillende benaderingen beschreven om het 
iontoforetisch transport van dopamine agonisten te verbeteren. Daarnaast wordt in dit 
proefschrift ook een raamwerk gepresenteerd om nieuwe kandidaat moleculen te 
screenen voor transdermale iontoforese. In dit raamwerk werden de fysisch-
chemische eigenschappen van de moleculen, de transport eigenschappen in vitro en 
de toepassing in vivo met elkaar verbonden. Dit raamwerk wordt ondersteund door 
kinetische modellen, die de transport profielen beschrijven tijdens en na iontoforese. 
Deze modellen kunnen gebruikt worden om simulaties uit te voeren en om nieuwe 
studies te ontwerpen. Deze kinetische modellen kunnen ook helpen om meer inzicht 
te krijgen in de in vitro-in vivo relatie en de PK-PD relaties. Verschillende van de 
onderzochte moleculen in dit proefschrift lieten veelbelovende resultaten zien in 
vitro en/of in vivo. Deze resultaten geven aanleiding tot verdere (pre)klinische 
ontwikkeling van een geschikte symptomatische behandeling van de ziekte van 
Parkinson met behulp van transdermale iontoforese.  
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 List of abbreviations 
List of abbreviations 
AAEC  area above the effect curve 
ACN   acetonitrile 
AIC  Akaike’s information criterion 
AUC  area under the curve 
C.I.  confidence interval 
CDA  striatal dopamine concentration  
CE  capillary electrophoresis 
CL  central clearance  
cLogP  calculated logP 
Cm  concentration of the molecule 
Cmax  maximum plasma concentration  
Cp  plasma concentration 
Cs  striatal concentration 
CZE  capillary zone electrophoresis 
DA   dopamine agonists 
DBS   deep brain stimulation 
DHS  dermatomed human skin 
DLB   dementia with Lewy Bodies  
EFF  pharmacodynamic efficiency 
F  bioavailability 
Fluxpss  passive steady state flux 
Fluxss  steady state flux 
Flux9h  flux after 9h of current application 
H  Hill-slope coefficient  
HPLC  high pressure liquid chromatography 
HSC  human stratum corneum 
I0  zero-order iontophoretic mass transfer 
IC50  the concentration of the drug required to produce 50% of Imax 
I.D.  inner diameter 
IDR  indirect response  
Imax  the maximum inhibition of the dopamine production 
IPRED  individual prediction  
IV  intravenous  
J  flux 
 215
Appendix   
J(t)  flux at time t 
JEM  electromigrative flux 
JEO  electroosmotic flux 
Jpass  passive flux 
Jss  steady state flux 
k  elimination rate constant 
ke0 
 
distribution rate constant from plasma to effect compartment 
elimination rate constant from effect compartment 
kij  distribution rate constant from compartment i to compartment j 
kin  zero order rate constant for the production of response 
kout  first order rate constant fro the loss of response 
KR  first order skin release constant 
KR1  first order skin release constant for first (fast) transport route 
KR2  first order skin release constant for second (slow) transport route 
LC  liquid chromatography 
Leff   the distance from the inlet to the detection point 
LOD  limit of detection  
LOQ  limit of quantification  
Ltot   total distance of the capillary 
MS  mass spectrometry  
MSA   multiple system atrophy 
MV  molecular volume 
Mw  molecular weight 
µeff  electrophoretic mobility 
µEOF  electrophoretic mobility of the electroosmotic marker 
µobs  electrophoretic mobility of the compound 
O.D.  outer diameter 
Pass 
 
zero-order drug input due to passive diffusion corrected for the 
surface area (passive flux post iontophoresis) 
PBS  phosphate buffered saline 
PD   pharmacodynamic(s) 
Pd    Parkinson’s disease 
PK  pharmacokinetic(s) 
PPI  zero-order drug input due to passive diffusion 
PRED  population prediction  
PSP   progressive supranuclear palsy  
Q  peripheral clearance 
RP  reversed phase  
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 List of abbreviations 
RSE  relative standard error of the estimate 
RT  retention time 
S  surface area of the patch 
SC   stratum corneum 
SD  standard deviation 
SE  standard error of the estimate 
SEM  standard error of the mean 
SNc   substantia nigra pars compacta 
SPE  solid phase extraction 
T  time of current application  
TEA  triethylamine 
tEOF 
 
time required to reach the detection point for the electroosmotic 
marker 
THF  tetrahydrofuran 
tL  kinetic lag time parameter 
Tmax  time to reach maximum plasma concentration or maximum effect 
tobs  the time required to reach the detection point for the analyte 
V2  central volume 
V3  peripheral volume 
Vd/F  apparent volume of distribution 
VPC  visual predictive check 
Vw  water flow 
  volume flow 
Xn(t)  drug amount at time t in compartment n 
λem  emission wavelength 
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Een proefschrift is de samenvatting van het werk van een assistent in opleiding 
(‘AIO’), waar hij of zij gedurende vier tot vijf jaar van zijn leven aan heeft gewijd. 
Het tot stand komen van dit proefschrift was enkel mogelijk met de hulp van vele 
verschillende mensen. Zonder jullie was dit boekje er nooit geweest en daarom wil ik 
graag mijn dankbaarheid uitdrukken. 
Om geneesmiddelen te formuleren en door de huid te transporteren heb je geschikte 
verbindingen nodig. Hiervoor kon ik rekenen op de deskundigheid en toewijding van 
Jeroen, mijn collega AIO aan de Universiteit van Groningen. Jeroen, we zijn 
ongeveer samen gestart met ons promotieonderzoek. De passie voor de organische 
chemie, je enthousiasme, onze (msn)-conversaties hebben mij steeds geïnspireerd en 
scherp gehouden. Het was een uitdagende zoektocht die we ook samen geëindigd 
zijn met de studies in Groningen. Op het einde waren we echt een geoliede machine, 
die goed op elkaar inspeelde. Ik zal met plezier terugkijken op onze samenwerking 
en ik denk dat we trots mogen zijn op het resultaat dat we hebben bereikt. 
1 tot 2 keer per jaar hadden we een vergadering met de leden van de 
gebruikerscommissie van het STW-project. Hoewel jullie niet steeds aanwezig 
konden zijn op alle vergaderingen van de commissie, werd jullie input toch steeds 
heel sterk gewaardeerd. Speciaal wil ik Ronald van der Geest bedanken. Ronald, jij 
was bijna altijd aanwezig op de vergaderingen van de gebruikerscommissie. Jouw 
opmerkingen en aanwijzingen waren heel waardevol en plaatsten het geheel steeds in 
een ander perspectief. Dit bracht het academische onderzoek dicht bij de 
farmaceutische toepassing.  
Je begint als jonge AIO met weinig ervaring aan je onderzoek. Gelukkig kon ik 
rekenen op de steun en hulp van de mensen bij de Sectie Drug Delivery Technology  
van het LACDR. In de beginfase van mijn onderzoek leerden Dirk-Jan en Ferry mij 
de ‘ins’ and ‘outs’ van iontoforese en HPLC. Dit vormde een goede basis om later 
zelf met deze technieken verder te gaan. Na het vertrek van Dirk-Jan kon ik steeds 
rekenen op de assistentie van Stefan, die altijd klaarstond en waarvoor niets te 
moeilijk of te vervelend was. Stefan, zonder jouw technische hulp bij de HPLC en bij 
de omschakeling van Adchrom naar Empower stond onze afdeling Drug Delivery 
Technology (DDT) nu nog in zijn HPLC-kinderschoenen. Ook bij de dierproeven in 
Leiden en in Groningen was je van onmisbare waarde. Kharis, the ending of your 
PhD was the beginning of mine. I really appreciate your efforts to help me 
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understand the principles of iontophoretic transport and how to translate this 
knowledge into kinetic models.  
Thanks to the help of Erik and later Romano I was able to gather the precious results, 
presented in this thesis. Romano, you started off as a student and continued on the 
same project as a technician. You performed a lot of transport studies well organized 
and with care. You were always on top of things and did everything with a smile. 
Besides your excellent work, I also appreciate very much the time we spent together 
in and outside the lab. Ik heb ook de hulp van Connie altijd zeer gewaardeerd; jij 
zorgde er altijd voor dat alles in goede banen werd geleid, dat deadlines op tijd 
werden gehaald, afspraken niet vergeten werden. En voor een gezellige babbel was 
ik bij jou ook aan het juiste adres.  
Voor de technische aangelegenheden kon ik aan de deur kloppen bij Raphaël Zwier 
en later ook Mirthe Bergman van de fijn mechanische afdeling (FMD). Ik waardeer 
jullie bijdrage aan het project door het maken van de ionto-patches en de ‘Fill and 
Twist’. Ook kon ik ook op de kennis rekenen van Rob Vreken en Shanna Shi van 
ABS voor het analyseren van mijn plasmamonsters.  
Daarnaast was de hulp en begeleiding van Oscar Della-Pasqua ook zeer belangrijk, 
vooral het ontwikkelen en toepassen van de modellen om de in vitro en in vivo 
resultaten te beschrijven. Oscar, jij hebt mij geïntroduceerd in de wereld van de PK-
PD analyse. Met veel geduld en toewijding heb je de basis gelegd van het 
modelleren. De bijeenkomsten die we hadden waren steeds heel efficiënt en nuttig. 
Dankzij jou heb ik ook de smaak te pakken gekregen van het modelleren en ga ik 
hierin verder.  
Het begeleiden van masterstudenten hoort ook bij het AIO-bestaan. Christina en 
Jeroen, dankzij jullie is het project een heel stuk verder gekomen. Het was niet altijd 
even gemakkelijk en soms werd er wat meer tijd en inspanning gevraagd van jullie. 
Maar jullie deden het onderzoek steeds met de glimlach. Jeroen, ik ben blij en trots 
dat je ook nu zelf als AIO bij DDT aan de slag bent gegaan.  
Ook in Groningen werd ik goed ontvangen en opgevangen. Het was niet gemakkelijk 
om de in vivo proeven te plannen en te regelen vanuit Leiden. Maar dankzij de hulp 
van Gunnar Flik, Thomas Cremers, Karola Jansen en de overige medewerkers van 
Brains on-Line konden deze proeven netjes ingepland en uitgevoerd worden. Deze 
hulp werd zeer gewaardeerd.  
It is important that technically everything is running smoothly, but it is also very 
important to have a good working atmosphere. During my time at the DDT-team 
there always was an inspiring, stimulating, but also relaxed atmosphere. Besides 
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working, there was also time for a joke, a nice chat, a game of indoor soccer,…. This 
made the trip from and to Roosendaal a lot less intense. Although at the Division of 
Drug Delivery Technology people were coming and going, the ‘gezellige’ 
atmosphere was constantly present thanks to Miranda & Miranda, Maytal, Julia, 
Wouter, Marc, Mogjan, Nazmoen, Gert, Jacob, Dennis, Tomo, Diogenes, Tue, Elly, 
Aat, Sun, Andrea, Robert, Vasco, Varsha, Christophe, Michelle, Wim, Myrra, Basak, 
Riccardo, Suzanne, Bram, Ana and the many Erasmusstudents that visited our lab. I 
will look back with great pleasure at our collaborations, the lunch-club, ‘lab-uitjes’ 
and various field trips (Biopharmacy Day, GPEN, pubcrawl(s),…). There are three 
people from the DDT-team I would like to acknowledge in particular. Robert and 
Ding, around the same time, we started our PhD-adventure in Leiden. And an 
adventure it was. We dealt with the same hazards, shared the same frustrations, but 
also enjoyed many nice moments, which I will never forget. Daniel, ik zal de 
gezellige tijd ‘at the office’ en daarbuiten niet snel vergeten. Onze theoretische 
discussies, de senseo-coffee breaks, maar ook de tennis games na het werk waren 
altijd plezierig. En als de laatste trein richting Roosendaal net iets te vroeg vertrok, 
kon ik bij jou altijd terecht. I’m very grateful for your friendship and I’m proud that 
the three of you are my paranimphs today.  
Om aan de druk en besognes van het proefschrift te ontsnappen kon ik ook altijd 
rekenen op mijn familie en vrienden in België. Onze weekends waren tijdens de 
laatste vier jaar altijd druk bezet met feestjes, dinertjes, of gewoon een gezellig 
‘after-work-pintje’ op vrijdag. Bedankt voor alle mooie momenten, die we samen al 
hebben beleefd en dat onze vriendschap nog lang mag blijven duren. Ook bij de 
familie Box in Neerpelt voel ik mij altijd zeer welkom, wat ik heel hard apprecieer.  
Lieve paps en mams, Mike en Dons, jullie hebben mij altijd veel liefde, vriendschap, 
plezier, steun en nog zoveel meer gegeven. Ik ben heel dankbaar voor alle kansen, 
die ik heb gekregen. Jullie zijn van onschatbare waarde geweest, ook bij het tot stand 
komen van deze thesis.  
Liefste Vienie, we zijn nu bijna vijf jaar geleden samen aan dit ‘hollands’ avontuur 
begonnen. Door dik en dun heb je mij gesteund en je hebt mij geleerd wat meer te 
relativeren. Zonder jouw liefde, onvoorwaardelijke steun, ondernemingszin en 
organisatietalent zou ik niet zo ver staan als nu. Ik ben blij dat ik elke dag bij jou kan 
thuiskomen in ons appartementje in Roosendaal. Ik zie je graag. 
 
Ik heb geschreven. 
Oliver
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